Clinical trial NCT04091438
Conditions: Idiopathic Hypersomnia
Keywords: Drug therapy
Sponsor: Millennium Pharmaceuticals, Inc.
Start date: 2020-01-26; Completion date: 2020-11-23
Enrollment: 28 participants; Allocation: RANDOMIZED; Intervention model: CROSSOVER

Brief summary:
The purpose of this study is to evaluate the safety and tolerability of administering a single intravenous (IV) infusion dose of TAK-925 to adult participants with idiopathic hypersomnia (IH).

Detailed description:
The drug being tested in this study in participants with IH is called TAK-925. The study will have 2-treatment crossover groups. The study will evaluate the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of a single intravenous (IV) dose of Dose A in participants with IH.

The study will enroll 40 patients. Participants will be randomly assigned to one of the two treatment sequence groups as indicated below:

* TAK-925 + Placebo
* Placebo + TAK-925

On Day 1 of each treatment period, TAK-925 or placebo will be administered as a single 9-hour IV infusion.

The multicenter study will be conducted in the United States and Japan. The overall duration of treatment in this study is approximately 41 days including screening up to 28 days, confinement for 6 days and end of study follow up telephone call on Study Day 11.

Arms: arm 1: TAK-925 112 milligram (mg), 9-hour intravenous infusion once on Day 1, Treatment Period 1 followed by 24 hours wash-out period, followed by TAK-925 placebo-matching 9-hour intravenous infusion once on Day 3, Treatment Period 2. arm 2: TAK-925 placebo-matching 9-hour intravenous infusion once on Day 1, Treatment Period 1 followed by 24 hours wash-out period, followed by, TAK-925 112 mg, 9-hour intravenous infusion once on Day 3, Treatment Period 2.
Interventions: intervention 1: TAK-925 intervention 2: TAK-925 Placebo
Intervention descriptions: intervention 1: TAK-925 IV infusion. intervention 2: TAK-925 placebo-matching IV infusion.

Protocol documents:
Prot_000.pdf: 



Title: A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Crossover Study of a Single
Intravenous Infusion Dose of TAK-925 in Patients With Idiopathic Hypersomnia
NCT Number: NCT04091438
Protocol Approve Date: 04 March 2020
Certain information within this protocol has been redacted (ie, specific content is masked irreversibly from 
view with a black/blue bar) to protect either personally identifiable information (PPD) or company 
confidential information (CCI). 
This may include, but is not limited to, redaction of the following: 
Named persons or organizations associated with the study.
Proprietary information, such as scales or coding systems, which are considered confidential 
information under prior agreements with license holder.
Other information as needed to protect confidentiality of Takeda or partners, personal information, or 
to otherwise protect the integrity of the clinical study.


TAKEDA PHARMACEUTICALS
PROTOCOL
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Crossover Study of a Single 
Intravenous Infusion Dose of TAK-925 in Patients With Idiopathic Hypersomnia
Sponsor:
Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda 
Pharmaceutical Company, Ltd
40 Landsdowne Street
Cambridge, MA 02319
Study Number:
TAK-925-2002
IND Number:
144843
EudraCT Number:
Not applicable
Compound:
TAK-925
Date:
04 March 2020
Version/Amendment 
Number: 
02
Amendment History:
Date
Amendment Number
Amendment Type
Region
01 August 2019
Initial Protocol
Not applicable
Global
07 November 2019
01
Substantial
Global
04 March 2020
02
Substantial
Global
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 2 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
1.0
ADMINISTRATIVE INFORMATION
1.1
Contacts
A separate contact information list will be provided to each site.
Takeda sponsored investigators per individual country requirements will be provided with 
emergency medical contact information cards to be carried by each subject.
General advice on protocol procedures should be obtained through the monitor assigned to the 
study site. Information on service providers is given in Section 3.1 and relevant guidelines 
provided to the site.
Contact Type/Role
North America Contact
Japan Contact
Serious adverse event and 
pregnancy reporting
Medical Monitor
(medical advice on protocol and 
study drug)
Responsible Medical Officer 
(carries overall responsibility for 
the conduct of the study)
PPD
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
itith
ssigned 
signe
nt guide
t guid
Japa
Jap
A
on Commercial Use Only and Subject to th


TAK-925
Study No. TAK-925-2002
Page 3 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
1.2
Approval
REPRESENTATIVES OF TAKEDA
This study will be conducted with the highest respect for the individual participants in accordance 
with the requirements of this study protocol and also in accordance with the following:
!
The ethical principles that have their origin in the Declaration of Helsinki.
!
International Council for Harmonisation (ICH) E6 Good Clinical Practice (GCP): 
Consolidated Guideline.
!
All applicable laws and regulations, including, without limitation, data privacy laws, clinical 
study disclosure laws, and regulations.
SIGNATURES
The signature of the responsible Takeda medical officer (and other signatories, as applicable) can 
be found on the signature page.
Electronic Signatures are provided on the last page of this document.
PPD
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
dance
ance
GCP):
GCP):
a privac
priva
other sig
ther si
his docu
is doc
da: For Non-Commercial Use Only and


TAK-925
Study No. TAK-925-2002
Page 4 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
INVESTIGATOR AGREEMENT
I confirm that I have read and that I understand this protocol, the Investigator’s Brochure, package 
insert and any other product information provided by the sponsor. I agree to conduct this study in 
accordance with the requirements of this protocol and also to protect the rights, safety, privacy, 
and well-being of study subjects in accordance with the following:

The ethical principles that have their origin in the Declaration of Helsinki.

ICH, E6 GCP: Consolidated Guideline.

All applicable laws and regulations, including, without limitation, data privacy laws and 
regulations.

Regulatory requirements for reporting serious adverse events (SAEs) defined in Section 10.2
of this protocol.

Terms outlined in the study site agreement.

Responsibilities of the Investigator (Appendix C)
I further authorize that my personal information may be processed and transferred in accordance 
with the uses contemplated in Appendix E of this protocol.
Signature of Investigator
Date
Investigator Name (print or type)
Investigator’s Title
Location of Facility (City, State/Province)
Location of Facility (Country)
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 5 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
1.3
Protocol Amendment 02 Summary of Changes
This document describes the changes to the protocol incorporating Amendment 02. 
In addition to the overview of changes provided below, in this amendment minor grammatical, 
editorial, formatting, and administrative changes not affecting the conduct of the study are 
included for clarification and administrative purposes only.
For specific descriptions of text changes and where the changes are located, see Appendix H.
Changes in amendment
The following is a summary of changes made in the amendment:
1. The number of participating sites was updated.
2. The description of the evaluation period in the study summary section was clarified.
3. The document referred to in the section on study-related responsibilities was corrected to 
“Transfer of Regulatory Obligations”.
4. It was clarified in the primary objective that the population consisted of adult subjects with 
idiopathic hypersomnia (IH).
5. The wording of the secondary objective was made consistent with the primary objective.
6.
7. It was clarified in the study design that the maintenance of wakefulness sessions will be 
terminated at approximately 1700.
8. It was clarified that subjects with an Epworth Sleepiness Scale (ESS) score <11 who are taking 
stimulants at screening may continue the screening process and repeat the ESS at Study Day -2 
following washout.
9. It was clarified in the study design that sodium oxybate must be discontinued at least 4 weeks 
prior to screening.
10. The subject’s normal bedtime was clarified to be between 2200 and 2300.
11.
12. The overview of inpatient unit study schedule was corrected and clarified.
13.
14.
CCI
CCI
CCI
CCI
Property of T
2. The o
Th
For Non-Commercial Use
that the 
hat the
0.
with an 
with a
ay conti
y cont
the stud
he stu
ng.g.
’s norm
s norm
Only and Subject to the Applicable Terms of Use
al,
e
ppendix
ppendi
y secti
section
esponsi
espons
pulat
pulatioi
 made c
ade
13.
13.
se O
Takeda: F
y 
C


TAK-925
Study No. TAK-925-2002
Page 6 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
15. The safety risk related to heart rate in the criteria for premature discontinuation was changed 
from 115 to 100 bpm.
16. The safety risk related to mood changes in the criteria for premature discontinuation was 
limited to only severe changes in mood.
17. A safety risk for treatment-emergent serious adverse events (AEs) or severe AEs that are 
considered related to treatment was added to the criteria for premature discontinuation.
18. Text was added to clarify that, if a subject with a history of IH has a diagnostic nocturnal 
polysomnography (nPSG) or multiple sleep latency test (MSLT) older than 10 years (or the 
test results are not available), the investigator will obtain a current nPSG/MSLT. 
19. The apnea-hypopnea index (AHI) for subject selection was changed from ≤15 to ≤10/hour. 
Also, it was added to the selection criteria that subjects should have a periodic limb movement 
arousal index (PLMAI) ≤15/hour.
20. Redundant and/or duplicate selection criteria were removed from the protocol.
21. Selection criteria related to contraception were reworded and clarified.
22. It was added to the selection criteria that subjects with an average nightly sleep duration ≤8 
hours (480 minutes) will be excluded.
23. It was clarified in the selection criteria that the alcohol test used during the study will be a 
breathalyzer.
24. It was clarified that subjects with a resting heart rate (HR) outside of the range 40-90 bpm 
(rather than 45-100 bpm) will not be eligible for selection.
25. It was clarified that subjects with a usual bedtime later than 2400 (midnight) rather than 0100 
are not eligible to participate.
26. The exclusion criterion on nicotine dependence that is likely to have an effect on sleep was 
expanded to include smoking ≥10 cigarettes per day.
27. It was added to the exclusion criteria that subjects unwilling to discontinue all caffeine during 
the confinement period of the study will not be eligible for selection.
28. Major depression was added as an example of psychiatric disorders for which subjects will be 
excluded from participation.
29. The period for refraining from certain food products was corrected to be through Study Day 4 
(including washout intervals between treatment periods) rather than until the follow-up visit.
30. It was clarified that known in vivo cytochrome P-450 (CYP)3A (not only CYP3A4) inhibitors 
or inducers were prohibited drug classes.
31. It was clarified that subjects will receive 3 standardized meals per day during confinement.
32. Food, drink, and other product restrictions were clarified.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 7 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
33. It was added to the protocol that subjects will be allowed to go on short supervised walks on 
washout days.
34. It was clarified that lack of efficacy should not be recorded in the voluntary withdrawal
category of discontinuation criteria. It was also clarified that the criterion is applicable to 
subjects or their legally acceptable representative.
35. It was corrected that details of the randomization schedule are provided in the pharmacy
manual rather than the interactive voice response (IVRS) manual.
36. It was clarified that informed consent must be obtained before beginning withdrawal of 
excluded medications.
37. The time subjects should rest in a bed following dosing was corrected from 4 to 2 hours.
38. The actigraphy procedure was clarified.
39. The duration of the nPSG was clarified.
40.
41. International normalized ratio (INR) measurement was added to the overview of laboratory 
tests for subjects with an alanine aminotransferase (ALT) or aspartate aminotransferase (AST) 
level >3 times the upper limit of normal (ULN).
42.
43. The procedure on collecting and reporting of serious adverse events (SAEs) was clarified.
44.
45. The term “adverse events of special interest” was removed from the description of the safety 
analyses.
46. A footnote was added to the Schedule of Study Procedures table to allow optional
pre-screening on a case-by-case basis.
47. The measurement of O2 saturation was added to the Schedule of Study Procedures table.
48.
49. It was added to the Schedule of Study Procedures that urine drug screen and pregnancy test
results should be available before dosing on Day 1 of Treatment Period 1.
50
51. The urine pregnancy test was moved from Study Day-1 to Study Day -2 in the Schedule of 
Study Procedures table.
52. A footnote was added to the Schedule of Study Procedures table to clarify that glycosylated 
hemoglobin will be assessed only in diabetic subjects.
CCI
CCI
CCI
CCI
CCI
Property of Takeda: 
s added 
added
ults sho
ts sh
l
For Non-Commerc
f special
specia
d to the 
to the
a case
a case-by
ment of O
nt of
l Use
orting o
rting 
Only and S
was ad
was 
ase (ALT
se (AL
LN).
N).
51.
5
a: Fo
e On
rcial U
y of Ta
CI
bject to the Applicable Terms of Use
o 
armacy
armac
withdraw
withdr
ted from
ted fro
Subj


TAK-925
Study No. TAK-925-2002
Page 8 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
53. Footnotes were added to the Schedule of Study Procedures table to clarify site staff will make 
every effort to keep subjects awake following completion of clinical testing procedures on 
Study Day -2 and during the day from 0700 until between 2200-2300 on Study Days 2 and 4.
54. Appendix G (Pregnancy and Contraception) was reorganized and completed where needed.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 9 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
TABLE OF CONTENTS
1.0
ADMINISTRATIVE INFORMATION ...........................................................................2
1.1
Contacts.....................................................................................................................2
1.2
Approval....................................................................................................................3
1.3
Protocol Amendment 02 Summary of Changes ..........................................................5
2.0
STUDY SUMMARY ....................................................................................................14
3.0
STUDY REFERENCE INFORMATION ......................................................................19
3.1
Study-Related Responsibilities.................................................................................19
3.2
Principal Investigator/Coordinating Investigator ......................................................19
3.3
List of Abbreviations ...............................................................................................20
3.4
Corporate Identification...........................................................................................22
4.0
INTRODUCTION.........................................................................................................23
4.1
Background .............................................................................................................23
4.1.1
Orexin and Idiopathic Hypersomnia...................................................................23
4.1.2
TAK-925 ...........................................................................................................24
4.2
Rationale for the Proposed Study.............................................................................25
4.3
Benefit/Risk Profile .................................................................................................26
5.0
STUDY OBJECTIVES AND ENDPOINTS..................................................................27
5.1
Objectives................................................................................................................27
5.1.1
Primary Objective ..............................................................................................27
5.1.2
Secondary Objective ..........................................................................................27
5.1.3
Exploratory Objectives.......................................................................................27
5.2
Endpoints.................................................................................................................27
5.2.1
Primary Endpoints .............................................................................................27
5.2.2
Secondary Endpoint ...........................................................................................27
5.2.3
Exploratory Endpoints .......................................................................................28
6.0
STUDY DESIGN AND DESCRIPTION.......................................................................29
6.1
Study Design ...........................................................................................................29
6.2
Justification for Study Design, Dose, and Endpoints ................................................31
6.2.1
Rationale for Study Design ................................................................................31
6.2.2
Rationale for Dose .............................................................................................31
6.2.3
Rationale for Endpoints......................................................................................32
6.3
Premature Termination or Suspension of Study or Study Site...................................34
6.3.1
Criteria for Premature Termination or Suspension of the Study..........................34
6.3.2
Criteria for Premature Termination or Suspension of Study Sites .......................35
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 10 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
6.3.3
Procedures for Premature Termination or Suspension of the Study or the 
Participation of Study Sites ................................................................................35
7.0
SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS..............36
7.1
Inclusion Criteria .....................................................................................................36
7.2
Exclusion Criteria ....................................................................................................37
7.3
Excluded Medications..............................................................................................39
7.4
Diet, Fluid, and Activity Control..............................................................................41
7.4.1
Diet and Fluids...................................................................................................41
7.4.2
Activity..............................................................................................................41
7.5
Criteria for Discontinuation or Withdrawal of a Subject...........................................42
7.6
Procedures for Discontinuation or Withdrawal of a Subject......................................43
7.7
Subject Replacement................................................................................................43
8.0
CLINICAL STUDY MATERIAL MANAGEMENT.....................................................44
8.1
Study Drug and Materials ........................................................................................44
8.1.1
Dosage Form, Manufacturing, Packaging, and Labeling.....................................44
8.1.1.1
Ancillary Supplies ...................................................................................44
8.1.1.2
Sponsor-Supplied Drug............................................................................44
8.1.2
Storage...............................................................................................................44
8.1.3
Dose and Regimen .............................................................................................44
8.1.4
Overdose............................................................................................................45
8.2
Study Drug Assignment and Dispensing Procedures ................................................45
8.3
Randomization Code Creation and Storage..............................................................45
8.4
Study Drug Blind Maintenance................................................................................45
8.5
Unblinding Procedure..............................................................................................45
8.6
Accountability and Destruction of Sponsor-Supplied Drugs.....................................46
9.0
STUDY PLAN ..............................................................................................................47
9.1
Administrative Procedures.......................................................................................47
9.1.1
Informed Consent Procedure..............................................................................47
9.1.2
Inclusion and Exclusion .....................................................................................47
9.1.3
Medical and Social History and Demographics ..................................................47
9.1.4
Prior and Concomitant Medication.....................................................................47
9.1.5
Washout of Prohibited Concomitant Medications...............................................48
9.1.6
Actigraphy and Sleep Diary ...............................................................................48
9.2
9.2.
9.2.
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
36
...... 36
36
.........
.......
3
........
......
........
....
.........
.....
........
.....
.........
......
ect
ect.....
.
........
....
.........
......
........
....
ing, and
ng, an
.........
.....
........
.......
.........
.....
........
.......
........
.....
ment and
ent an
Code Cre
de Cr
lind Ma
nd M
g Proce
g Proc
ntabilit
abilit
Y PLAN
PLA
Ad
Admini
mi
9.1.1
.1.1
9.1.2
9.1
9


TAK-925
Study No. TAK-925-2002
Page 11 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
9.2.3
9.2.4
9.2.5
9.2.6
9.2.7
9.2.8
9.3
PD Evaluation/Assessments.....................................................................................50
9.3.1
nPSG .................................................................................................................50
9.3.2
9.3.3
ESS....................................................................................................................50
9.3.4
9.3.5
9.4
Laboratory Assessments/Procedures ........................................................................51
9.5
PK 
 Samples...............................................................................................53
9.5.1
PK 
 Evaluations....................................................................................53
9.5.2
PK Measurements..............................................................................................53
9.5.2.1
Blood for PK Measurements....................................................................53
9.5.2.2
PK Sample Analysis ................................................................................54
9.6
Blood Volume .........................................................................................................55
9.7
Confinement ............................................................................................................56
9.8
Documentation of Screen Failure.............................................................................56
9.9
Documentation of Study Entrance/Randomization ...................................................57
9.10
Monitoring Subject Treatment Compliance..............................................................57
10.0
PRETREATMENT EVENTS AND AES ......................................................................58
10.1
Definitions...............................................................................................................58
10.1.1 PTEs..................................................................................................................58
10.1.2 AEs....................................................................................................................58
10.1.3 Additional Points to Consider for PTEs and AEs................................................58
10.1.4 SAEs..................................................................................................................60
10.1.5 AEs of Special Interest.......................................................................................61
10.1.6 Intensity of PTEs and AEs .................................................................................61
10.1.7 Causality of AEs ................................................................................................61
CCI
CCI
CCI
CCI
CCI
CCI
Property of Takeda: For Non-Comm
........
.....
.........
...
tati
ation o
on 
mentati
entat o
onitorin
torin
i
ETREA
TRE
1
Def
D
Use Only and Subjec
.........
.......
........
.......
........
....
........
.... .
ments
ents.
........
......
the A
.........
......
10.
10
ject to th
mercial Us
f Use
ble Terms of U
pplicab
........
.....
.........
.....
e App


TAK-925
Study No. TAK-925-2002
Page 12 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
10.1.8 Relationship to Study Procedures.......................................................................62
10.1.9 Start Date...........................................................................................................62
10.1.10
Stop Date .....................................................................................................62
10.1.11
Frequency ....................................................................................................62
10.1.12
Action Concerning Study Drug ....................................................................62
10.1.13
Outcome.......................................................................................................62
10.2
Procedures...............................................................................................................63
10.2.1 Collection and Reporting of AEs........................................................................63
10.2.1.1
PTE and AE Collection Period.................................................................63
10.2.1.2
PTE and AE Reporting ............................................................................63
10.2.2 Collection and Reporting of SAEs......................................................................64
10.2.3 Reporting of Abnormal LFTs.............................................................................65
10.3
Follow-up of SAEs ..................................................................................................65
10.3.1 Safety Reporting to Investigators, IRBs or IECs, and Regulatory Authorities.....65
11.0
STUDY-SPECIFIC COMMITTEES .............................................................................66
12.0
DATA HANDLING AND RECORDKEEPING............................................................67
12.1
eCRFs......................................................................................................................67
12.2
Record Retention .....................................................................................................67
13.0
STATISTICAL METHODS..........................................................................................69
13.1
Statistical and Analytical Plans ................................................................................69
13.1.1 Analysis Sets......................................................................................................69
13.1.1.1
Safety Set ................................................................................................69
13.1.1.2
PK Set .....................................................................................................69
13.1.1.3
PD Set .....................................................................................................69
13.1.2 Analysis of Demographics and Other Baseline Characteristics ...........................69
13.1.3 PK Analysis .......................................................................................................69
13.1.4 PD Analysis .......................................................................................................69
13.1.5 Safety Analysis ..................................................................................................70
13.2
Interim Analysis and Criteria for Early Termination ................................................70
13.3
Determination of Sample Size..................................................................................70
14.0
QUALITY CONTROL AND QUALITY ASSURANCE...............................................72
14.1
Study Site Monitoring Visits....................................................................................72
14.2
Protocol Deviations..................................................................................................72
14.3
Quality Assurance Audits and Regulatory Agency Inspections ................................72
15.0
ETHICAL ASPECTS OF THE STUDY........................................................................73
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 13 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
15.1
IRB and/or IEC Approval ........................................................................................73
15.2
Subject Information, Informed Consent, and Subject Authorization .........................74
15.3
Subject Confidentiality ............................................................................................75
15.4
Publication, Disclosure, and Clinical Trial Registration Policy.................................75
15.4.1 Publication and Disclosure.................................................................................75
15.4.2 Clinical Study Registration.................................................................................75
15.4.3 Clinical Study Results Disclosure.......................................................................76
15.5
Insurance and Compensation for Injury....................................................................76
16.0
REFERENCES..............................................................................................................77
LIST OF IN-TEXT TABLES
Table 6.a
Summary of Treatment Assignment for Each Sequence .....................................29
Table 6.b
Overview of the Inpatient Unit Study Schedule..................................................31
Table 7.a
Prohibited Drug Classes.....................................................................................40
Table 7.b
List of Restricted Food, Drinks and Other Products............................................41
Table 9.a
Clinical Laboratory Tests...................................................................................52
Table 9.b
Primary Specimen Collection for
PK Samples .....................................53
Table 9.c
Blood Volume....................................................................................................56
Table 10.a
Takeda Medically Significant AE List................................................................61
LIST OF APPENDICES
Appendix A 
Schedule of Study Procedures............................................................................78
Appendix B
Treatment Day 1 Hourly Schedule of Procedures (Approximate Times) for 
Treatment Periods 1 and 2..................................................................................82
Appendix C
Responsibilities of the Investigator.....................................................................83
Appendix D
Elements of the Subject Informed Consent.........................................................85
Appendix E
Investigator Consent to Use of Personal Information..........................................88
Appendix F
ICSD-3 Diagnostic Criteria for IH......................................................................89
Appendix G
Contraception and Pregnancy.............................................................................90
Appendix H
Detailed Description of Amendments to Text.....................................................94
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
75
........75
.75
.........
.......
........
......
........
.....
.........
.....
........
.....
Sequen
Seque
edule
dule.
.........
.....
d Other 
d Other
.........
......
on for
n for
........
......
gnifican
nifica
e of Stu
of St
atment D
ment 
reatmen
reatme
Respo
Res
x D
El
E
ndix E
ndix E
ppendix 
pendi
Appen
Appe
Ap
A
O
CC
C


TAK-925
Study No. TAK-925-2002
Page 14 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
2.0
STUDY SUMMARY
Name of Sponsor:
Millennium Pharmaceuticals, Inc. (MPI)*
40 Landsdowne Street 
Cambridge MA 02139, USA
* Millennium Pharmaceuticals is a wholly-owned 
subsidiary of Takeda Pharmaceutical Company Limited and 
thereafter, any reference to the sponsor will use Takeda’s
name
Compound:
TAK-925
Title of Protocol: A Phase 1b Randomized, Double-Blind, 
Placebo-Controlled, Crossover Study of a Single 
Intravenous Infusion Dose of TAK-925 in Patients With 
Idiopathic Hypersomnia
IND No.: 144843
EudraCT No.:
Not applicable
Study Number: TAK-925-2002
Phase: 1b
Study Design:
This is a randomized, double-blind, placebo-controlled, 2-period, 2-treatment crossover study to evaluate the 
pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of a single intravenous (IV) infusion dose of 
TAK-925 in subjects with idiopathic hypersomnia (IH). Subjects will be males and females aged 18 through 75 years, 
inclusive, with IH diagnosed according to the International Classification of Sleep Disorders-3 (ICSD-3) criteria as 
verified by a previous nocturnal polysomnogram (nPSG) and multiple sleep latency test (MSLT) study performed 
within the last 10 years. 
The treatment periods begin on Day 1 of Treatment Period 1 (Study Day 1) with Treatment Period 2 commencing on 
Study Day 3. In the morning of Day 1 of Treatment Period 1, eligible subjects will be randomized to 1 of 2 sequence 
groups as listed in the table below. After randomization, the subject will be dosed in 2 treatment periods according to 
the order defined by the sequence group to which he/she is randomized. On Day 1 of each treatment period, TAK-925 
(or placebo) will be administered as a single 9-hour IV infusion commencing at approximately 0800. The infusion will 
be terminated at approximately 1700.
 summary of study drug assignment for each sequence follows:
Sequence
N
Treatment Period 1
Treatment Period 2
1
20
TAK-925 112 mg
Placebo
2
20
Placebo
TAK-925 112 mg
 A total of 40 subjects will be randomized so that at 
least 36 subjects will complete the study. To avoid enrollment of short sleepers with chronic sleep deprivation, 
prospective participants will complete approximately 7 consecutive days of actigraphy supported by a sleep diary 
beginning on Study Day -9 and ending on Study Day -3 (ie, the day before their Study Day -2 admission to the clinical 
unit), to ensure an average nightly sleep duration of ≥420 minutes (7 hours) during the subject’s normal nocturnal 
sleep period and also, that if the subject’s average nightly sleep duration is ≤480 minutes (8 hours), that the subject 
does not have insufficient sleep syndrome (sleeping >2 hours/night more on “off days” than on “work days”). After 
screening, eligible subjects must discontinue their stimulant medications used for treatment of IH. Medications must 
be discontinued for a minimum of 7 days or at least 5 half-lives of each medication, whichever is longer, before the 
first day of dosing (Day 1 of Treatment Period 1). Sodium oxybate must be discontinued at least 4weeks prior to 
CCI
CCI
Property of
least 36 s
ast 3
prosp
pros
beg
be
For Non-Co
Co
n
20
No
or
pe
pe
da: F
keda
aked
Tak
of T
rcial Use Only and Subject to the Applicable Terms of Use
of
of
EudraC
udraC
Not a
Not 
pli
e
o
atment cr
ment c
ility of a 
ity of 
will be m
ll be m
assificatio
sificat
d multip
d multi
eriod 1 (
riod 1
nt Period 
t Perio
mization,
mization
hich he/s
hich h
le 9
e 9-hour
-hou
ct
merc
mme
Comm
CI


TAK-925
Study No. TAK-925-2002
Page 15 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
screening.
The screening period is up to 28 days. Following screening, subjects who meet all screening entry criteria will be 
admitted to the clinical unit on Study Day -2Semi-recumbent vital signs will be obtained following admission; the ESS 
will be recorded in the late afternoon. An overnight 8-hour nocturnal polysomnography (nPSG) will be performed, 
commencing at the subject’s usual bedtime (eg, between 2200 and 2300) to confirm that the subject does not have 
other comorbid sleep disorders or clinically significant nocturnal hypoxemia (O2 saturation ≤80% for ≥5% of total 
sleep time), and to confirm the apnea-hypopnea index (AHI) is ≤10/hour and the periodic limb movement index 
associated with arousals (PLMAI) is ≤15/hour.
Study Day -1 is the designated baseline assessment day and is also intended for accommodation to sleeping in the 
clinical unit without nPSG hookups.
There will be a minimum 24-hour washout interval between the end of TAK-925 
infusion and the commencement of treatment in the subsequent treatment period to allow for complete elimination of 
the preceding treatment effect. Study Days 2 and 4 are washout days. 
 During the study, adverse events (AEs) will be recorded, and clinical labs, vital signs, and ECGs will be 
obtained. Subjects will be discharged from the unit following completion of study exit procedures in the afternoon of 
Study Day 4 (Day 2 of Treatment Period 2). 
Subjects will be contacted by telephone approximately 7 days (±2 days) following unit discharge for a safety check 
and all women of childbearing potential will be asked to return to the clinic to complete a urine pregnancy test. If 
needed, subjects may be seen in the clinic for any safety issues or concerns.
An overview of the inpatient unit study schedule follows:
Screening 
Period
Check-in and 
Baseline
Treatment Periods 1 and 2
End-of-Study Visit
Dosing
Washout
Study Days 
-28
to -3
Study Days -2 
(nPSG a) and -1 
(Baseline)
Study Days 1 and 3
Study drug 
administration/PD, 
PK, and safety 
assessments
Study Days 2 and 4 b
PK and safety 
assessments
Study Day 11 (±2 days)
Follow-up (in clinic or by 
phone call) 
∀#### Confinement Study Day -2 to Study Day 4 ####∃
nPSG: nocturnal polysomnography; PD: pharmacodynamic; PK: pharmacokinetic.
a nPSG only on Study Day-2.
b Discharge from unit on Study Day 4.
Primary Objective:
To evaluate the safety and tolerability of administering a single IV infusion of TAK-925 to adult subjects with IH.
Secondary Objective:
To investigate the PK of a single IV infusion of TAK-925 in adult subjects with IH.
CCI
CCI
CCI
CCI
Property of Takeda: For Non-Commercial Use Only and Subject t
rval betw
val b
period to
period 
recorded,
orded
ng comp
g com
ly 7
y 7 day
day
sked to re
ked to 
any safety
ny safe
edule fol
dule fo
rc
m
ys -2
) and 
) and -1
Baseline)
aseline
Co
∀#
a:
ed
cturnal po
urnal 
only on S
only on
scharge fr
charge
ked
ed
ed
Primary
rima
To ev
To e
of
pe
pe
S
pe
pe
pe
pe
pe
Subj
CI
d Su
nd S
e Applicable Terms of Use
S 
ed, 
d, 
have
ave
of total
of tota
nt index
t index
o sleepin
sleep
of
of
plica
Appli
the A
o the
t to 


TAK-925
Study No. TAK-925-2002
Page 16 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
Exploratory Objectives:
Subject Population: Male and female subjects aged 18 through 75 years, inclusive, with IH diagnosed according to 
the ICSD-3 criteria as verified by a previous nPSG and MSLT study performed within the last 10 years.
Number of Subjects:
Up to 40 randomized subjects
Number of Sites:
Approximately 21 sites in the United States and 3 sites 
in Japan.
Dose Levels:
TAK-925 112 mg
Placebo
Route of Administration:
TAK-925 or placebo IV infusion
Duration of Treatment:
Single 9-hour IV infusion in each treatment period, with a 
washout period of 24 hours between the end of infusion and 
the start of the next treatment
Period of Evaluation:
Up to 41 days (including screening up to 28 days, 
confinement for 6 days [Treatment Periods 1 to 2 with 
a minimum 24-hour washout between periods]), and 
end of study follow-up telephone call on Study Day 11 
(±2 days)
Main Criteria for Inclusion:
!
A diagnosis of IH, as defined by the ICSD-3, as verified by a previous nPSG and MSLT study performed within 
the last 10 years.
!
Onset of hypersomnia between 10 and 30 years of age.
!
Body mass index (BMI) of 18 through 33 kg/m2 inclusive.
!
Seven consecutive days of actigraphy supported by a sleep diary (recorded while the subject was wearing the 
actigraph) obtained prior to the nPSG (Study Day -2) shows an average nightly sleep duration of ≥420 minutes 
during the subject’s normal nocturnal sleep period.
!
nPSG (Study Day -2) demonstrates that subject does not have other comorbid sleep disorders or clinically 
significant nocturnal hypoxemia (O2 saturation ≤80% for ≥5% of total sleep time) and that their AHI is ≤10/hour, 
their periodic limb movement arousal index (PLMAI) is ≤15/hour, and total sleep time is ≥6.5 hours.
!
!
Subjects taking medication for treatment of excessive daytime sleepiness must be willing to discontinue 
medication prior to randomization into the study.
!
ESS score ≥11 at screening and on Day -2. Subjects with an ESS score of <11 who are taking stimulants at 
screening may continue the screening process and repeat the ESS at Study Day -2 following washout.
!
Blood pressure (BP) must be <140 mmHg (systolic) and <90 mmHg (diastolic) at screening and Study Day -2. BP 
measures should be obtained after the subject has been resting for a minimum of 10 minutes and may be repeated 
3 times if the BP is elevated above these parameters. The median BP reading will be used.
CCI
CCI
Property of Taked
jects taki
cts ta
medicatio
edicati
ESS s
ESS
scre
!
pe
pe
ms of Use
of
of
e Terms
For Non-Commercial Use Only and Subject to the Applicable T
osed 
sed acc
ac
0 years.
year
ble
the Unit
he Unit
lic
ration:
ion
acebo IV 
ebo IV
the
f Evalua
Evalu
41 days
41 day
nfinemen
finem
a minim
minim
end o
end 
(±2
(±
bje
nl
, as verif
 as ve
d 30 year
30 yea
ough 33
ugh 33
igraphy s
graphy
o the nPS
the nP
mal noctu
al noc
) demo
demon
o
nal hypo
al hyp
imb mo
imb m v
O
eda: Fo


TAK-925
Study No. TAK-925-2002
Page 17 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
Main Criteria for Exclusion:

Average nightly sleep duration is ≤8 hours (480 minutes) and the subject has insufficient sleep syndrome as 
evidenced by sleeping >2 hours/night more on “off-days” relative to “work days” as determined by actigraphy 
and sleep diary obtained prior to the nPSG (Study Day -2).

Resting heart rate (HR) outside of the range of 40 to 90 beats per minute, off stimulants.

Screening ECG reveals a QT interval with Fridericia correction method >450 ms (men) or >470 ms (women).

Usual bedtime later than 2400 (midnight) or an occupation requiring nighttime shift work or variable shift work 
within the past 6 months, or travel with significant jet lag within 14 days before Study Day -2.

History of sleep disorder other than IH, based on interviews at the screening visit, such as obstructive sleep apnea 
(OSA), restless legs syndrome, or periodic limb movements of sleep (PLMS) associated with arousals.

Use of any over the counter or prescription medications with stimulating properties within 7 days prior to dosing 
or 5 half-lives (whichever is longer) that could affect the evaluation of excessive daytime sleepiness, or any use of 
sodium oxybate within 4 weeks of screening.

Nicotine dependence that is likely to have an effect on sleep (eg, a subject who routinely awakens at night to 
smoke) or challenge the conduct of this study (smokes ≥10 cigarettes/day) and/or an unwillingness to discontinue 
all smoking and nicotine use during the confinement portion of the study (Day -2 to Day 4).

Caffeine consumption of more than 600 mg/day for 7 days before Study Day 1 (1 serving of coffee is 
approximately equivalent to 120 mg of caffeine) and/or unwilling to discontinue all caffeine during the 
confinement portion of the study (Day -2 to Day 4).

Alcohol use that is likely to have an effect on sleep and/or an unwillingness to discontinue all alcohol use from 72 
hours before check-in through discharge on Study Day 4.

History or presence of any unstable medical condition, behavioral or psychiatric disorder (including major 
depression or active suicidal ideation), or surgical history that could affect the safety of the subject or interfere 
with study efficacy, safety, PK assessments, or the ability of the subject to complete the study per the judgment 
of the investigator.
Main Criteria for Evaluation and Analyses:
The primary endpoints for this study are:

Percentage of subjects who experience at least 1 treatment-emergent adverse event (TEAE).

Percentage of subjects who meet the markedly abnormal criteria for clinical safety laboratory tests at least once 
post a regimen.

Percentage of subjects who meet the markedly abnormal criteria for vital sign measurements at least once post a 
regimen.

Percentage of subjects who meet the markedly abnormal criteria for 12-lead safety ECG parameters at least once 
post a regimen.
The secondary endpoints for this study are:

TAK-925 PK parameters:
–
Observed plasma concentration at the end of infusion (Ceoi).
–
Area under the plasma concentration-time curve from time 0 to infinity (AUC∞).
–
Area under the plasma concentration-time curve from time 0 to time of the last quantifiable concentration 
(AUClast).
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 18 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
The exploratory endpoints for this study are:
Statistical Considerations:
Standard summaries of TEAEs, adverse events of special interest (AESIs), clinical safety labs, vital signs, and ECGs 
will be performed. Where appropriate, BP and QT parameters will be summarized (N, mean, SD, median, minimum 
and maximum) for baseline, post-dose, change from baseline, and change from time-matched baseline to post-dose by 
treatment.
The observed HR and BP will be analyzed using linear mixed effect model for repeated measures in crossover studies. 
The model will include sequence, period, treatment, time points, and treatment by time point interaction as fixed 
effects and a random effect for subject. The estimated mean HR and BP for each treatment and the associated standard 
error and 95% CI will be extracted from the model at each time, along with all pairwise differences from placebo and 
associated standard errors, 95% CIs, and p-values. The same quantities, averaged over all timepoints during the 
infusion and post the end of the infusion, will also be extracted from the model using appropriate contrasts.
Individual plasma concentrations of TAK-925 
and PK parameter estimates will be listed for each 
subject and summarized using descriptive statistics, as appropriate.
Sample Size Justification:
Up to 40 subjects are planned to be randomized equally to each treatment sequence to ensure 36 subjects complete the 
study. This number of subjects is typical for phase 1 crossover study designs and is considered sufficient for 
assessment of safety.
In addition, when the true difference between TAK-925 and placebo is minimal, 
the chance to observe the same event is no more than 10%. Non-informative prior distributions were used in the above 
probability calculation. Allowing for 4 dropouts (10%), 40 subjects are planned to be randomized.
CCI
CCI
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
of
of
(AESIs)
AESIs
will be su
ill be 
e, and ch
e, and c
r mixed e
mixed
nt, time p
t, time
mated me
mated m
model at 
model
p-values.
values
n, will al
, will
f TAK
TAK-92
escriptive
escripti
ubj
nned to b
ned to
f subjects
ubjec
y.y.
ce to obs
e to ob
ability ca
ability c
Co
of
bject to the Applicabl
For 
: Fo
da: 
keda
CCI
CCI


TAK-925
Study No. TAK-925-2002
Page 19 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
3.0
STUDY REFERENCE INFORMATION
3.1
Study-Related Responsibilities
The sponsor will perform all study-related activities with the exception of those identified in the 
Transfer of Regulatory Obligations. The vendors identified in the template for specific 
study-related activities will perform these activities in full or in partnership with the sponsor.
3.2
Principal Investigator/Coordinating Investigator
Not applicable.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 20 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
3.3
List of Abbreviations
AE
adverse event
AESI
adverse event of special interest
AHI
Apnea-Hypopnea Index
ALT
alanine aminotransferase
AST
aspartate aminotransferase
AUC∞
area under the plasma concentration-time curve from time 0 to infinity
AUClast
area under the plasma concentration-time curve from time 0 to time of the last quantifiable 
concentration
bpm
beats per minute
BMI
body mass index
BP
blood pressure
Ceoi
observed plasma concentration at the end of infusion
CHO
Chinese hamster ovary
CI
confidence interval
CL
total clearance after IV administration
Cmax
maximum observed plasma concentration
CRO
contract research organization
C-SSRS
Columbia Suicide Severity Rating Scale
DBP
diastolic blood pressure
DSM-5
Diagnostic and Statistical Manual of Mental Disorders, Edition 5
ECG
electrocardiogram
eCRF
electronic case report form 
EDS
excessive daytime sleepiness
EEG
electroencephalogram
ESS
Epworth Sleepiness Scale
FDA
Food and Drug Administration
FSH
follicle-stimulating hormone
GCP
Good Clinical Practice
HR
heart rate
ICH
International Council for Harmonisation
ICSD-3
International Classification of Sleep Disorders-3
IEC
independent ethics committee
IH
idiopathic hypersomnia
IRB
institutional review board
IV
intravenous(ly)
IVRS
interactive voice response system
IWRS
interactive web response system
CCI
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
y
e of the la
of the
nfusion
nfusion
ion
ncentratio
centr
ion
rity Rat
ty R in
sure
sure
Statistica
atistic
gram
ram
c case rep
case re
sive dayt
ve day
ectroence
troen
Epwort
Epwo
Foo
F
D-3
EC
IH
IH
IR
I


TAK-925
Study No. TAK-925-2002
Page 21 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
LFT
liver function test
LS
least square
MedDRA
Medical Dictionary for Regulatory Activities
MSLT
multiple sleep latency test
MWT
Maintenance of Wakefulness Test
nPSG
nocturnal polysomnography
NT1
narcolepsy type 1
NT2
narcolepsy type 2
OSA
obstructive sleep apnea
OTC
over the counter
OX
orexin
OX1R
orexin type-1 receptor
OX2R
orexin type-2 receptor
PK
pharmacokinetic(s)
PLMAI
Periodic Limb Movement Arousal Index
PLMS
Periodic Limb Movements of Sleep
PTE
pretreatment event
PSG
polysomnogram
REM
rapid eye movement
RLS
restless legs syndrome
RT
reaction time
SAE
serious adverse event
SAP
statistical analysis plan
SBP
systolic blood pressure
SC
subcutaneous(ly)
SUSAR
suspected unexpected serious adverse reaction
t1/2z
terminal disposition phase half-life
TEAE
treatment-emergent adverse event
tmax
time of first occurrence of Cmax
ULN
upper limit of normal
Vss
volume of distribution at steady state after IV administration
Vz
volume of distribution during the terminal disposition phase after IV administration
WHO
World Health Organization
CCI
CCI
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
dex
ex
ep
nt
ndrome
drome
me
adverse e
dverse
stical ana
stical a
systolic b
stolic 
subcu
subc
su
s
Vz
WH
WH
e O


TAK-925
Study No. TAK-925-2002
Page 22 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
3.4
Corporate Identification
TDC Japan
Takeda Development Center Japan
TDC Americas
Takeda Development Center Americas, Inc.
TDC
TDC Japan, TDC Asia, TDC Europe and/or TDC Americas, as applicable
Takeda
TDC Japan, TDC Asia, TDC Europe and/or TDC Americas, as applicable
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 23 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
4.0
INTRODUCTION
4.1
Background
4.1.1
Orexin and Idiopathic Hypersomnia
Orexin (OX) is a neuropeptide and the orexinergic system is a major wake-promoting system of 
the brain. Two orexinergic neuropeptides, OX-A and OX-B, have been identified to date. These 
neuropeptides exert effects via 2 types of receptors: orexin type-1 receptor (OX1R) and orexin 
type-2 receptor (OX2R). OX-A has a high affinity to OX1R and OX2R, and OX-B has a high 
affinity to OX2R. The 2 types of OX receptors have a distinct distribution in the arousal network: 
the locus coeruleus contains only OX1Rs, the tuberomammillary nucleus contains only OX2Rs, 
and both receptor types occur in the dorsal raphe nucleus and ventral tegmental area. The 2 types 
of OX receptors also make distinct contributions to the regulation of arousal. OX2Rs in the 
tuberomammillary nucleus are essential for the maintenance of wakefulness, whereas both 
receptor types are required for the inhibition of rapid eye movement (REM) sleep [1].
The pathological loss of orexinergic neurons is associated with the development of narcolepsy 
type 1 (NT1) [2]. Narcolepsy with cataplexy, or NT1, has been defined by International 
Classification of Sleep Disorders, Edition 3 (ICSD-3) criteria as having low levels of orexin in 
cerebrospinal fluid (<110 pg/mL; <30% of normal levels), coming from the nearly complete loss 
of orexin producing neurons [3].
Idiopathic hypersomnia (IH), defined by ICSD-3, is a chronic neurological disorder that results in 
excessive daytime sleepiness and is frequently accompanied by long nocturnal or daytime sleep, 
unrefreshing sleep, difficulty in awakening, cognitive dysfunction, and autonomic symptoms [4].
The etiology of the condition is unknown. Orexin levels in patients with IH are within normal 
limits. IH is thought to be a relatively rare disease with the prevalence rate of 0.02% to 0.010% [5].
However, the lack of clear distinguishing symptoms, the unknown mechanism of disease, and lack 
of a diagnostic biomarker result in difficulties in discriminating IH from other types of 
hypersomnia, and thus the prevalence remains unclearly established.
Very few clinical studies have been conducted for the treatment of IH. A double-blind 
placebo-controlled crossover study with a treatment period of 3 weeks each with 200 mg of 
modafinil vs placebo in 33 drug-free adult IH patients without long sleep according to ICSD-2 
criteria found that modafinil significantly decreased the Epworth Sleepiness Scale (ESS) by 
4.5 points. Change in sleep latency on the Maintenance of Wakefulness Test (MWT) versus 
placebo was not significant. The clinical global impression improved significantly on modafinil 
from baseline to the last visit on treatment [6]. Medications used for the treatment of IH include 
stimulants such as modafinil, armodafinil methylphenidate, dextroamphetamine, and pemoline as 
well as in some patients, sodium oxybate, clarithromycin, and flumazenil. Antidepressants with 
activating effects such a bupropion and venlafaxine may also be used. Modafinil is the only drug 
that had a marketing authorization in some European countries for the treatment of patients with 
IH. However, the European Medicines Agency withdrew the indication of modafinil for the 
treatment of IH because the risk for development of skin or hypersensitivity reactions and 
neuropsychiatric disorders outweighed the evidence for clinically important efficacy. There is no 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 24 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
gold standard treatment for IH. As such, there is a huge unmet medical need for an effective 
treatment of the excessive daytime sleepiness (EDS) in this condition.
4.1.2
TAK-925
TAK-925 is a first-in-class OX2R-selective agonist. TAK-925 has a half-maximal effective 
concentration of 5.5 nM in OX2R– Chinese hamster ovary (CHO) cells, versus >30 μM in OX1R–
CHO cells, indicating over 5,000-fold selectivity for OX2R. In vivo pharmacology studies 
demonstrated significant effects of TAK-925 on increasing wakefulness and decreasing 
cataplexy-like events in the OX/ataxin-3 transgenic mouse model of narcolepsy. In contrast,
TAK-925 did not show an arousal effect in OX2R knock-out mice, consistent with selectivity for 
OX2R. In addition, the arousal effect of TAK-925 after single dosing was demonstrated in 
3 different species of wild-type animals without orexin deficiency, including mice, cynomolgus 
monkeys, and marmosets during their normal sleep phase. These preclinical studies suggest that 
TAK-925 should show arousal effects in hypersomnolent states, whether or not due to orexin 
deficiency.
The first-in-human phase 1 study (TAK-925-1001), was conducted in Japan. This study was 
designed to assess the safety, tolerability, pharmacokinetics (PK), and PD of single, ascending 
doses of TAK-925 when administered via a 9-hour IV infusion to healthy adult and healthy elderly 
subjects (aged ≥65 years old) and subjects with NT1. Single doses ranging from 7 to 240 mg in 
healthy subjects, and single doses of 5, 11.2, and 44.8 mg tested in subjects with NT1, were safe 
and well-tolerated with no severe adverse events (AEs) or serious adverse events (SAEs). All AEs 
except influenza (considered as moderate) were mild in severity. A single event of euphoric mood 
was reported for a subject receiving 44.8 mg TAK-925, the event was considered related to study
drug and resolved the same day. All cardiovascular-related AEs (increased blood pressure [BP], 
pulse rate increased) were considered mild by the investigator. The incidence of increased BP was 
increased in a dose-dependent manner starting from 134 mg (2 of 6 healthy adult subjects [33.3%]) 
and was most evident in the 240-mg group (4 of 6 healthy adult subjects [66.7%]). At the same 
dose of 112 mg, the incidence of increased BP was higher in Cohort 3 healthy elderly subjects (3 
of 6 subjects [50.0%]), compared with Cohort 1 and 2 healthy adult subjects (2 of 6 subjects 
CCI
Property of Takeda: For No
an phase
n pha
sess the 
ess th
K-925 w
925
(aged 
aged ≥
y subjec
y subje
well
well-to
ubject to the Applicable Terms of Use
ve
M in OX
n OX
studi
studies
e
reasing
reasing
sy. In co
. In c
ent with
nt wit
as demo
s dem
cluding
ludin
preclinic
preclin
s, wheth
whe
except i
xcept
was r
was
dr
d
Non-Commercial Use Only and Subj


TAK-925
Study No. TAK-925-2002
Page 25 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
[33.3%]). Dose-related increases in BP and pulse after single dosing were observed in healthy 
cohorts. 
.
Following a single IV infusion, mean plasma systemic exposure of TAK-925 increased 
approximately dose proportionally across cohorts. On average, time to reach plateau was 
approximately 3 hours and the plasma terminal elimination t1/2 ranged from approximately 3 to 
5 hours across all doses. TAK-925 exposure was increased by <30% in elderly subjects (aged 65 to 
80 years) possibly due to decreased hepatic clearance. Furthermore, a proof-of-mechanism (POM) 
study in sleep-deprived healthy subjects was conducted in the United States (TAK-925-1002). 
 All regimens were well-tolerated with no severe or SAEs, and most AEs 
were mild. A single event of euphoric mood was reported for a subject during treatment with 
112 mg TAK-925; the event was considered mild in intensity, related to study drug, and resolved 
the following day. Changes in DBP appeared to increase with increasing concentration of 
TAK-925 but there were no apparent trends in the change from time-matched baseline in heart rate 
(HR) or SBP when compared to TAK-925 plasma concentration. Lastly, another study, 
TAK-925-1003, is evaluating both NT1 subjects (orexin deficient) as well as narcolepsy type 2 
(NT2) subjects (orexin levels though to be within normal) with TAK-925 administered as a 9-hour 
IV infusion for 7 days.
For more detailed background on TAK-925 nonclinical and clinical studies, please refer to the 
Investigator's Brochure.
The purpose of this study is to evaluate the safety, tolerability, PK, and PD of a single IV infusion 
of TAK-925 in subjects with IH to support further development of TAK-925 as a potential 
treatment for this condition.
4.2
Rationale for the Proposed Study
Results from Study TAK-925-1002 in sleep-deprived subjects suggest that there may be potential
benefit of TAK-925 in other patient populations who have EDS associated with primary sleep 
disorders that are not associated with orexin deficiency, including patients with NT2, IH, and EDS 
associated with obstructive sleep apnea (OSA). Hence in this proposed phase 1b study, adult 
patients diagnosed with IH according to the ICSD-3 criteria will be evaluated.
CCI
CCI
CCI
Property of Takeda: For Non-Commercial Use On
ellll-toler
tole
od was r
d wa
ered mi
ered m
appeared
ppear
ent 
nt trend
tren
o TAK
TAK
g both N
both
vels thou
els th
backgro
ackg
rochure
rochu
e of this
of th
925 in s
925 in
ment f
ent for 
f
t to the Applicable
creased 
eased
plateau 
lateau
m appro
appro
elderly s
elderly
proof
proof
ited Stat
ted St
4.2
Res
Res
b
y and
Only a
ject t
ubjec
Subj
nd S
Terms of Use
erms
Te
ble T


TAK-925
Study No. TAK-925-2002
Page 26 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
4.3
Benefit/Risk Profile
TAK-925 is a first-in-class OX2R-selective agonist. Nonclinical pharmacology studies 
demonstrated that TAK-925 had arousal effects in hypersomnolent states both in animals with 
orexin deficiency (mice) and animals without orexin deficiency (mice, cynomolgus monkeys and 
marmosets). To explore potential effects in humans, the TAK-925-1001 (first-in-human) and 
TAK-925-1002 studies included healthy adult subjects, healthy elderly subjects, narcolepsy 
subjects with orexin deficiency (NT1), and sleep-deprived healthy subjects. In this proposed phase 
1b study, subjects with IH will be evaluated. The results may provide an early indication of 
whether TAK-925 has PD effects in subjects with IH and is safe and well-tolerated.
Increased SBP was noted in the safety pharmacology study in monkeys. This is considered a 
potentially on-mechanism effect based on published literature [7]. In the completed clinical studies 
of TAK-925, mild treatment-emergent adverse events (TEAEs) of increased BP and HR have been 
observed, which resolved after treatment discontinuation. The 112 mg dose level proposed in this 
study was found to be safe and tolerable in these studies in which healthy subjects received single 
IV doses of TAK-925 up to 240 mg (Study TAK-925-1001). In sleep-deprived healthy subjects, 
administration of the 112 mg dose level resulted in some elevation of placebo-adjusted mean DBP 
of approximately 6 to 9 mmHg throughout much of the nocturnal infusion time although not 
reported as TEAEs (Study TAK-925-1002). In this study, BP will be frequently monitored for all 
subjects. As TAK-925 has been shown to have a short elimination half-life, discontinuation of 
infusion, if needed, would be expected to result in rapid resolution of increased BP. Stopping 
criteria for effects on BP are provided (see Section 6.3).
CCI
Property of Takeda: For Non-Commercial Use Only an
gy stud
stu
y
shed lite
shed lit
se even
e event
discont
discon i
e in the
e in th
(Study
Study
e level r
level 
g throug
throu
TAK
AK-92
9
as been 
been
ould be
ould b
plicable Terms of Use
ys and 
 and
and 
and 
lepsy 
lepsy 
proposed
ropos
dicat
icatioio
erated.
ated.
on BP a
n BP 
and Subject to the App


TAK-925
Study No. TAK-925-2002
Page 27 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
5.0
STUDY OBJECTIVES AND ENDPOINTS
5.1
Objectives
5.1.1
Primary Objective
The primary objective of this study is to evaluate the safety and tolerability of administering a 
single IV infusion of TAK-925 to adult subjects with IH.
5.1.2
Secondary Objective
The secondary objective of this study is to investigate the PK of a single IV infusion of TAK-925 
in adult subjects with IH.
5.1.3
Exploratory Objectives
5.2
Endpoints
5.2.1
Primary Endpoints
!
Percentage of subjects who experience at least 1 TEAE.
!
Percentage of subjects who meet the markedly abnormal criteria for clinical safety laboratory
tests at least once post a regimen.
!
Percentage of subjects who meet the markedly abnormal criteria for vital sign measurements at
least once post a regimen.
!
Percentage of subjects who meet the markedly abnormal criteria for 12-lead safety
electrocardiogram (ECG) parameters at least once post a regimen.
5.2.2
Secondary Endpoint
!
TAK-925 PK parameters:
–
Observed plasma concentration at the end of infusion (Ceoi).
–
Area under the plasma concentration-time curve from time 0 to infinity (AUC∞).
–
Area under the plasma concentration-time curve from time 0 to time of the last quantifiable
concentration (AUClast).
CCI
Property of Takeda: For Non-Commercial Us
who ex
who e
ects wh
cts w
ce post a
e post
of subje
of subj
ce post a
ce post
centage 
entage
lectroca
ectroc
5.2.2
.2.2
!
t to the Applicable Terms of Use
tering a
ering 
V infusi
infus
Use Only and Subject t


TAK-925
Study No. TAK-925-2002
Page 28 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
mmercial Use Only and Subject to the Applicable Terms of Us


TAK-925
Study No. TAK-925-2002
Page 29 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
6.0
STUDY DESIGN AND DESCRIPTION
6.1
Study Design
This is a phase 1b, randomized, double-blind, placebo-controlled, 2-period, 2-treatment crossover 
study to evaluate the PK, 
safety, and tolerability of a single IV infusion dose of TAK-925 in 
subjects with IH. Subjects will be males and females aged 18 through 75 years, inclusive, with IH 
diagnosed according to the ICSD-3 criteria (Appendix F) as verified by a previous nocturnal 
polysomnography (nPSG) and multiple sleep latency test (MSLT) study performed within the last 
10 years. 
The treatment periods begin on Day 1 of Treatment Period 1 (Study Day 1) with Treatment 
Period 2 commencing on Study Day 3. In the morning of Day 1 of Treatment Period 1, eligible 
subjects will be randomized to 1 of 2 sequence groups as listed in Table 6.a. After randomization, 
the subject will be dosed in 2 treatment periods according to the order defined by the sequence 
group to which he/she is randomized. On Day 1 of each treatment period, TAK-925 (or placebo) 
will be administered as a single 9-hour IV infusion commencing at approximately 0800. The 
infusion will be terminated at approximately 1700.
. 
A summary of the treatment assignment and sequence is presented in Table 6.a. The Schedule of 
Study Procedures is included in Appendix A and Treatment Day 1 Hourly Schedule is in Appendix 
B.
Table 6.a
Summary of Treatment Assignment for Each Sequence
Sequence
N
Treatment Period 1
Treatment Period 2
1
20
TAK-925
112 mg
Placebo
2
20
Placebo
TAK-925
112 mg
At the screening visit, eligible subjects who have an ESS score of ≥11 will complete medical 
histories and physical examinations, semi-recumbent vital signs assessment, a 12-lead ECG, Beck 
Depression Inventory II (BDI-II), Columbia Suicide Severity Rating Scale (C-SSRS), and clinical 
safety laboratory tests. Subjects with an ESS score of <11 who are taking stimulants at screening 
may continue the screening process and repeat the ESS at Study Day -2 following washout. A total 
of 40 subjects will be randomized so that at least 36 subjects will complete the study. To avoid 
enrollment of short sleepers with chronic sleep deprivation, prospective participants will complete 
approximately 7 consecutive days of actigraphy supported by a sleep diary beginning on Study 
Day -9 and ending on Study Day -3 (ie, the day before their Study Day -2 admission to the clinical 
unit), to ensure an average nightly sleep duration of ≥420 minutes (7 hours) during the subject’s 
normal nocturnal sleep period, and, if the subject’s average nightly sleep duration is ≤480 minutes 
CCI
CCI
Property of Takeda: For Non-Commercial Use Only 
d sequen
seque
x A and
an
eatment
atme
N
m
Com
For
eening v
ning 
s and ph
and 
ressio
ression n
fetet
Subject to the Applicable Terms of Use
sover 
over
925 in
925 i
ve, with
e, wit
nocturna
noctur
ed wit
d with
1) wi
with
th
i h
atment 
atment
able
ble 6.a
6
order de
rder d
ment per
ent p
ncing at
cing a
y y lab
may c
may
of
of 4
f
d Su
and S
ly an


TAK-925
Study No. TAK-925-2002
Page 30 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
(8 hours), that the subject does not have insufficient sleep syndrome (sleeping >2 hours/night more 
on “off days” than on “work days”). During screening, eligible subjects must discontinue their 
stimulant medications used for treatment of IH. Medications must be discontinued for a minimum 
of 7 days or at least 5 half-lives of each medication, whichever is longer, before the first day of
dosing (Day 1 of Treatment Period 1). Sodium oxybate must be discontinued at least 4weeks
before screening. 
The screening period is up to 28 days. Following screening, subjects who meet all screening entry 
criteria will be admitted to the clinical unit (Study Day -2). Semi-recumbent vital signs will be 
obtained following admission, and the ESS will be recorded in the late afternoon. An overnight 
8-hour nPSG will be performed commencing at approximately the subject’s normal bedtime (eg, 
between 2200 and 2300) to confirm that the subject does not have other comorbid sleep disorders 
or clinically significant nocturnal hypoxemia (O2 saturation ≤80% for ≥5% of total sleep time), 
and to confirm the apnea hypopnea index (AHI) is ≤10/hour and the periodic limb movement 
index associated with arousals (PLMAI) is ≤15/hour.
Safety assessments including BP, pulse, respiration 
rate, and ECG will be collected per the Schedule of Study Procedures (Appendix A).
On Day 1 of Treatment Period 1 (Study Day 1), all eligible subjects will be randomized and 
receive the first dose of study drug. TAK-925 or placebo will be administered as a single 9-hour IV 
infusion commencing at approximately 08:00.
tudy Days 2 and 4 are washout days.
 Safety assessments 
including AEs, vital signs, and ECGs will be recorded. During the study, AEs will be recorded, 
and clinical labs, vital signs, and safety ECGs will be obtained. Subjects will be discharged from 
the unit following completion of study exit procedures in the afternoon of Study Day 4 (Day 2 of
Treatment Period 2). 
Subjects will return to the study site or be contacted by telephone approximately 7 days (±2 days) 
following unit discharge for a safety check and all women of childbearing potential must return to 
the study site to complete a urine pregnancy test at the end-of-study visit. 
An overview of the inpatient unit study schedule is presented in Table 6.b.
CCI
CCI
CCI
Property of Takeda: 
AEs, vita
Es, v
cal labs
cal lab
it fo
it follo
llo
atme
atment
Subjec
Subje
fofoll
ercial Use Only
afety
afety as
a
y
dule of 
dule o
Day
Day 1),
1
y
AK
AK-925
9
ately 08
ely 0
bject to the Applicable Terms of Use
m
of
eks
ks
screenin
creen
l signs 
signs
l
oon. An
on. A
’s norm
s norm
r comorb
r como
r ≥5% o
≥5%
he perio
he per
Subje
d Su
and 
ly an
mer
omm
Com
on-C
Non
or N
: For


TAK-925
Study No. TAK-925-2002
Page 31 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
Table 6.b
Overview of the Inpatient Unit Study Schedule
Screening 
Period
Check-in and 
Baseline
Treatment Periods 1 and 2
End-of-Study Visit
Dosing
Washout
Study 
Days -28
to -3
Study Days -2 
(nPSG a) and -1 
(Baseline)
Study Days 1 and 3
Study drug 
administration/
 
PK, and safety 
assessments
Study Days 2 and 4 b
PK and safety 
assessments
Study Day 11 (±2 days)
Follow-up (in clinic or by
phone call)
Confinement
Study Day -2 to Study Day 4
nPSG: nocturnal polysomnography; 
 PK: pharmacokinetic.
a nPSG only on Study Day -2.
b Discharge from unit on Study Day 4.
6.2
Justification for Study Design, Dose, and Endpoints
6.2.1
Rationale for Study Design
This is a study with a 2-period Williams crossover design to evaluate the safety, tolerability, PK, 
 of TAK-925. The endpoints in such studies have smaller variability than those in the 
parallel design as the subjects are used as their own control. Such design has been previously used 
in other studies of drugs that have been evaluated for effects on wakefulness [8]. As previously 
shown, mean TAK-925 concentrations decline rapidly after the end of infusion with levels 
quantifiable up to 18 hours post-dose at a dose of 112 mg; hence, a greater than 24-hour period 
from the end of dosing of TAK-925 to the start of the next dosing is deemed sufficient to ensure 
adequate drug washout. The short washout interval also enables full confinement from Treatment 
Period 1 to Treatment Period 2, which will potentially reduce the dropout rates and increase study 
compliance. Some subjects with IH have severe daytime sleepiness despite their best efforts to stay 
awake.
6.2.2
Rationale for Dose
Based on the currently available information, this study will evaluate a single-dose of TAK-925 at 
112 mg.
Single-dose administration of TAK-925 in a slow infusion over 9 hours up to 240 mg in healthy 
adult subjects, up to 112 mg in healthy elderly subjects, and up to 44.8 mg in subjects with NT1, 
was well-tolerated with no major safety concerns. BP and HR increases were the most frequently 
reported TEAEs. While these increases were consistently observed with TAK-925 doses 
≥134.4 mg/day in healthy adult subjects (or 112 mg/day in healthy elderly subjects) with a greater 
incidence of these AEs at the maximum dose of 240 mg, no BP or HR increase AEs were reported 
with lower TAK-925 doses.
CC
I
CCI
CCI
CCI
Property of Takeda: Fo
onale f
onal
on the cu
n the c
mg.
mg.
Single
ngle-d
adul
adu tl
wa
w
on-Commercial Use Only and Subject to the Applicable Terms of Use
of
s o
±2 days)
±2 days)
n clinic o
linic 
ne call)
ne cal
m
he
oints
oints
er desig
r des
udies h
udies 
heir own
eir ow
evaluate
valua
ns declin
s dec
ose at a 
e at a
-925 to 
925 to
short w
hort w
iod 2, w
od 2, 
ects wit
cts wi
Non
For N


TAK-925
Study No. TAK-925-2002
Page 32 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
A single dose of 112 mg is selected to evaluate a dose of TAK-925 that is expected to produce 
wake-promoting effects, while maintaining an acceptable clinical safety profile in this IH subject 
population. 
6.2.3
Rationale for Endpoints
As this is a single-dose study, the standard safety endpoints for early clinical development will be 
included. In a safety pharmacology study of TAK-925 as well as in the first-in-human study
(TAK-925-1001), cardiovascular-related adverse findings including PR prolongation and 
elevation of BP and HR were reported. Based on these observations, the following assessments 
will be included:
!
TEAEs; subjects will be monitored closely throughout the study for any AEs.
!
Physical examinations.
!
Vital signs, including frequent monitoring of BP, pulse, and respiratory rate.
!
12-lead ECGs.
!
Clinical laboratory safety evaluations (standard hematology, serum chemistry, and urinalysis).
To characterize the PK of TAK-925 
administered as a single IV infusion dose 
to subjects with IH, the following PK parameters will be estimated as data permit.
!
AUC∞.
!
AUClast.
!
Cmax.
!
Ceoi.
!
Time of first occurrence of Cmax (tmax).
!
Terminal disposition phase half-life (t1/2z).
!
Volume of distribution at steady state after IV administration (Vss) (only for TAK-925).
!
Volume of distribution during the terminal disposition phase after IV administration (Vz) (only 
for TAK-925).
!
Total clearance after IV administration (CL) (only for TAK-925).
!
CCI
CCI
CCI
Property of Takeda: For Non-Commerci
5
ng PK p
g PK 
f fir
first o
st
erminal 
ermina
Vol
Vo um
l
!
V
Use Only and Subject to the Applicable Terms of Use
nical de
cal 
he first
 first
ng PR pr
ng PR
ions, th
ns, 
out the s
ut the 
of BP, p
of BP, p
ns (stan
ns (sta
m
T
ble T
ial 
rcia
CCI
CCI


TAK-925
Study No. TAK-925-2002
Page 33 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
CCI
Prope
perty of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 34 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
6.3
Premature Termination or Suspension of Study or Study Site
6.3.1
Criteria for Premature Termination or Suspension of the Study
The study will be completed as planned unless 1 or more of the following criteria are satisfied that 
require temporary suspension or early termination of the study:
!
New information or other evaluation regarding the safety or efficacy of the study drug that 
indicates a change in the known risk/benefit profile for the compound, such that the risk is no 
longer acceptable for subjects participating in the study.
!
Significant violation of GCP that compromises the ability to achieve the primary study
objectives or compromises subject safety.
!
If the interim analysis results meet the stopping criteria (see Section 13.2).
Other Safety Monitoring and Specific Stopping Criteria for Individual Subjects
!
Any subject who experiences a treatment-emergent serious AE or a severe AE that is 
considered related to treatment.
CCI
CCI
Property
!
and Subject to the Applicable Terms 
are sati
are sa
f the stu
the st
f
und, such
nd, su
o achiev
achie
ria (see 
ria (se
eria
ria for 
for
e
s of Use
an
f
an
erty of Takeda: For Non-Commercial Use Only a


TAK-925
Study No. TAK-925-2002
Page 35 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
6.3.2
Criteria for Premature Termination or Suspension of Study Sites
A study site may be terminated prematurely or suspended if the site (including the investigator) is 
found in significant violation of GCP, protocol, or contractual agreement, is unable to ensure 
adequate performance of the study, or as otherwise permitted by the contractual agreement.
6.3.3
Procedures for Premature Termination or Suspension of the Study or the 
Participation of Study Sites
In the event that the sponsor, an institutional review board (IRB)/independent ethics committee 
(IEC) or regulatory authority, elects to terminate or suspend the study or the participation of a 
study site, a study-specific procedure for early termination or suspension will be provided by the 
sponsor; the procedure will be followed by applicable study sites during the course of termination 
or study suspension.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 36 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
7.0
SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS
All entry criteria, including test results, need to be confirmed prior to randomization.
7.1
Inclusion Criteria
Subject eligibility is determined according to the following criteria prior to entry into the study:
1. In the opinion of the investigator, the subject is capable of understanding and complying with 
protocol requirements.
2. The subject signs and dates a written informed consent form and any required privacy 
authorization prior to the initiation of any study procedures.
3. The subject is male or female, aged 18 to 75 years, inclusive, at the time of informed consent.
4. A diagnosis of IH, as defined by the ICSD-3 (Appendix F), as verified by a previous nPSG and 
MSLT study performed within the last 10 years.
Note: If there is a potential subject with a history of IH whose diagnostic nPSG/MSLT was 
performed more than 10 years ago or is not available and the subject continues to experience 
symptoms consistent with IH, the PI will obtain a current nPSG/MSLT.
5. Onset of hypersomnia between 10 and 30 years of age.
6. Seven consecutive days of actigraphy supported by a sleep diary (recorded while the subject 
was wearing the actigraph) obtained prior to the nPSG (Study Day -2) shows an average 
nightly sleep duration of ≥420 minutes during the subject’s normal nocturnal sleep period.
7. nPSG (Study Day -2) demonstrates that subject does not have other comorbid sleep disorders 
or clinically significant nocturnal hypoxemia (O2 saturation ≤80% for ≥5% of total sleep time)
and that their AHI is ≤10/hour, their PLMAI is ≤15/hour, and that their total sleep time is 
≥6.5 hours.
8.
9. Subjects taking medication for treatment of EDS must be willing to discontinue medication 
prior to randomization into the study.
10. Body mass index (BMI) of 18 through 33 kg/m2 inclusive.
11. ESS score ≥11 at screening and on Day -2. Subjects with an ESS score of <11 who are taking 
stimulants at screening may continue the screening process and repeat the ESS at Study Day -2 
following washout (see Table 7.a).
12. Male subjects who are non-sterilized and their female sexual partners of childbearing potential 
must follow the contraception methods described in Appendix G. In addition, male subjects 
must agree to not donate sperm from the first dose of study drug until 5 half-lives plus 90 days 
after the last dose of study drug.
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
e study
e study
mplying
mply
uired pr
ired p
e time o
 time
verified
verifie
whose
whose
e and th
and 
a curren
curre
ars of ag
rs of
pported
ported
prior to t
rior to
utes dur
tes du
rates tha
tes th
urnal hy
urnal h
/hour, th
hour, 
s taking 
taking
to rando
o rand
Body
ody m
y
1. ESS 
ES
st
Non-C
r No
For N


TAK-925
Study No. TAK-925-2002
Page 37 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
13. Female subjects of childbearing potential who are sexually active with a non-sterilized male 
partner must agree to use a highly effective method of contraception as described in Appendix 
G from signing of informed consent until 5 half-lives of TAK-925 plus 30 days.
14. Female subjects who are post-menopausal or permanently sterile according to the definitions 
in Appendix G. 
15. Female subjects of childbearing potential must have a negative urine pregnancy test at 
screening and Study Day -1.
16. BP must be <140 mmHg (systolic) and <90 mmHg (diastolic) at screening and Study Day -2. 
BP measures should be obtained after the subject has been resting for a minimum of 
10 minutes and may be repeated 3 times if the BP is elevated above these parameters. The 
median BP reading will be used.
7.2
Exclusion Criteria
Any subject who meets any of the following criteria will not qualify for entry into the study:
1. Average nightly sleep duration is ≤8 hours (480 minutes) and the subject has insufficient sleep 
syndrome as evidenced by sleeping >2 hours/night more on “off-days” relative to “work days” 
as determined by actigraphy and sleep diary obtained prior to the nPSG (Study Day -2).
2. Positive urine screen for drugs of abuse and/or positive alcohol breathalyzer test at screening 
and/or Study Day -2. An exception at screening is made for stimulants or other drugs that the 
subject has been prescribed, but the drug screen must be negative at Study Day -2.
3. History of drug or alcohol abuse within the 12 months prior to screening (Diagnostic and 
Statistical Manual of Mental Disorders, Edition 5 [DSM-5 criteria]).
4. Women who are pregnant or breastfeeding.
5. Resting HR outside of the range of 40 to 90 bpm off stimulants.
6. Screening ECG reveals a QT interval with Fridericia correction method >450 ms (men) or 
>470 ms (women).
7. Usual bedtime later than 24:00 (midnight) or an occupation requiring nighttime shift work or 
variable shift work within the past 6 months, or travel with significant jet lag within 14 days 
before Study Day -2.
8. History of a sleep disorder other than IH, based on interviews at the screening visit, such as 
OSA, restless legs syndrome, or periodic limb movements of sleep (PLMS) associated with 
arousals.
9. Used of any over-the-counter (OTC) or prescription medications with stimulating properties 
within 7 days prior to dosing or 5 half-lives (whichever is longer) that could affect the 
evaluation of EDS, or any use of sodium oxybate within 4 weeks of screening (see Table 7.a).
10. Nicotine dependence that is likely to have an effect on sleep (eg, a subject who routinely 
awakens at night to smoke) or challenge the conduct of this study (smokes ≥10 cigarettes/day) 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 38 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
and/or an unwillingness to discontinue all smoking and nicotine use during the confinement 
portion of the study (Day -2 to Day 4).
11. Caffeine consumption of more than 600 mg/day for 7 days before Study Day 1 (1 serving of
coffee is approximately equivalent to 120 mg of caffeine) and/or unwilling to discontinue all 
caffeine during the confinement portion of the study (Day -2 to Day 4).
12. Alcohol use that is likely to have an effect on sleep and/or an unwillingness to discontinue all 
alcohol use from 72 hours before check-in through discharge on Study Day 4.
13. History or presence of any unstable medical condition, behavioral or psychiatric disorder 
(including major depression or active suicidal ideation), or surgical history that could affect the 
safety of the subject or interfere with study efficacy, safety, PK assessments, or the ability of 
the subject to complete the study per the judgment of the investigator.
14. Employee or family member of the investigator, study site, contract research organization 
(CRO), or sponsor.
15. Previously participated in a TAK-925 study or has participated in another investigational study 
within 4 weeks prior to the screening visit.
16. In the opinion of the clinical investigator, should not participate in the study.
17. Allergic to any excipient in the study drug.
18. History of epilepsy or seizures, including having had a single seizure or a history of childhood 
febrile seizures or has a clinically significant history of head trauma.
19. Positive test result for hepatitis B surface antigen, hepatitis C virus antibody, or human 
immunodeficiency antibody/antigen, at the screening visit. Note: Subjects with positive 
hepatitis B virus or hepatitis C virus serology may be enrolled if quantitative polymerase chain 
reaction for hepatitis B virus or hepatitis C virus RNA is negative.
20. Donated blood or plasma within 6 weeks prior to Study Day 1 or planning to donate blood or 
plasma within 12 weeks after study exit.
21. Answered “YES” on Questions 4 or 5 on the Suicidal Ideation subscale of the C-SSRS at 
screening (defined period as 3 months prior to screening) or evidence of suicidal behavior 
within 6 months of screening as measured by the Suicidal Behavior subscale of the C-SSRS.
22. Diagnosis of major depressive disorder (DSM-5) within the past 6 months or BDI-II total score 
of >16 at the screening visit.
23. Renal creatinine clearance ≤60 mL/min at the time of screening and Study Day -2.
24. History of cerebral ischemia, transient ischemic attack, intracranial aneurysm, or arteriovenous 
malformation.
25. Known coronary artery disease, a history of myocardial infarction, angina, cardiac rhythm 
abnormality, or heart failure.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 39 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
26. Abnormal laboratory test values that suggest a clinically significant underlying disease or any 
subject with transaminase (alanine aminotransferase [ALT] and/or aspartate aminotransferase 
[AST]) >2.0 ×upper limit of normal (ULN) at the screening visit or Study Day -2.
27. Unable to refrain from or anticipates using food products listed in Table 7.b, beginning 
approximately 7 days prior to administration of the first dose of study drug, through Study Day 
4 inclusive.
7.3
Excluded Medications
Subjects must be instructed not to take any medications during the study, including OTC products, 
without first consulting with the investigator. Occasional use of acetaminophen and aspirin is 
allowed.
Subjects who require treatment with 1 or more of prohibited medications should be excluded or 
discontinued (as appropriate) from the study. If a subject is prescribed treatment with a prohibited 
medication during the conduct of the study, the investigator should contact the sponsor or designee 
to review the relevant clinical information and medication treatment to determine subject 
disposition.
Additional detailed guidance on excluded/allowed medications may be provided in separate 
reference documentation provided to study sites.
Table 7.a provides a list of medications/drug classes that are prohibited for 7 days or 5 half-lives, 
before the first day of dosing (Day 1 of Treatment Period 1).
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 40 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
Table 7.a
Prohibited Drug Classes
Prohibited Drug Classes
Starting from 7 days or 5- half-lives, whichever 
period is longer for the drug classes listed below, 
before administration of study drug
Psychostimulants
Including methylphenidate hydrochloride, modafinil, 
armodafinil, solriamfetol, pitolisant, 
methamphetamine hydrochloride, pemoline, 
venlafaxine, duloxetine, atomoxetine, reboxetine, 
esreboxetine, decongestants, diet aids
Antipsychotic drugs
Benzodiazepines (minor tranquilizers)
Mood stabilizers
Sedating anticonvulsants
Sedative hypnotics
Parkinson’s disease/RLS drugs
Adrenocorticosteroids
Interferon, interleukin-formulation
Muscle-relaxants (eg, baclofen)
Sedating antihistamines and decongestants
Non-sedating antihistamines are allowed
Sodium oxybate
Requires no use for 4 weeks prior to screening
Sedating antitussives
Sedating antiemetics
Sedating analgesics
Sedating antihypertensives
St. John's wort, kava-kava, gingko biloba, health foods 
containing melatonin. 
Known in vivo CYP3A inhibitors or inducers:
1.
Potent CYP3A inhibitors: boceprevir, clarithromycin, 
cobicistat, conivaptan, danoprevir, ritonavir, 
elvitegravir, indinavir, saquinavir, idelalisib, 
itraconazole, ketoconazole, lopinavir, nefazodone, 
nelfinavir, paritaprevir, ombitasvir, dasabuvir, 
posaconazole, telaprevir, tipranavir, troleandomycin, 
voriconazole.
2.
Moderate CYP3A inhibitors: amprenavir, aprepitant, 
atazanavir, casopitant, cimetidine, ciprofloxacin, 
clotrimazole, crizotinib, cyclosporin, diltiazem, 
dronedarone, erythromycin, fluconazole, fosamprenavir, 
fluvoxamine, miconazole, imatinib, istradefylline, 
tofisopam, verapamil.
3.
Potent CYP3A inducers: carbamazepine, enzalutamide, 
mitotane, phenobarbital, phenytoin, rifabutin, 
rifampicin.
4.
Moderate CYP3A inducers: bosentan, efavirenz, 
etravirine.
CYP3A4: cytochrome P450 3A4; RLS: restless legs syndrome.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 41 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
7.4
Diet, Fluid, and Activity Control
7.4.1
Diet and Fluids
Subjects will receive 3 standardized meals per day each including approximately 30% fat (relative 
to the total calories) during confinement in the unit. Breakfast will be served at approximately 
0700 each morning; lunch and dinner will be served at standardized times so as not to coincide or 
interfere with clinical testing 
Subjects will follow the restrictions of food, drinks, and other products listed in Table 7.b.
Table 7.b
List of Restricted Food, Drinks and Other Products
Category
Screening Period (Days -28 to -3)
Inpatient Day -2 to Discharge on 
Day 4
Tobacco- and nicotine-containing 
products
Restricted to less than 10 cigarettes 
per day
Completely restricted
Alcohol
Restricted for 72 hours prior to 
check-in
Completely restricted
Xanthine and/or caffeine
No more than 600 mg/day 7 days 
before dosing
Completely restricted
Food Products
Grapefruit/grapefruit juice and 
Seville oranges
Completely restricted 7 days before 
dosing
Completely restricted
Other fruit juices
Restricted for 12 hours before and 
after administration of each dose of 
study drug on pharmacokinetic 
sampling days (Days 1 and 3 of 
each treatment period). 
Consumption of all fruits other than 
grapefruit and Seville oranges is 
allowed on all days of the study.
Mustard greens (ie, kale, broccoli, 
watercress, collard greens, kohlrabi, 
Brussel sprouts, and mustard)
Completely restricted 7 days before 
dosing
Completely restricted
Charbroiled meat
Completely restricted 7 days before 
dosing
Completely restricted
7.4.2
Activity
Subjects will avoid unaccustomed strenuous physical activity (ie, weight lifting, running, 
bicycling) from the screening visit until administration of the initial dose of study drug, throughout 
the study (including the washout interval between treatment periods), and until the follow-up visit. 
Short supervised walks outside the unit are permitted on washout days.
CCI
Property of Takeda: For Non
e, brocco
brocc
reens, k
eens, ko
on-Commercial Use Only and Subject to the Applicable Terms of Use
latative
ive
ately
ately
coioincid
nci
i
Table
Table 7
patient D
patient
Day
Day 4
e A
Com
Com
to
bje
ay 7 day
7 da
y
d S
y a
estricted 7
ricted
On
Us
nd musta
d mus
on
eat
eat
F
ke
2
Act
Ac
Subjec
Subje
bicy
bicy
th


TAK-925
Study No. TAK-925-2002
Page 42 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
7.5
Criteria for Discontinuation or Withdrawal of a Subject
The primary reason for discontinuation or withdrawal of the subject from the study or study drug 
should be recorded in the electronic case report form (eCRF) using the following categories. For 
screen failure subjects, refer to Section 9.8.
1. Pretreatment event (PTE) or AE: The subject has experienced a PTE or AE that requires early 
termination because continued participation imposes an unacceptable risk to the subject’s 
health or the subject is unwilling to continue because of the PTE or AE.

Liver function test (LFT) abnormalities:
Study drug should be discontinued immediately with appropriate clinical follow-up 
(including repeat laboratory tests, until a subject’s laboratory profile has returned to 
normal/baseline status, see Section 9.4), if the following circumstances occur at any time 
during study drug treatment:
–
ALT or AST >8 × ULN, or
–
ALT or AST >3 × ULN in conjunction with elevated total bilirubin >2 × ULN or 
international normalized ratio >1.5, or
–
ALT or AST >3 × ULN with appearance of fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, fever, rash and/or eosinophilia (>5%).

Suicidality:
–
Study drug should be discontinued immediately for subjects at imminent risk of suicide 
per the investigator’s clinical judgment.

BP and HR increase: Criteria for stopping an infusion due to elevated BP or HR are defined 
as follows (“sustained” is defined as 2 readings separated by approximately 15 minutes):
–
Sustained SBP ≥160 mmHg or sustained post-dose change from pre-dose baseline of 
≥30 mmHg.
–
Sustained DBP ≥100 mmHg or sustained post-dose change from pre-dose baseline of 
≥30 mmHg
–
Sustained HR >100 bpm or sustained post-dose change from pre-dose baseline of 
≥30 bpm.

Seizures

Severe changes in mood.

Any subject who experiences a treatment-emergent serious AE or a severe AE that is 
considered related to treatment.
Note: The reasons above should be recorded on the eCRF if the PTE or AE is chosen as the 
primary reason of discontinuation.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 43 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
2. Significant protocol deviation: The discovery post-randomization that the subject failed to 
meet protocol entry criteria or did not adhere to protocol requirements, and continued 
participation poses an unacceptable risk to the subject’s health.
3. Lost to follow-up: The subject did not return to the clinic and attempts to contact the subject 
were unsuccessful. Attempts to contact the subject must be documented in the subject’s source 
documents.
4. Voluntary withdrawal: The subject (or subject’s legally acceptable representative) wishes to 
withdraw from the study. The reason for withdrawal, if provided, should be recorded in the 
eCRF. 
Note: All attempts should be made to determine the underlying reason for the withdrawal and, 
where possible, the primary underlying reason should be recorded (ie, withdrawal due to an 
AE should not be recorded in the “voluntary withdrawal” category). Similarly, lack of efficacy 
should not be recorded in the “voluntary withdrawal” category.
5. Study termination: The sponsor, IRB, IEC, or regulatory agency terminates the study.
6. Pregnancy: The subject is found to be pregnant.
Note: If the subject is found to be pregnant, the subject must be withdrawn immediately. The 
procedure is described in Appendix G.
7. Other:
Note: The primary reason should be recorded in the “specify” field of the eCRF.
7.6
Procedures for Discontinuation or Withdrawal of a Subject
The investigator may discontinue a subject’s study participation at any time during the study when 
the subject meets the study termination criteria described in Section 7.5. In addition, a subject may 
discontinue his or her participation without giving a reason at any time during the study. Should a 
subject’s participation be discontinued, the primary criterion for termination must be recorded by 
the investigator. In addition, efforts should be made to perform all procedures scheduled for the 
early termination visit.
7.7
Subject Replacement
If deemed appropriate by the investigator or sponsor, additional subjects may be randomized due 
to subject discontinuation from the study to achieve the targeted number of completers.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 44 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
8.0
CLINICAL STUDY MATERIAL MANAGEMENT
8.1
Study Drug and Materials
8.1.1
Dosage Form, Manufacturing, Packaging, and Labeling
In this protocol, the term study drug refers to all or any of the drugs defined below.
1. TAK-925 solution for IV infusion.
2. Matched placebo solution for IV infusion.
Takeda will supply all clinical drug supplies for this study. Each United States Pharmacopeia Type 
I glass vial nominally contains 10 mL of compounded sterile solution, sealed with a 
fluoropolymer-coated butyl rubber stopper and over-sealed with an aluminum seal and a plastic 
cap. Study drug containers will be affixed with clinical labels in accordance with local regulatory 
requirements.
8.1.1.1
Ancillary Supplies
All ancillary supplies will be provided by either the study site or the sponsor or designee, based 
upon availability. The list of ancillary supplies and source information can be found in the 
pharmacy manual or in the referenced compounding manual when applicable. If provided by the 
sponsor, unused ancillary supplies will be accounted for and disposed of as directed by the sponsor 
or designee.
8.1.1.2
Sponsor-Supplied Drug
Sponsor-supplied drugs referenced in other sections of the protocol include the following:
1. TAK-925 solution for IV infusion.
2. Matched placebo solution for IV infusion.
8.1.2
Storage
Study drug at the sites must be stored in a secure, limited-access location under the storage 
conditions specified on the label and remain in the original container until dispensed. The 
temperature excursion information can be found in the pharmacy manual or in the referenced 
compounding manual when applicable. Receipt and dispensing of study drug must be recorded by 
authorized personnel at the study site.
The study drug will be stored at 20°C to 25°C (68°F -77°F); excursions permitted to 15°C to 30°C 
(59°F -86°F).
A daily temperature log of the drug storage area must be maintained every working day.
8.1.3
Dose and Regimen
Doses and regimens are provided in Table 6.a.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 45 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
8.1.4
Overdose
An overdose is defined as a known deliberate or accidental administration of study drug, to or by a 
study subject, at a dose above that which is assigned to that individual subject according to the 
study protocol.
All cases of overdose (with or without associated AEs) will be documented in the eCRF in order to 
capture this important safety information consistently in the database. Cases of overdose without 
manifested signs or symptoms are not considered AEs. AEs associated with an overdose will be 
documented on AE CRF(s) according to Section 10.0.
SAEs associated with overdose should be reported according to the procedure outlined in 
Section 10.2.2.
In the event of drug overdose, the subject should be treated symptomatically.
8.2
Study Drug Assignment and Dispensing Procedures
Subjects will be randomized using an interactive voice response (IVRS)/(interactive web response 
system [IWRS]). On Day 1 of Treatment Period 1, subjects will be assigned a randomization 
number in ascending numerical order at the clinical site. The randomization number encodes the 
sequence which describes the order in which each subject will receive TAK-925 112 mg or 
placebo. Each subject will be administered blinded study drug, labeled with his/her unique 
randomization number, throughout the study.
8.3
Randomization Code Creation and Storage
Randomization personnel of the sponsor or designee will generate the randomization schedule for 
the IVRS/IWRS system. Details are in the pharmacy manual. In addition, the pharmacy manual 
includes instructions for emergency unblinding. Storage conditions are also specified in the 
pharmacy manual.
8.4
Study Drug Blind Maintenance
The study drug blind will be maintained through a randomization schedule held by the 
IVRS/IWRS system and by the site pharmacists.
8.5
Unblinding Procedure
The study drug blind shall not be broken by the investigator unless information concerning the 
study drug is necessary for the medical treatment of the subject. If possible, the medical 
monitor/monitor should be contacted before the blind is broken. Unblinding will be performed per 
the standard operating procedures of the study site.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 46 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
8.6
Accountability and Destruction of Sponsor-Supplied Drugs
The investigator is responsible for keeping accurate records of the study drug received from the 
sponsor or designee, the amount dispensed to and returned by the subjects, and the amount 
remaining at the end of the study. For all study sites, the local country sponsor personnel or 
designee will provide appropriate documentation that must be completed for study drug 
accountability, return, and destruction.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 47 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
9.0
STUDY PLAN
The following sections describe the study procedures and data to be collected as indicated in the 
Schedule of Study Procedures (Appendix A). For each procedure, subjects are to be assessed by
the same investigator or site personnel whenever possible. Assessments should be completed at the 
designated visit/time points. An hourly schedule of procedures for Day 1 of each treatment period 
is listed in Appendix B
9.1
Administrative Procedures
9.1.1
Informed Consent Procedure
Informed consent must be obtained before the subject enters the study, and before any
protocol-directed procedures are performed, including withdrawal of prohibited medications. The 
requirements of the informed consent are described in Section 15.2.
A unique subject identification number (subject number) will be assigned to each subject at the 
time that informed consent is obtained/explained; this subject number will be used throughout the 
study.
9.1.2
Inclusion and Exclusion
Each subject will be assessed through randomization according to the eligibility criteria provided 
in Section 7.0.
9.1.3
Medical and Social History and Demographics
Demographic information to be obtained will include date of birth, sex, ethnicity, and race (as 
described by the subject) at screening.
Medical and social history, including use of tobacco and alcohol, will include determining whether 
the subject has any significant conditions or diseases relevant to the disease under study that 
resolved at or prior to signing of informed consent. Ongoing conditions are considered concurrent 
medical conditions.
9.1.4
Prior and Concomitant Medication
Qualified site personnel will review subject’s prior and concomitant medication use. Medications 
are defined as prescription and OTC drugs, vaccines, supplements, nutraceuticals, and oral herbal 
preparations.
Medication history information to be obtained includes any medication relevant to eligibility 
criteria and safety evaluation prior to randomization.
CCI
Property of Takeda: For Non-Commercial Use 
gh rando
h rand
l Histor
Histo
on to be
n to b
ject) at 
ject) at
ial histo
ial hist
s any si
any s
or prio
or pri
condit
conditi
.4
Pr
P
nd Subject to the Applicable Terms of Use
by
at 
at th
the
nt perio
nt peri
and bef
and be
f prohib
prohi
2.
l be assi
be ass
ject num
ect num
Qualif
Qua
are
ar
e Only and


TAK-925
Study No. TAK-925-2002
Page 48 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
Concomitant medication is any drug given in addition to the study drug. These may be prescribed 
by a physician or obtained by the subject OTC.
9.1.5
Washout of Prohibited Concomitant Medications
The use of concomitant medications is prohibited starting from 7 days or 5 half-lives, whichever 
period is longer for the drug classes listed in Table 7.a before administration of the first dose of 
study drug.
9.1.6
Actigraphy and Sleep Diary
Approximately 7 consecutive days of actigraphy supported by a sleep diary will be recorded 
beginning on Study Day -9 and ending on Study Day -3 (ie, the day before their Study Day -2 
admission to the clinical unit). Data from the actigraphy device will be downloaded by the site to 
ensure that a subject sleeps on average 420 min (7 hours)/night and does not have insufficient 
sleep syndrome, as specified in the exclusion criteria.
9.2
Clinical Procedures/Assessments
9.2.1
Physical Examination Procedure
A full physical examination will be performed at the times specified in the Schedule of Study 
Procedures (Appendix A) and will consist of the following body systems: (1) eyes; (2) ears, nose, 
throat; (3) cardiovascular system; (4) respiratory system; (5) gastrointestinal system; 
(6) dermatologic system; (7) extremities; (8) musculoskeletal system; (9) nervous system; 
(10) lymph nodes; and (11) other.
All postbaseline physical examinations should assess clinically significant changes from the 
baseline assessment.
9.2.2
Height, Weight, and BMI
Body weight and height will be obtained with the subject’s shoes off, and jacket or coat removed.
BMI equals a subject’s weight in kilograms divided by height in meters squared (BMI = kg/m2). 
BMI will be rounded to the nearest whole number according to the standard convention of 0.1 to 
0.4, round down, and 0.5 to 0.9, round up.
9.2.3
BDI-II
The Beck Depression Inventory is a widely used psychometric test for measuring the intensity, 
severity, and depth of depression in patients with psychiatric diagnoses. This study will use the 
most updated version of the Beck Depression Inventory (1996, BDI-II).
The test is composed of 21 questions, each designed to assess a specific symptom common among 
people with depression. Each answer is scored on a scale value of 0 to 3. Higher total scores 
indicate more severe depressive symptoms. The standardized cutoffs used are:

0–13: minimal depression.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 49 of 118
Protocol Incorporating Amendment No. 02
04 March 2020

14–19: mild depression.

20–28: moderate depression.

29–63: severe depression.
The BDI-II is positively correlated with the Hamilton Depression Rating Scale with a Pearson r of 
0.71, showing good agreement. The test was also shown to have a high one-week test-retest 
reliability (Pearson r = 0.93), suggesting that it was not overly sensitive to daily variations in mood 
[12]. The test also has high internal consistency (α = .91) [13].
9.2.4
C-SSRS
Suicidal ideation will be assessed using the C-SSRS at the times stipulated in the Schedule of 
Study Procedures (see Appendix A). Two versions of the C-SSRS will be used in this study: the 
screening/baseline C-SSRS lifetime and the since-last-visit C-SSRS. Any suicidal ideation or 
suicidal behavior during study periods detected by C-SSRS will be recorded as AEs. The 
investigator will ensure that any suicidal ideation or behavior is medically addressed, including 
assessment and treatment by qualified medical personnel.
9.2.5
Study Drug Administration
On Day 1 of each treatment period, study drug (TAK-925 112 mg or placebo) will be administered 
as described in Section 6.1.
9.2.6
Vital Sign Procedure
Vital signs will include SBP and DBP, HR, body temperature, and respiratory rate. The same 
method (eg, same size cuff, manual or automated) must be used for all measurements for each 
individual subject and should be the same for all subjects.
Body temperature will be measured with an oral (temperature taken at floor of the mouth) or 
tympanic thermometer. O2 saturation index will be measured at screening (finger monitor).
Subjects should rest in a bed with the head of the bed at 30 degrees for at least 5 minutes before 
vital signs are measured. Vital signs will include HR, respiratory rate, SBP, and DBP. The same 
method (eg, same size cuff, manual or automated) must be used for all measurements for each 
individual subject and should be the same for all subjects.
Subjects should continue to rest in a bed with the head of the bed at 30 degrees from the time of 
dosing until 2 hours post-dose except to stand if necessary for study-related procedures.
9.2.7
12-Lead ECG
A standard 12-lead ECG will be recorded. The following parameters will be recorded 
electronically by a central reader from the subject’s ECG trace: HR, RR interval, PR interval, QT 
interval, QRS interval.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 50 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
9.2.8
AE Monitoring
AE monitoring begins after signing of the informed consent form. Changes in subject health status 
from the baseline assessment until study drug administration should be captured as pre-treatment 
events. A complete description of AE collection and reporting procedure is provided in 
Section 10.0.
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
nt
operty of Takeda: For Non-Commercial Use Only and Subject to the Applicable T


TAK-925
Study No. TAK-925-2002
Page 51 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
9.4
Laboratory Assessments/Procedures
All samples will be collected in accordance with acceptable laboratory procedures. Details of these 
procedures and required safety monitoring will be given in the laboratory manual.
Table 9.a lists the tests that will be obtained for each laboratory specimen.
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
edures
edure
ordance
rdanc
monit
nitori
o
will be o
will be
e Only and Subject to the Applicable Terms of Us


TAK-925
Study No. TAK-925-2002
Page 52 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
Table 9.a
Clinical Laboratory Tests
Hematology
Serum Chemistry
Urinalysis
Hematocrit
Hemoglobin
Platelets
RBC
WBC
Albumin
Alkaline phosphatase
ALT
AST
Bilirubin (total); if above 
ULN, total bilirubin will be 
fractionated
Blood urea nitrogen
Calcium
Carbon dioxide
Chloride
Creatinine
GGT
Glucose
HDL
LDL
Phosphate
Potassium
Protein (total)
Sodium
Total cholesterol
Triglycerides
Blood
Glucose
Nitrite
Protein
Specific gravity
Other
Serum
Urine
HIV
HBsAg and anti-HCV
HbA1C a
FSH b
INR c
Drug screen including amphetamines, barbiturates, 
benzodiazepines, buprenorphine/metabolite, cannabinoids, 
cocaine/metabolites, MDMA, methadone/metabolite, 
opiates, oxycodone/oxymorphone, and phencyclidine;
hCG (for pregnancy) c
ALT: alanine aminotransferase; anti-HCV: antibody to hepatitis C virus; AST: aspartate aminotransferase; 
FSH: follicle-stimulating hormone; GGT: γ-glutamyl transferase; HBsAg: hepatitis B surface antigen; hCG: human 
chorionic gonadotropin; HDL: high-density lipoprotein; HIV: human immunodeficiency virus; INR: international 
normalized ratio; LDL: low-density lipoprotein; MDMA, 3,4-methylenedioxy-methamphetamine; RBC: red blood 
cells; ULN: upper limit of normal; WBC: white blood cells.
a Diabetic subjects only.
b Postmenopausal women only.
c If ALT or AST >3 times the ULN.
d Women of childbearing potential only.
The central laboratory will perform laboratory tests for hematology, serum chemistries, and 
urinalysis. The results of laboratory tests will be returned to the investigator, who is responsible for 
reviewing and filing these results.
If subjects experience ALT or AST >3 ×ULN, follow-up laboratory tests (at a minimum, serum 
alkaline phosphatase, ALT, AST, total bilirubin, γ-glutamyl transferase, and international 
normalized ratio) should be performed within a maximum of 7 days and preferably within 
48 to 72 hours after the abnormality was noted. (Refer to Section 7.5 and Section 10.2.3 for the 
appropriate guidance on reporting abnormal LFTs.)
If ALT or AST remains elevated >3 ×ULN on these 2 consecutive occasions the investigator must 
contact the medical monitor/monitor for consideration of additional testing, close monitoring, 
possible discontinuation of study drug, discussion of the relevant subject details and possible 
alternative etiologies. The abnormality should be recorded as an AE (please refer to 
Section 10.2.3).
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 53 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
9.5
PK 
Samples
9.5.1
PK 
Evaluations
Primary specimen collection for PK 
are provided in Table 9.b. Samples for PK 
 
analysis will be collected as specified in the schedule in Appendix A.
Table 9.b
Primary Specimen Collection for 
PK Samples
Specimen Name
Primary 
Specimen
Primary 
Specimen 
Derivative
Description of 
Intended Use
Sample 
Collection
Plasma sample for TAK-925 
 
Blood
Plasma
PK measurements
Mandatory
PK: pharmacokinetic(s).
9.5.2
PK Measurements
The PK parameters of TAK-925 
will be determined from plasma 
concentrations from all evaluable subjects using noncompartmental analysis methods. Actual 
sampling times, rather than scheduled sampling times, will be used in all computations involving 
sampling times.
The following PK parameters will be calculated from plasma concentrations of TAK-925 
as data permit:
AUC∞
t1/2z
AUClast
Vss (TAK-925 only)
Cmax
Vz (TAK-925 only)
Ceoi
CL (TAK-925 only)
tmax
Additional PK parameters may be calculated as appropriate. A detailed PK analysis plan will be 
prepared before PK parameter computation.
9.5.2.1
Blood for PK Measurements
Blood samples (one 3-mL sample per scheduled time) for determination of plasma concentrations 
of TAK-925 
will be collected into chilled blood collection tubes (vacutainer) 
containing the anticoagulant K2EDTA (dipotassium ethylenediaminetetraacetic acid) according to 
the Schedule of Study Procedures in Appendix A. An hourly schedule of sampling on Day 1 of
each treatment period is provided in Appendix B.
To reflect the plasma exposure more precisely, blood samples will be collected from the arm
opposite to the one on which IV infusion is performed. If the opposite arm in not available, blood 
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
Property of Takeda: For Non-Commercial Use Only and Subject t
willll b
l e d
ncompa
omp
imes, w
mes
culated f
ulated
l PK par
PK pa
d befor
d befo
5.2.1
2.1
Bl
Blood
o
of
of
the Applicable Term
Sam
Sa
C
ab
ments
ents
Ap
ms of Use
t to th
ms o


TAK-925
Study No. TAK-925-2002
Page 54 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
samples should be collected at a site that is as distant to the infusion site as possible, and the site of 
the blood sampling should be documented. The blood sampling times and times of the start and 
end of infusions should be recorded accurately on the source document and eCRF; particular care 
should be given when recording the blood sampling times during the infusion and around the time 
close to the infusion. Sampling time points may be adjusted based on the preliminary emerging 
concentration data collected from prior subjects, but the total number of samples collected per 
subjects should not exceed the planned number.
Instructions for collecting, processing, and shipping of PK samples are provided in the laboratory
manual.
9.5.2.2
PK Sample Analysis
Plasma concentration of TAK-925 
 will be measured by a validated 
high-performance liquid chromatography with tandem mass spectrometry assay. Part of the 
archival plasma samples may be used for potential analysis of unknown 
characterization, if appropriate.
CCI
CCI
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
re
time
me
rging 
ging 
ted per 
ed per
d in the l
in the
asured b
sured 
ctrometr
rome
f unknow
unkno
Subje
operty of Takeda: For Non-Commercial Use Only and S


TAK-925
Study No. TAK-925-2002
Page 55 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
9.6
Blood Volume
It is anticipated that the total blood volume drawn for each subject will be approximately 107 mL.
The amount of blood for each type of sample is summarized in Table 9.c.
CCI
Property of Takeda: For Non-Commercia
blood vo
lood v
ach ty
ach type
y
cial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 56 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
Table 9.c
Blood Volume
Sample 
Volume 
(mL)
Number of Samples
Total 
Volume 
(mL)
Screening
Study 
Day -2
Study 
Day -1
Treatment 
Periods
1-2
Follow-up
Day 1-2
Laboratory safety tests
10
1
1
0
1
0
30
FSH a
5
1
5
HIV/hepatitis screen
6
1
0
0
0
0
6
Blood for PK
3
0
0
0
20
0
60
Total blood volume per 
subject
107
FSH: follicle-stimulating hormone; HIV: human immunodeficiency virus;
PK: pharmacokinetics.
a Postmenopausal women only.
9.7
Confinement
Subjects will report to the clinical site on Study Day -2 and will leave after completion of all 
study-related procedures on Study Day 4.
At the discretion of the investigator, subjects may be requested to remain in the clinical site longer 
to further assess safety.
9.8
Documentation of Screen Failure
Investigators must account for all subjects who sign informed consent.
If the subject is withdrawn at the screening visit, the investigator should complete the eCRF. The 
IVRS/IWRS should be contacted as a notification of screen failure.
The primary reason for screen failure is recorded in the eCRF using the following categories:
!
PTE/AE.
!
Did not meet inclusion criteria or did meet exclusion criteria (specify reason).
!
Significant protocol deviation.
!
Lost to follow-up.
!
Voluntary withdrawal (specify reason).
!
Study termination.
Subject identification numbers assigned to subjects who fail screening should not be reused.
CCI
CCI
Property of Takeda: For Non-Commercial Use Only and Subje
Day
ay -
y 2 a
2
cts may 
cts ma
n Failur
Failu
r all sub
all su
n at the 
at the
contac
onta
n for scr
for s
ot meet 
ee
gnifican
gnifica
Lost 
Lo
!
t to the Ap
t t
plicable Terms of Use
otal 
al
Volume 
olum
(mL
(m
e T
0
V
Appl
ject t
CI


TAK-925
Study No. TAK-925-2002
Page 57 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
9.9
Documentation of Study Entrance/Randomization
Only subjects who meet all of the inclusion criteria and none of the exclusion criteria are eligible 
for entrance/randomization into the treatment phase.
If the subject is found to be not eligible for randomization/treatment phase, the investigator should 
record the primary reason for failure on the applicable eCRF.
9.10
Monitoring Subject Treatment Compliance
Study drug (TAK-925 and matching placebo) will be administered as a continuous IV infusion at 
the clinical site by authorized personal. Interruptions of the IV infusion and reason(s) for such 
interruptions will be recorded on the eCRF.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 58 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
10.0
PRETREATMENT EVENTS AND AEs
10.1
Definitions
10.1.1 PTEs
A PTE is defined as any untoward medical occurrence in a clinical investigation subject who has 
signed informed consent to participate in a study but prior to administration of any study drug; it 
does not necessarily have to have a causal relationship with study participation.
10.1.2 AEs
An AE is defined as any untoward medical occurrence in a clinical investigation subject 
administered a drug; it does not necessarily have to have a causal relationship with this treatment.
An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal 
laboratory value), symptom, or disease temporally associated with the use of a drug whether or not 
it is considered related to the drug.
10.1.3 Additional Points to Consider for PTEs and AEs
An untoward finding generally may:

Indicate a new diagnosis or unexpected worsening of a pre-existing condition. (Intermittent 
events for pre-existing conditions or underlying disease should not be considered PTEs or 
AEs.)

Necessitate therapeutic intervention.

Require an invasive diagnostic procedure.

Require discontinuation or a change in dose of study drug or a concomitant medication.

Be considered unfavorable by the investigator for any reason.
PTEs/AEs caused by a study procedure (eg, a bruise after blood draw) should be recorded as a 
PTE/AE.
Diagnoses vs signs and symptoms:

Each event should be recorded to represent a single diagnosis. Accompanying signs (including 
abnormal laboratory values or ECG findings) or symptoms should NOT be recorded as 
additional AEs. If a diagnosis is unknown, sign(s) or symptom(s) should be recorded 
appropriately as a PTE(s) or as an AE(s).
Laboratory values and ECG findings:

Changes in laboratory values or ECG findings are only considered to be PTEs or AEs if they 
are judged to be clinically significant (ie, if some action or intervention is required or if the 
investigator judges the change to be beyond the range of normal physiologic fluctuation). 
A laboratory or ECG retest and/or continued monitoring of an abnormal value or finding are 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 59 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
not considered an intervention. In addition, repeated or additional noninvasive testing for 
verification, evaluation or monitoring of an abnormality is not considered an intervention.

If abnormal laboratory values or ECG findings are the result of pathology for which there is an 
overall diagnosis (eg, increased creatinine in renal failure), the diagnosis only should be 
reported appropriately as a PTE or as an AE.
Pre-existing conditions:

Pre-existing conditions (present at the time of signing of informed consent) are considered 
concurrent medical conditions and should NOT be recorded as PTEs or AEs. Baseline 
evaluations (eg, laboratory tests, ECG, etc.) should NOT be recorded as PTEs unless related to 
study procedures. However, if the subject experiences a worsening or complication of such a 
concurrent medical condition, the worsening or complication should be recorded appropriately 
as a PTE (worsening or complication occurs before start of study drug) or an AE (worsening or 
complication occurs after start of study drug). Investigators should ensure that the event term 
recorded captures the change in the condition (eg, “worsening of…”).

If a subject has a pre-existing episodic concurrent medical condition (eg, asthma, epilepsy) any 
occurrence of an episode should only be captured as a PTE/AE if the condition becomes more 
frequent, serious, or severe in nature. Investigators should ensure that the AE term recorded 
captures the change in the condition from baseline (eg “worsening of…”).

If a subject has a degenerative concurrent medical condition (eg, cataracts, rheumatoid 
arthritis), worsening of the condition should only be recorded as a PTE/AE if occurring to a 
greater extent to that which would be expected. Investigators should ensure that the AE term 
recorded captures the change in the condition (eg, “worsening of…”).
Worsening of PTEs or AEs:

If the subject experiences a worsening or complication of a PTE after the start of study drug, 
the worsening or complication should be recorded as an AE. Investigators should ensure that 
the AE term recorded captures the change in the PTE (eg, “worsening of…”).

If the subject experiences a worsening or complication of an AE after any change in study 
drug, the worsening or complication should be recorded as a new AE. Investigators should 
ensure that the AE term recorded captures the change in the condition (eg, “worsening of…”).
Changes in intensity of AEs/serious PTEs:

If the subject experiences changes in intensity of an AE/serious PTE, the event should be 
captured once with the maximum intensity recorded.
Preplanned procedures (surgeries or interventions):

Preplanned procedures (surgeries or therapies) that were scheduled prior to signing of 
informed consent are not considered PTEs or AEs. However, if a preplanned procedure is 
performed early (eg, as an emergency) due to a worsening of the pre-existing condition, the 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 60 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
worsening of the condition should be recorded as a PTE or an AE. Complications resulting 
from any planned surgery should be reported as AEs.
Elective surgeries or procedures:

Elective procedures performed where there is no change in the subject’s medical condition 
should not be recorded as PTEs or AEs, but should be documented in the subject’s source 
documents. Complications resulting from an elective surgery should be reported as AEs.
Insufficient clinical response (lack of efficacy):

Insufficient clinical response, efficacy, or pharmacologic action should NOT be recorded as an 
AE. The investigator must make the distinction between exacerbation of pre-existing illness 
and lack of therapeutic efficacy.
Overdose:

Cases of overdose with any medication without manifested side effects are NOT considered 
PTEs or AEs, but instead will be documented in the eCRF. Any manifested side effects will be 
considered PTEs or AEs and will be recorded on the AE page of the eCRF.
10.1.4 SAEs
An SAE is defined as any untoward medical occurrence that at any dose fulfills 1 or more of the 
serious criteria below:
1. Results in DEATH.
2. Is LIFE THREATENING.

The term “life threatening” refers to an event in which the subject was at risk of death at the 
time of the event; it does not refer to an event that hypothetically might have caused death 
if it were more severe.
3. Requires inpatient HOSPITALIZATION or prolongation of existing hospitalization.
4. Results in persistent or significant DISABILITY/INCAPACITY.
5. Leads to a CONGENITAL ANOMALY/BIRTH DEFECT.
6. Is an IMPORTANT MEDICAL EVENT that satisfies any of the following:

May require intervention to prevent items 1 through 5 above.

May expose the subject to danger, even though the event is not immediately life 
threatening or fatal or does not result in hospitalization.

Includes any event or synonym described in the Takeda Medically Significant AE List 
(Table 10.a).
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 61 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
Table 10.a
Takeda Medically Significant AE List
Term
Acute respiratory failure/acute respiratory distress 
syndrome
Hepatic necrosis
Torsade de pointes / ventricular fibrillation / ventricular 
tachycardia
Acute liver failure
Anaphylactic shock
Malignant hypertension
Acute renal failure
Convulsive seizure
Pulmonary hypertension
Agranulocytosis
Pulmonary fibrosis
Aplastic anemia
Confirmed or suspected endotoxin shock
Toxic epidermal necrolysis/Stevens-Johnson syndrome Confirmed or suspected transmission of infectious agent by 
a medicinal product
Neuroleptic malignant syndrome / malignant hyperthermia
Spontaneous abortion / stillbirth and fetal death
Terms identified on the Medically Significant AE List represent the broad medical concepts to be considered as 
“Important Medical Events” satisfying SAE reporting requirements.
PTEs that fulfill 1 or more of the serious criteria above are also to be considered SAEs and should 
be reported and followed up in the same manner (see Sections 10.2.2 and 10.3).
10.1.5 AEs of Special Interest
AESIs will be collected and reported as AEs or SAEs, as defined in 
Section 10.1.2 and 10.1.4, according to the procedures in Section 10.2.1 and 10.2.2, respectively.
10.1.6 Intensity of PTEs and AEs
The different categories of intensity (severity) are characterized as follows:
Mild:
The event is transient and easily tolerated by the subject.
Moderate:
The event causes the subject discomfort and interrupts the subject’s usual activities.
Severe:
The event causes considerable interference with the subject’s usual activities.
10.1.7 Causality of AEs
The relationship of each AE to study drug(s) will be assessed using the following categories:
Related:
An AE that follows a reasonable temporal sequence from administration of a drug (including the 
course after withdrawal of the drug), or for which possible involvement of the drug cannot be 
ruled out, although factors other than the drug, such as underlying diseases, complications, 
concomitant medications, and concurrent treatments may also be responsible.
Not Related:
An AE that does not follow a reasonable temporal sequence from administration of a drug and/or 
that can reasonably be explained by other factors, such as underlying diseases, complications, 
concomitant medications, and concurrent treatments.
CCI
Property of Takeda: For Non-Commercia
collecte
ollect
ording
ding to
s and A
and A
es o
es of in
The even
he eve
The e
The
T
Causa
Cau
he rel
e re ati
Relate
Rela
l Use Only and Subject to the Applicable Terms of Use
f
xin n sh
shock
ock
nsmission
smissio
t syndrom
syndr
tion / stil
tion / st
bje
oad medi
ad med
bove ar
bove a
er (see S
er (see 
cial U


TAK-925
Study No. TAK-925-2002
Page 62 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
10.1.8 Relationship to Study Procedures
Relationship (causality) to study procedures should be determined for all PTEs and AEs.
The relationship should be assessed as related if the investigator considers that there is reasonable 
possibility that an event is due to a study procedure. Otherwise, the relationship should be assessed 
as not related.
10.1.9 Start Date
The start date of the AE/PTE is the date that the first signs/symptoms were noted by the subject 
and/or investigator.
10.1.10Stop Date
The stop date of the AE/PTE is the date at which the subject recovered, the event resolved but with 
sequelae or the subject died.
10.1.11Frequency
Episodic AEs/PTE (eg, vomiting) or those which occur repeatedly over a period of consecutive 
days are intermittent. All other events are continuous.
10.1.12Action Concerning Study Drug

Drug withdrawn – a study drug is stopped due to the particular AE.

Dose not changed – the particular AE did not require stopping a study drug.

Unknown – only to be used if it has not been possible to determine what action has been taken.

Not applicable – a study drug was stopped for a reason other than the particular AE eg, the 
study has been terminated, the subject died, dosing with study drug was already stopped before 
the onset of the AE.

Dose interrupted – the dose was interrupted due to the particular AE.

Dose delayed – the dose was delayed due to the particular AE.
10.1.13Outcome

Recovered/resolved – Subject returned to first assessment status with respect to the AE/PTE.

Recovering/resolving – the intensity is lowered by 1 or more stages: the diagnosis or 
signs/symptoms has almost disappeared; the abnormal laboratory value improved, but has not 
returned to the normal range or to baseline; the subject died from a cause other than the 
particular AE/PTE with the condition remaining “recovering/resolving”.

Not recovered/not resolved – there is no change in the diagnosis, signs or symptoms; the 
intensity of the diagnosis, signs/ symptoms or laboratory value on the last day of the observed 
study period has got worse than when it started; is an irreversible congenital anomaly; the 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 63 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
subject died from another cause with the particular AE/PTE state remaining “Not 
recovered/not resolved”.

Resolved with sequelae – the subject recovered from an acute AE/PTE but was left with 
permanent/significant impairment (eg, recovered from a cardiovascular accident but with 
some persisting paresis).

Fatal – the AEs/PTEs which are considered as the cause of death.

Unknown – the course of the AE/PTE cannot be followed up due to hospital change or 
residence change at the end of the subject’s participation in the study.
10.2
Procedures
10.2.1 Collection and Reporting of AEs
10.2.1.1
PTE and AE Collection Period
Collection of PTEs will commence from the time the subject signs the informed consent to 
participate in the study and continue until the subject is first administered study drug (Study 
Day 1) or until screen failure. For subjects who discontinue prior to study drug administration, 
PTEs are collected until the subject discontinues study participation.
Collection of AEs will commence from the time that the subject is first administered study drug 
(Study Day 1). Routine collection of AEs will continue until the follow-up/early termination visit.
10.2.1.2
PTE and AE Reporting
At each study visit, the investigator will assess whether any subjective AEs have occurred. A 
neutral question, such as “How have you been feeling since your last visit?” may be asked. 
Subjects may report AEs occurring at any other time during the study. Subjects experiencing a 
serious PTE must be monitored until the symptoms subside and any clinically relevant changes in 
laboratory values have returned to baseline or there is a satisfactory explanation for the change. 
Non-serious PTEs, related or unrelated to the study procedure, need not to be followed-up for the 
purposes of the protocol.
All subjects experiencing AEs, whether considered associated with the use of the study drug or 
not, must be monitored until the symptoms subside and any clinically relevant changes in 
laboratory values have returned to baseline or until there is a satisfactory explanation for the 
changes observed. All PTEs and AEs will be documented in the PTE/AE page of the eCRF, 
whether or not the investigator concludes that the event is related to the drug treatment. The 
following information will be documented for each event:
1. Event term.
2. Start and stop date and time.
3. Frequency.
4. Intensity.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 64 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
5. Investigator’s opinion of the causal relationship between the event and administration of study 
drug(s) (related or not related) (not completed for PTEs).
6. Investigator’s opinion of the causal relationship to study procedure(s), including the details of 
the suspected procedure.
7. Action concerning study drug (not applicable for PTEs).
8. Outcome of event.
9. Seriousness.
10.2.2 Collection and Reporting of SAEs
When an SAE occurs through the AE collection period it should be reported according to the 
following procedure:
SAEs should be reported via SAE eCRF in Rave EDC, which is the preferred method of reporting 
SAEs. A Takeda SAE eCRF must be completed in English and signed by the investigator 
immediately or within 24 hours of first onset or notification of the event. The information should 
be completed as fully as possible but should contain, at a minimum:

A short description of the event and the reason why the event is categorized as serious.

Subject identification number.

Investigator’s name.

Name of the study drug(s).

Causality assessment.
If access to Rave EDC is not feasible within 24 hours of receiving the event, the paper SAE forms 
should be submitted via fax. The SAE form should be completed within 24 hours of first onset or 
notification of the event, signed by the investigator, and transmitted via fax or email to the 
attention of the contact listed in Section 1.1. In case of fax, site personnel need to confirm 
successful transmission of all pages and include an e-mail address on the fax cover sheet so that an 
acknowledgment of receipt can be returned via e-mail within 1 business day.
Email submission of SAE forms (to the appropriate e-mail address listed below) with a portable 
document format (PDF) attachment should only be used in the case where fax is not possible and 
access to Rave EDC is not feasible within 24 hours of receiving the event. In case of e mail, site 
personnel need to confirm successful transmission by awaiting an acknowledgment of the receipt 
via e mail within 1 business day.

United States and Canada: PVSafetyAmericas@tpna.com

Rest of World: eupv@tgrd.com
If SAEs are reported via fax or by email, Rave EDC must be updated as soon as possible with the 
appropriate information.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 65 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
Any SAE spontaneously reported to the investigator following the AE collection period should be 
reported to the sponsor if considered related to study participation. 
10.2.3 Reporting of Abnormal LFTs
If a subject is noted to have ALT or AST elevated >3 ×ULN on 2 consecutive occasions, the 
abnormality should be recorded as an AE. In addition, an LFT Increases eCRF must be completed 
providing additional information on relevant recent history, risk factors, clinical signs and 
symptoms and results of any additional diagnostic tests performed.
If a subject is noted to have ALT or AST >3 ×ULN and total bilirubin >2 ×ULN for which an 
alternative etiology has not been identified, the event should be recorded as an SAE and reported 
as per Section 10.2.2. The investigator must contact the medical monitor for discussion of the 
relevant subject details and possible alternative etiologies, such as acute viral hepatitis A or B or 
other acute liver disease or medical history/concurrent medical conditions. Follow-up laboratory 
tests as described in Section 9.4 must also be performed. In addition, an LFT Increases eCRF must 
be completed and transmitted with the Takeda SAE form (as per Section 10.2.2).
10.3
Follow-up of SAEs
If information not available at the time of the first report becomes available later, the investigator 
should complete a follow-up SAE form or provide other written documentation and fax it 
immediately. Copies of any relevant data from the hospital notes (eg, ECGs, laboratory tests, 
discharge summary, postmortem results) should be sent to the addressee, if requested.
All SAEs should be followed up until resolution or permanent outcome of the event. The timelines 
and procedure for follow-up reports are the same as those for the initial report.
10.3.1 Safety Reporting to Investigators, IRBs or IECs, and Regulatory Authorities
The sponsor will be responsible for reporting all suspected unexpected serious adverse reactions 
(SUSARs) and any other applicable SAEs to regulatory authorities, investigators, and IRBs or 
IECs, as applicable, in accordance with national regulations in the countries where the study is 
conducted. Relative to the first awareness of the event by/or further provision to the sponsor or 
sponsor’s designee, SUSARs will be submitted to the regulatory authorities as expedited reports
within 7 days for fatal and life-threatening events and 15 days for other serious events, unless 
otherwise required by national regulations. The sponsor will also prepare an expedited report for 
other safety issues where these might materially alter the current benefit-risk assessment of a study 
drug/sponsor-supplied drug or that would be sufficient to consider changes in the study 
drug/sponsor-supplied drug administration or in the overall conduct of the study. The study site 
also will forward a copy of all expedited reports to his or her IRB or IEC in accordance with local
regulations.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 66 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
11.0
STUDY-SPECIFIC COMMITTEES
No steering committee, data safety monitoring committee, or clinical endpoint committee will be 
used in this study.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 67 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
12.0
DATA HANDLING AND RECORDKEEPING
The full details of procedures for data handling will be documented in the Data Management Plan. 
AEs, PTEs, medical history, and concurrent medical conditions will be coded using the Medical 
Dictionary for Regulatory Activities (MedDRA). Drugs will be coded using the World Health 
Organization (WHO) Drug Dictionary.
12.1
eCRFs
Completed eCRFs are required for each subject who signs an informed consent.
The sponsor or its designee will supply study sites with access to eCRFs. The sponsor will make 
arrangements to train appropriate site staff in the use of the eCRF. These forms are used to transmit 
the information collected in the performance of this study to the sponsor and regulatory authorities. 
eCRFs must be completed in English.
After completion of the entry process, computer logic checks will be run to identify items, such as 
inconsistent dates, missing data, and questionable values. Queries may be issued by Takeda 
personnel (or designees) and will be answered by the site.
Corrections are recorded in an audit trail that captures the old information, the new information, 
identification of the person making the correction, the date the correction was made, and the reason 
for change. Reasons for significant corrections should additionally be included.
The principal investigator must review the eCRFs for completeness and accuracy and must e-sign 
the appropriate eCRFs as indicated. Furthermore, the investigator must retain full responsibility 
for the accuracy and authenticity of all data entered on the eCRFs.
After the lock of the study database, any change of, modification of, or addition to the data on the 
eCRFs should be made by the investigator with use of change and modification records of the 
eCRFs. The principal investigator must review the data change for completeness and accuracy and 
must sign and date.
eCRFs will be reviewed for completeness and acceptability at the study site during periodic visits 
by the sponsor or its designee. The sponsor or its designee will be permitted to review the subject’s 
medical and hospital records pertinent to the study to ensure accuracy of the eCRFs. The 
completed eCRFs are the sole property of the sponsor and should not be made available in any 
form to third parties, except for authorized representatives of appropriate governmental health or 
regulatory authorities, without written permission of the sponsor.
12.2
Record Retention
The investigator agrees to keep the records stipulated in Section 12.1 and those documents that 
include (but are not limited to) the study-specific documents, the identification log of all 
participating subjects, medical records, temporary media such as thermal sensitive paper, source 
worksheets, all original signed and dated informed consent forms, subject authorization forms 
regarding the use of personal health information (if separate from the informed consent forms), 
electronic copy of eCRFs, including the audit trail, and detailed records of drug disposition to 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 68 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
enable evaluations or audits from regulatory authorities, the sponsor or its designees. Any source 
documentation printed on degradable thermal sensitive paper should be photocopied by the site 
and filed with the original in the subject’s chart to ensure long-term legibility. Furthermore, ICH 
E6 Section 4.9.5 requires the investigator to retain essential documents specified in ICH E6 
(Section 8) until at least 2 years after the last approval of a marketing application for a specified 
drug indication being investigated or, if an application is not approved, until at least 2 years after 
the investigation is discontinued and regulatory authorities are notified. In addition, ICH E6 
Section 4.9.5 states that the study records should be retained until an amount of time specified by 
applicable regulatory requirements or for a time specified in the study site agreement between the 
investigator and sponsor.
Refer to the study site agreement for the sponsor’s requirements on record retention. The 
investigator should contact and receive written approval from the sponsor before disposing of any 
such documents.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 69 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
13.0
STATISTICAL METHODS
13.1
Statistical and Analytical Plans
A statistical analysis plan (SAP) will be prepared and finalized prior to unblinding of subject’s 
treatment assignment. This document will provide further details regarding the definition of 
analysis variables and analysis methodology to address all study objectives.
A blinded data review will be conducted prior to unblinding of subject’s treatment assignment. 
This review will assess the accuracy and completeness of the study database, subject evaluability,
and appropriateness of the planned statistical methods.
13.1.1 Analysis Sets
13.1.1.1
Safety Set
The safety set will consist of all subjects who were randomized and received at least 1 dose of 
study drug. Subjects in this analysis set will be used for demographic, baseline characteristics, and 
safety summaries.
13.1.1.2
PK Set
The PK analysis set will consist of all subjects who received at least 1 dose of study drug and have
at least 1 measurable plasma concentration.
13.1.2 Analysis of Demographics and Other Baseline Characteristics
Demographic and other baseline characteristics will be summarized and listed by treatment 
sequence and overall. Descriptive statistics will be used to summarize data for continuous 
variables such as age and weight (number of subjects [N], mean, median, SD, minimum, and 
maximum) and for categorical variables such as sex, ethnicity, and race (number and percentage of 
subjects within each category). Tobacco and alcohol use will also be summarized. Medical history 
and medication history will be listed by subject.
13.1.3 PK Analysis
Individual plasma concentrations of TAK-925 
and PK parameter estimates 
will be listed for each subject and summarized using descriptive statistics as appropriate.
CCI
CCI
CCI
Property of Takeda: For Non-Com
ographi
graph
her basel
er bas
all. Des
ll. De
as age an
s age 
nd for c
d for
within ea
thin e
dicat
icat
Use Only and Subject to the Applicable Terms of Use
t’s s 
of 
of 
t ass
assignm
ign
ubject ev
bject e
ed and
ed and
mograph
mograp
who rec
who rec
ioi
3.1.3
1.3 P
Indiv
Ind
wi
w
mmercial Us


TAK-925
Study No. TAK-925-2002
Page 70 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
13.1.5 Safety Analysis
AEs will be summarized using the safety analysis set.
All AEs will be coded using MedDRA. Data will be summarized using preferred term and primary 
system organ class.
Standard summaries of TEAEs, clinical safety labs, vital signs and ECGs will be performed. 
Where appropriate, BP and QT parameters will be summarized (N, mean, SD, median, minimum 
and maximum) for baseline, post-dose, change from baseline and change from time-matched 
baseline to post-dose by treatment.
The observed HR and BP will be analyzed using linear mixed effect model for repeated measures 
in crossover studies. The model will include sequence, period, treatment, time points, and 
treatment by time point interaction as fixed effects and a random effect for subject within 
sequence. The estimated mean HR and BP for each treatment and the associated standard error and 
95% CI will be extracted from the model at each time, along with all pairwise differences from 
placebo and associated standard errors, 95% CIs, and p-values. The same quantities, averaged over 
all timepoints during the infusion and post the end of the infusion, will also be extracted from the 
model using appropriate contrasts.
13.2
Interim Analysis and Criteria for Early Termination
When at least 12 subjects completed both treatment periods, an interim analysis may be performed 
for futility, superiority, and/or sample size re-estimation. The criteria for futility and superiority 
will be described in the SAP.
13.3
Determination of Sample Size
Up to 40 subjects are planned to be randomized equally to each treatment sequence to ensure 
36 subjects complete the study. This number of subjects is typical for phase 1 crossover study
designs and is considered sufficient for assessment of safety.
CCI
CCI
Property of Takeda: For Non-Commercial Use Only and Subject t
ummariz
mma
lalabs, vi
bs, vi
will be s
ill be
hange fr
hange 
analyze
nalyz
l will in
will i
raction a
action
mean HR
ean H
ted from
ed fro
ted stan
ed sta
uring the
ring th
appropri
ppropr
nter
terim 
im
e
en at lea
en at le
r futut
f ilit
will be
wil
1
t to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 71 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
In addition, when the true difference between TAK-925 
and placebo is minimal, the chance to observe the same event is no more than 10%. 
Non-informative prior distributions were used in the above probability calculation. Allowing for 4 
dropouts (10%), 40 subjects are planned to be randomized.
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
5
ng for 4
g for 


TAK-925
Study No. TAK-925-2002
Page 72 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
14.0
QUALITY CONTROL AND QUALITY ASSURANCE
14.1
Study Site Monitoring Visits
Monitoring visits to the study site will be made periodically during the study to ensure that all 
aspects of the protocol are followed. Source documents will be reviewed for verification of data 
recorded on the eCRFs. Source documents are defined as original documents, data, and records. 
The investigator and the study site guarantee access to source documents by the sponsor or its 
designee (CRO) and by the IRB or IEC.
All aspects of the study and its documentation will be subject to review by the sponsor or sponsor’s 
designee (as long as blinding is not jeopardized), including but not limited to the investigator’s
binder, study drug, subject medical records, informed consent documentation, and review of 
eCRFs and associated source documents. It is important that the investigator and other study 
personnel are available during the monitoring visits and that sufficient time is devoted to the 
process.
14.2
Protocol Deviations
The investigator should not deviate from the protocol, except where necessary to eliminate an 
immediate hazard to study subjects. Should other unexpected circumstances arise that will require 
deviation from protocol-specified procedures, the investigator should consult with the sponsor or 
designee (and IRB or IEC, as required) to determine the appropriate course of action. There will be 
no exemptions (a prospectively approved deviation) from the inclusion or exclusion criteria.
Significant deviations include, but are not limited to, those that involve fraud or misconduct, 
increase the health risk to the subject, or confound interpretation of primary study assessment.
14.3
Quality Assurance Audits and Regulatory Agency Inspections
The study site also may be subject to quality assurance audits by the sponsor or designees. In this 
circumstance, the sponsor-designated auditor will contact the site in advance to arrange an 
auditing visit. The auditor may ask to visit the facilities where laboratory samples are collected, 
where the medication is stored and prepared, and any other facility used during the study. In 
addition, there is the possibility that this study may be inspected by regulatory agencies, including 
those of foreign governments (eg, the United States Food and Drug Administration [FDA], the 
United Kingdom Medicines and Healthcare Products Regulatory Agency, the Pharmaceuticals and 
Medical Devices Agency of Japan). If the study site is contacted for an inspection by a regulatory 
body, the sponsor should be notified immediately. The investigator and study site guarantee access 
for quality assurance auditors to all study documents as described in Section 14.1.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 73 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
15.0
ETHICAL ASPECTS OF THE STUDY
This study will be conducted with the highest respect for the individual participants (ie, subjects) 
according to the protocol, the ethical principles that have their origin in the Declaration of 
Helsinki, and the ICH Harmonised Tripartite Guideline for GCP. Each investigator will conduct 
the study according to applicable local or regional regulatory requirements and align his or her 
conduct in accordance with the “Responsibilities of the Investigator” that are listed in Appendix C. 
The principles of Helsinki are addressed through the protocol and through appendices containing 
requirements for informed consent and investigator responsibilities.
15.1
IRB and/or IEC Approval
IRBs and IECs must be constituted according to the applicable state and federal/local requirements 
of each participating region. The sponsor or designee will require documentation noting all names 
and titles of members who make up the respective IRB or IEC. If any member of the IRB or IEC 
has direct participation in this study, written notification regarding his or her abstinence from 
voting must also be obtained. Those American sites unwilling to provide names and titles of all 
members due to privacy and conflict of interest concerns should instead provide a Federal Wide 
Assurance Number or comparable number assigned by the Department of Health and Human 
Services.
The sponsor or designee will supply relevant documents for submission to the respective IRB or 
IEC for the protocol’s review and approval. This protocol, the Investigator’s Brochure, a copy of 
the informed consent form, and, if applicable, subject recruitment materials and/or advertisements 
and other documents required by all applicable laws and regulations, must be submitted to a 
central or local IRB or IEC for approval. The IRB’s or IEC’s written approval of the protocol and 
subject informed consent must be obtained and submitted to the sponsor or designee before 
commencement of the study (ie, before shipment of the sponsor-supplied drug or study-specific 
screening activity). The IRB or IEC approval must refer to the study by exact protocol title, 
number, and version date; identify versions of other documents (eg, informed consent form) 
reviewed; and state the approval date. The sponsor will ship drug/notify site once the sponsor has 
confirmed the adequacy of site regulatory documentation and, when applicable, the sponsor has 
received permission from competent authority to begin the study. Until the site receives 
drug/notification no protocol activities, including screening may occur.
Study sites must adhere to all requirements stipulated by their respective IRB or IEC. This may 
include notification to the IRB or IEC regarding protocol amendments, updates to the informed 
consent form, recruitment materials intended for viewing by subjects, local safety reporting 
requirements, reports and updates regarding the ongoing review of the study at intervals specified 
by the respective IRB or IEC, and submission of the investigator’s final status report to IRB or 
IEC. All IRB and IEC approvals and relevant documentation for these items must be provided to 
the sponsor or its designee.
Subject incentives should not exert undue influence for participation. Payments to subjects must 
be approved by the IRB or IEC and sponsor.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 74 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
15.2
Subject Information, Informed Consent, and Subject Authorization
Written consent documents will embody the elements of informed consent as described in the 
Declaration of Helsinki and the ICH Guidelines for GCP and will be in accordance with all 
applicable laws and regulations. The informed consent form, subject authorization form (if 
applicable), and subject information sheet (if applicable) describe the planned and permitted uses, 
transfers, and disclosures of the subject’s personal and personal health information for purposes of 
conducting the study. The informed consent form and the subject information sheet (if applicable) 
further explain the nature of the study, its objectives, and potential risks and benefits, as well as the 
date informed consent is given. The informed consent form will detail the requirements of the 
subject and the fact that he or she is free to withdraw at any time without giving a reason and 
without prejudice to his or her further medical care.
The investigator is responsible for the preparation, content, and IRB or IEC approval of the 
informed consent form and if applicable, the subject authorization form. The informed consent 
form, subject authorization form (if applicable), and subject information sheet (if applicable) must 
be approved by both the IRB or IEC and the sponsor prior to use.
The informed consent form, subject authorization form (if applicable), and subject information 
sheet (if applicable) must be written in a language fully comprehensible to the prospective subject. 
It is the responsibility of the investigator to explain the detailed elements of the informed consent 
form, subject authorization form (if applicable), and subject information sheet (if applicable) to the 
subject. Information should be given in both oral and written form whenever possible and in the 
manner deemed appropriate by the IRB or IEC. If the subject is not capable of rendering adequate 
written informed consent, then the subject’s legally acceptable representative may provide such 
consent for the subject in accordance with applicable laws and regulations.
The subject, or the subject’s legally acceptable representative, must be given ample opportunity to: 
(1) inquire about details of the study and (2) decide whether or not to participate in the study. If the 
subject, or the subject’s legally acceptable representative, determines he or she will participate in 
the study, then the informed consent form and subject authorization form (if applicable) must be 
signed and dated by the subject, or the subject’s legally acceptable representative, at the time of 
consent and prior to the subject entering into the study. The subject or the subject’s legally 
acceptable representative should be instructed to sign using their legal names, not nicknames, 
using blue or black ballpoint ink. The investigator must also sign and date the informed consent 
form and subject authorization (if applicable) at the time of consent and prior to subject entering 
into the study; however, the sponsor may allow a designee of the investigator to sign to the extent 
permitted by applicable law.
Once signed, the original informed consent form, subject authorization form (if applicable), and 
subject information sheet (if applicable) will be stored in the investigator’s site file. The 
investigator must document the date the subject signs the informed consent in the subject’s 
medical record. Copies of the signed informed consent form, the signed subject authorization form 
(if applicable), and subject information sheet (if applicable) shall be given to the subject.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 75 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
All revised informed consent forms must be reviewed and signed by relevant subjects or the 
relevant subject’s legally acceptable representative in the same manner as the original informed 
consent. The date the revised consent was obtained should be recorded in the subject’s medical 
record, and the subject should receive a copy of the revised informed consent form.
15.3
Subject Confidentiality
The sponsor and designees affirm and uphold the principle of the subject’s right to protection 
against invasion of privacy. Throughout this study, a subject’s source data will only be linked to 
the sponsor’s clinical study database or documentation via a subject identification number. As 
permitted by all applicable laws and regulations, limited subject attributes, such as sex, age, or date 
of birth, and subject initials may be used to verify the subject and accuracy of the subject’s unique 
identification number.
To comply with ICH Guidelines for GCP and to verify compliance with this protocol, the sponsor 
requires the investigator to permit the monitor or the sponsor’s designee, representatives from any 
regulatory authority (eg, FDA, Medicines and Healthcare products Regulatory Agency, 
Pharmaceuticals and Medical Devices Agency), the sponsor’s designated auditors, and the 
appropriate IRBs and IECs to review the subject’s original medical records (source data or 
documents), including, but not limited to, laboratory test result reports, ECG reports, admission 
and discharge summaries for hospital admissions occurring during a subject’s study participation, 
and autopsy reports. Access to a subject’s original medical records requires the specific 
authorization of the subject as part of the informed consent process (see Section 15.2).
Copies of any subject source documents that are provided to the sponsor must have certain 
personally identifiable information removed (ie, subject name, address, and other identifier fields 
not collected on the subject’s eCRF).
15.4
Publication, Disclosure, and Clinical Trial Registration Policy
15.4.1 Publication and Disclosure
The investigator is obliged to provide the sponsor with complete test results and all data derived by 
the investigator from the study. During and after the study, only the sponsor may make study
information available to other study investigators or to regulatory agencies, except as required by
law or regulation. Except as otherwise allowable in the study site agreement, any public disclosure 
(including publicly accessible websites) related to the protocol or study results, other than study
recruitment materials and/or advertisements, is the sole responsibility of the sponsor.
15.4.2 Clinical Study Registration
In order to ensure that information on clinical studies reaches the public in a timely manner and to 
comply with applicable laws, regulations and guidance, Takeda will, at a minimum register all 
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applica
s right t
right
data wil
data wi
t identifi
identi
ttributes
tribute
and accu
nd ac
comp
mplia
l
 sponso
spons
alalth
th
l care
car
y), the sp
), the sp
ubjec
ect’s 
t’
o, labora
, labor
admissi
admiss
ubject’s 
ject’s
art of th
rt of 
e docum
docu
format
ormati
ubject’s 
bject
ion, D
ion, Dis
lication
licati
vestigato
estiga
nvest
nvestigi
form
ormati
law or
law
(i(inc
ms of Use
cable Terms


TAK-925
Study No. TAK-925-2002
Page 76 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
interventional clinical studies it sponsors anywhere in the world on ClinicalTrials.gov and/or other 
publicly accessible websites before start of study, as defined in Takeda Policy/Standard. Takeda 
contact information, along with investigator’s city, state (for Americas investigators), country, and 
recruiting status will be registered and available for public viewing.
For some registries, Takeda will assist callers in locating study sites closest to their homes by 
providing the investigator name, address, and phone number to the callers requesting study 
information. Once subjects receive investigator contact information, they may call the site 
requesting enrollment into the study. The investigative sites are encouraged to handle the study 
inquiries according to their established subject screening process. If the caller asks additional 
questions beyond the topic of study enrollment, they should be referred to the sponsor.
Any investigator who objects to the sponsor providing this information to callers must provide the 
sponsor with a written notice requesting that their information not be listed on the registry site.
15.4.3 Clinical Study Results Disclosure
Takeda will post the results of clinical studies on ClinicalTrials.gov and/or other publicly 
accessible websites, as required by Takeda Policy/Standard, applicable laws and/or regulations.
15.5
Insurance and Compensation for Injury
Each subject in the study must be insured in accordance with the regulations applicable to the site 
where the subject is participating. If a local underwriter is required, then the sponsor or sponsor’s 
designee will obtain clinical study insurance against the risk of injury to study subjects. Refer to 
the study site agreement regarding the sponsor’s policy on subject compensation and treatment for 
injury. If the investigator has questions regarding this policy, he or she should contact the sponsor 
or sponsor’s designee.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 77 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
16.0
REFERENCES
1. Ohno K, Sakurai T. Orexin neuronal circuitry: role in the regulation of sleep and wakefulness. 
Front Neuroendocrinol 2008;29(1):70-87.
2. Scammell TE, Winrow CJ. Orexin receptors: pharmacology and therapeutic opportunities. 
Annu Rev Pharmacol Toxicol 2011;51:243-66.
3. American Academy of Sleep Medicine. International classiﬁcation of sleep disorders. 3rd ed. 
(ICSD-3). Rochester, MN: American Academy of Sleep Medicine; 2014.
4. Trotti LM. Idiopathic hypersomnia. Sleep Med Clin 2017;12(3):331-44.
5. Sowa NA. Idiopathic hypersomnia and hypersomnolence disorder: A systematic review of the 
literature. Psychosomatics 2016;57(2):152-64.
6. Mayer G, Benes H, Young P, Bitterlich M, Rodenbeck A. Modafinil in the treatment of 
idiopathic hypersomnia without long sleep time--a randomized, double-blind, 
placebo-controlled study. J Sleep Res 2015;24(1):74-81.
7. Huang SC, Dai YW, Lee YH, Chiou LC, Hwang LL. Orexins depolarize rostral ventrolateral 
medulla neurons and increase arterial pressure and heart rate in rats mainly via orexin 2 
receptors. J Pharmacol Exp Ther 2010;334(2):522-9.
8. Gasior M, Freeman J, Zammit G, Donnelly P, Gao J, Ferreira-Cornwell MC, et al. 
Maintenance of wakefulness with lisdexamfetamine dimesylate, compared with placebo and 
armodafinil in healthy adult males undergoing acute sleep loss. J Clin Psychopharmacol 
2014;34(6):690-6.
9. Kaida K, Takahashi M, Akerstedt T, Nakata A, Otsuka Y, Haratani T, et al. Validation of the 
Karolinska sleepiness scale against performance and EEG variables. Clin Neurophysiol 
2006;117(7):1574-81.
10. Reyner LA, Horne JA. Falling asleep whilst driving: are drivers aware of prior sleepiness? Int 
J Legal Med 1998;111(3):120-3.
11. Thomann J, Baumann CR, Landolt H-P, Werth E. Psychomotor vigilance task demonstrates 
impaired vigilance in disorders with excessive daytime sleepiness. Journal of Clinical Sleep 
Medicine 2014;10(09):1019-24.
12. Beck AT, Steer RA, Brown GK. Beck depression inventory-II. San Antonio 1996;78(2):490-8.
13. Beck AT, Steer RA, Ball R, Ranieri WF. Comparison of Beck Depression Inventories-IA 
and-II in psychiatric outpatients. Journal of personality assessment 1996;67(3):588-97.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 78 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
CONFIDENTIAL
Appendix A
Schedule of Study Procedures
Screening a
nPSG
Baseline
Treatment 
Period 1
Treatment 
Period 2
Follow-up 
Period n
Early 
Termination
Period Day
Study Day -28 to 
Study Day -3
Study Day -2
Day -1
Day 1
Day 2
Day 1
Day 2
Study Day 11 
(±2 days)
-
Study Day
Study Day -1
Study 
Day 1
Study 
Day 2
Study 
Day 3
Study 
Day 4
Administrative procedures
Informed consent b
X
Inclusion/exclusion criteria
X
X
X
Medical history/demographics
X
Prior and concomitant medication 
review – Continuous review
X
X
X
X
X
X
X
X
X
Washout of prohibited concomitant 
medications
X
X
Clinical procedures/assessments
Full physical examination
X
X
X
X
X
Height
X
Weight
X
X
X
BMI
X
C-SSRS
X
X
X
X
BDI-II
X
Actigraphy c
X
TAK-925/placebo administration d
X
X
Vital signs (HR, pulse, BP) e
X
X
X
X
X
X
X
X
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 79 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
CONFIDENTIAL
Screening a
nPSG
Baseline
Treatment 
Period 1
Treatment 
Period 2
Follow-up 
Period n
Early 
Termination
Period Day
Study Day -28 to 
Study Day -3
Study Day -2
Day -1
Day 1
Day 2
Day 1
Day 2
Study Day 11 
(±2 days)
-
Study Day
Study Day -1
Study 
Day 1
Study
Day 2
Study 
Day 3
Study
Day 4
O2 saturation index (finger monitor)
X
Continuous monitoring of AEs
X
X
X
X
X
X
X
X
X
Pharmacodynamic 
evaluation/assessments
nPSG
X
Laboratory procedures/assessments
Hematology i
X
X
X
X
Urinalysis
X
X
X
X
Serum chemistry
X
X
X
X
Urine drug screen and breathalyzer 
screen for alcohol j
X
X k
Hepatitis screen
X
HIV screen
X
Urine pregnancy test l
X
X k
X
X
X
FSH (for postmenopausal women 
only)
X
CCI
CCI
CCI
Property of Takeda: For Non-Commerci
erci
X
e
X
mm
Co
C
n-C
X
r N
X
Fo
X
a:
ed
Ta
Tak
Ta
Only and Sub
X
Su
d
y and
and 
d S
d
y a
bject
je
a
cial Use On
ubje
e Applicable Terms of Use
Te
nt t
d 2
lelele
Day 
Day
ica
ppl
tudy 
udy 
Day 3
Day 3
S
pp
pp
pp
pp
ct to the A


TAK-925
Study No. TAK-925-2002
Page 80 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
CONFIDENTIAL
Screening a
nPSG
Baseline
Treatment 
Period 1
Treatment 
Period 2
Follow-up 
Period n
Early 
Termination
Period Day
Study Day -28 to 
Study Day -3
Study Day -2
Day -1
Day 1
Day 2
Day 1
Day 2
Study Day 11 
(±2 days)
-
Study Day
Study Day -1
Study 
Day 1
Study
Day 2
Study 
Day 3
Study
Day 4
PK evaluations
Blood sample for PK TAK-925
 
X
X
X
X
X
Other
Confinement
X o
X
X
X p
X
X p
AE: adverse event; BDI-II: Beck Depression Inventory II; BMI: body mass index; C-SSRS: Columbia Suicide Severity Rating Scale; DBP: diastolic blood pressure; 
ECG: electrocardiogram; ESS: Epworth Sleepiness Scale; ET: early termination; FSH: follicle-stimulating hormone; HIV: human immunodeficiency virus; HR: heart rate; 
; nPSG: nocturnal polysomnography; 
; 
; 
PK: pharmacokinetic; 
; SBP: systolic blood pressure.
a Optional pre-screening testing on a case-by-case basis as approved by Takeda. PI is responsible for performance and interpretation of nPSG/MSLT.
b Must be signed prior to any study-related procedures.
c Nocturnal actigraphy testing, supported by a sleep diary, will be collected for 7 consecutive days (beginning on Study Day -9 and ending on Study Day -3, ie, the day before their 
Study Day-2 admission to the clinical unit for the nPSG) to document the subject does not have “insufficient sleep syndrome”.
d On Day 1 of each period, TAK-925 or placebo will be administered as a single 9-hour IV infusion commencing at approximately 0800.
e Semi-recumbent BP and HR will be recorded during screening and Study Day -2; On Study Day -1, BP and HR will be recorded at the approximate times matched to Study Day 1 
assessment times indicated in Appendix B: on Day 1 of each treatment period, BP and HR will be recorded immediately prior to the start of infusion, and approximately 1, 3, 5, 7, 9, 
10, and 13 hours post-start of infusion. On Day 2 of each treatment period, BP and HR will be recorded 24 hours post-start of infusion.
f Respiratory rate and body temperature will be recorded at screening and Study Day -2. On Study Day -1, and on Study Days 2 and 4. On Day 1 of each treatment period, respiratory 
rate and body temperature will be recorded immediately prior to the start of infusion and at approximately 3, 5, 7, and 13 hours after the start of infusion.
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CC
I
Property of Takeda: For Non-Commercial Use Only and Subject
je
bjejec
ectct
je
X
bj
d
j
nd
and 
d S
d
an
ly 
RS: Colum
RS: Colu
H: follicle
follicl
nocturna
octurn
pressure.
pressure.
eda. PI is 
da. PI i
lected fo
cted 
ment the s
ent the
nistered a
nistered
eening an
ning 
f each tre
each t
th
th
th
th
the Applicable Terms of Use
Te
nt t
d 2
lelele
Day 
Day
ica
ppl
tudy 
udy 
Day 3
Day 3
S
pp
pp
pp
pp
f each trea
each tr
recorded a
recorded
mmediate
media
erty of Taked
the A
ct to th
eda: F


TAK-925
Study No. TAK-925-2002
Page 81 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
CONFIDENTIAL
i Glycosylated hemoglobin only in diabetic subjects.
j A urine screen for drugs of abuse and breathalyzer screen for alcohol will be conducted at screening and Study Day -2. An exception at screening is made for stimulants or other 
drugs that the subject has been prescribed, but the drug screen must be negative at Study Day -2.
k Urine drug screen and pregnancy test results should be available before dosing on Day 1 of Treatment Period 1.
l Female subjects of childbearing potential only. Women of childbearing potential must return to the study site to complete a urine pregnancy test at the end-of-study visit.
m During each treatment period, blood for PK analysis of TAK-925 
 will be obtained: pre-dose, 1, 3, 5, 7 and 9 hours after start of infusion, and at 0.17, 1, 4, and 
15 hours after end of the infusion.
n Safety follow-up assessments will be conducted. The follow-up assessments can either be conducted as a visit to the site or as a telephone contact.
o Following completion of clinical testing procedures, site staff will make every effort to keep subjects awake until between 2200-2300.
p On Study Days 2 and 4, site staff will make every effort to keep subjects from sleeping during the day from 0700 until between 2200-2300.
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Te
on at scree
on at scr
e a u
a urine p
rin
u
3, 5, 7 an
, 5, 7 a
t to the si
to the 
ke until b
e until 
 from 070
 from 070


TAK-925
Study No. TAK-925-2002
Page 82 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
CONFIDENTIAL
Appendix B
Treatment Day 1 Hourly Schedule of Procedures (Approximate Times) for Treatment Periods 1 and 2
24-Hour Clock Time
Procedure
Day 1 
Pre-dose 08:00
09:00
10:00
11:00
12:00
13:00
14:00
15:00
16:00
17:00
18:00
19:00
20:00
21:00
23:00
Awaken
X
TAK-925 or placebo IV
administration
START
X
X
X
X
X
X
X
X
STOP
PK sampling b
X
X
X
X
X
X
X
X
; IV: intravenous;
; PK: pharmacokinetic; 
 Vigilance Task.
a These assessments will be obtained immediately prior to the start of study drug infusion.
b Blood for PK analysis of TAK-925 (
) will be obtained predose, 1, 3, 5, 7 and 9 hours after start of infusion, and at 0.17, 1, 4, and 15 hours after end of the infusion 
on Day 1. The 0.17 time point does not fall on the hour and the 15-hour postdose assessment falls on Day 2; therefore, these assessments are not indicated in the table.
CCI
CCI
CCI
CCI
CCI
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Te
Treatme
eatm
ica
00
17:0
17:
pp
e A
he
X
th
to
X
ial
art of stud
t of stu
l be obtain
l be obta
nd the 15
he 1
al Use Only
merc
nly and Subject


TAK-925
Study No. TAK-925-2002
Page 83 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
roperty of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 84 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
icable Terms o


TAK-925
Study No. TAK-925-2002
Page 85 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
operty of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Us


TAK-925
Study No. TAK-925-2002
Page 86 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
operty of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of U


TAK-925
Study No. TAK-925-2002
Page 87 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
and Subject to the Applicable Terms of U


TAK-925
Study No. TAK-925-2002
Page 88 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
operty of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of U


TAK-925
Study No. TAK-925-2002
Page 89 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 90 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Us


TAK-925
Study No. TAK-925-2002
Page 91 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
operty of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Us


TAK-925
Study No. TAK-925-2002
Page 92 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
operty of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 93 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Non-Commercial Use Only and Subject to the Applicable Terms of Us


TAK-925
Study No. TAK-925-2002
Page 94 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
Appendix H
Detailed Description of Amendments to Text
The primary section(s) of the protocol affected by the changes in Amendment 02 are indicated. 
The corresponding text has been revised throughout the protocol.
Change 1: The number of participating sites was updated.
The primary change occurs in Section 2.0:STUDY SUMMARY. 
Initial Wording: Approximately 15 in the United States and 2 sites in Japan.
New or Amended Wording: Approximately 1521 sites in the United States and 23 sites in Japan.
Rationale for Change: The expected number of participating sites was updated.
Change 2: The description of the evaluation period in the study summary section was clarified.
The primary change occurs in Section 2.0:STUDY SUMMARY.
Initial Wording: Up to 43 days: including up to a 28-day screening period, 6-day confinement 
(including polysomnogram [PSG] and baseline assessments, and Treatment Periods 1 and 2 with a 
minimum 24 hour washout between periods), and an outpatient site visit or telephone follow-up 
after 7 (±2) days.
New or Amended Wording: Up to 4341 days: (including up to a 28-day screening period up to 28 
days, 6-day confinement for 6 days (including polysomnogram [PSG] and baseline assessments, 
and [Treatment Periods 1 andto 2 with a minimum 24-hour washout between periods]), and end of 
study an outpatient site visit or follow-up telephone call follow-up after 7 on Study Day 11
(±2) days.
Rationale for Change: Clarification of study duration.
Change 3: The document referred to in the section on study-related responsibilities was corrected 
to “Transfer of Regulatory Obligations”.
The primary change occurs in Section 3.1: Study-Related Responsibilities.
Initial Wording: The sponsor will perform all study-related activities with the exception of those 
identified in the Study-Related Responsibilities template.
New or Amended Wording: The sponsor will perform all study-related activities with the 
exception of those identified in the Study-Related Responsibilities templateTransfer of 
Regulatory Obligations.
Rationale for Change: Correction of document name.
Change 4: It was clarified in the primary objective that the population consisted of adult subjects 
with idiopathic hypersomnia (IH).
The primary change occurs in Section 5.1.1: Primary Objective.
Initial Wording: The primary objective of this study is to evaluate the safety and tolerability of 
administering a single IV infusion dose of TAK-925 to patients with IH.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 95 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
New or Amended Wording: The primary objective of this study is to evaluate the safety and 
tolerability of administering a single IV infusion dose of TAK-925 to patients adult subjects with 
IH.
Rationale for Change: Consistency.
Section 2.0:STUDY SUMMARY also contains this change.
Change 5: The wording of the secondary objective was made consistent with the primary
objective.
The primary change occurs in Section 5.1.2: Secondary Objective.
Initial Wording: The secondary objective of this study is to investigate the PK of TAK-925 when 
administered via infusion to patients with IH.
New or Amended Wording: The secondary objective of this study is to investigate the PK of 
TAK-925 when administered via a single IV infusion of TAK-925 to patients in adult subjects
with IH.
Rationale for Change: Consistency.
Section 2.0:STUDY SUMMARY also contains this change.
Rationale for Change: Consistency.
Section 2.0:STUDY SUMMARY also contains this change.
Change 7: It was clarified in the study design that the maintenance of wakefulness sessions will be 
terminated at approximately 1700.
The primary change occurs in Section 6.1: Study Design.
Added text: …. On Day 1 of each treatment period, TAK-925 (or placebo) will be administered as 
a single 9-hour IV infusion commencing at approximately 0800. The infusion will be terminated 
at approximately 1700.
Rationale for Change: clarification of study procedures.
Section 2.0:STUDY SUMMARY also contains this change.
Change 8: It was clarified that subjects with an Epworth Sleepiness Scale (ESS) score <11 who 
are taking stimulants at screening may continue the screening process and repeat the ESS at Study 
Day -2 following washout.
The primary change occurs in Section 6.1: Study Design.
CCI
Property of Takeda: 
: ….
…. On
O
9-
: For Non-Comme
stency.
tency.
MARY
MAR
m
ified in t
ified i
oximatel
imate
-C
hange oc
ange o
or 
hour 
hour
pproxim
proxi
a:
Rationa
ation
f T
Sect
Sec
ty
p
nly and Subject to the Applicable Terms of Use
s o
erm
primary
rimary
e
pli
the PK o
he PK
Ap
dy i
y s to i
s to
K-925
-925 to
c to
S
is chang
is chan
an
mercial Use Only


TAK-925
Study No. TAK-925-2002
Page 96 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
Added text: Subjects with an ESS score of <11 who are taking stimulants at screening may 
continue the screening process and repeat the ESS at Study Day -2 following washout.
Rationale for Change: Clarification of study procedures.
The following sections also contain this change:
!
Section 2.0: STUDY SUMMARY.
!
Section 7.1: Inclusion Criteria.
Change 9: It was clarified in the study design that sodium oxybate must be discontinued at least 
4 weeks prior to screening.
The primary change occurs in Section 6.1: Study Design.
Added text: Sodium oxybate must be discontinued at least 4 weeks before screening.
Rationale for Change: Clarification.
Section 2.0:STUDY SUMMARY also contains this change.
Section 7.3: Excluded Medications, Table 7.a: Prohibited Drug Classes also contains this change
Change 10: The subject’s normal bedtime was clarified to be between 2200 and 2300.
The primary change occurs in Section 6.1: Study Design.
Added text: An overnight 8-hour nPSG will be performed commencing at approximately the 
subject’s normal bedtime (eg, between 2200 and 2300) to confirm that the subject does not have 
other comorbid sleep disorders…
Rationale for Change: Clarification.
Section 2.0:STUDY SUMMARY also contains this change.
Change 11:
The primary change occurs in Section 6.1: Study Design.
Rationale for Change: Clarification.
Section 2.0:STUDY SUMMARY also contains this change.
Change 12: The overview of inpatient unit study schedule was corrected and clarified.
The primary change occurs in Section 6.1: Study Design as revisions to Table 6.b: Overview of the 
Inpatient Unit Study Schedule
CCI
CCI
Property o
Ratio
Rat
S
pe
For Non-Commercial Use Only and Subject to the Applicable Terms of Use
f
ms
iscont
contini
ic
e A
eeks bef
eks b
o t
ct
ge.e.
ubj
bited Dr
ted D
d S
arified 
arified
a
tudy
udy De
D
y
On
G will be
will b
n 2200 
2200
se
catatioion.n
e
MARY
MAR
m
y ch
change
ang
F
Non-C
r No
For N
eda: F
d
y of Taked


TAK-925
Study No. TAK-925-2002
Page 97 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
Description of Changes: It was clarified that on Study Days 1 and 3, 
assessment would be 
performed in addition to study drug administration and PK and safety assessments. 
Rationale for Change: Clarification of study procedures.
Section 2.0:STUDY SUMMARY also contains this change.
The primary change occurs in Section 6.2.3: Rationale for Endpoints
Rationale for Change: Clarification.
Change 15: The safety risk related to heart rate in the criteria for premature discontinuation was 
changed from 115 to 100 bpm.
The primary change occurs in Section 6.3.1: Criteria for Premature Termination or Suspension of 
the Study
Initial Wording: Sustained HR >115 beats per minute (bpm) or sustained post-dose change from 
pre-dose baseline of ≥30 bpm.
New or Amended Wording: Sustained HR >115100 beats per minute (bpm) or sustained post-dose 
change from pre-dose baseline of ≥30 bpm.
CCI
CCI
CCI
C
C
I
CCI
Property o
The pr
The p
of Takeda:
for Ch
or C
ge
ge 15
15: : T
anged fr
nged f
ke
th
the
o
p
Ap
Applicable Terms of Use
f
ms
licable Te
Appli
a: For Non-Commercial Use Only and Subject to the A


TAK-925
Study No. TAK-925-2002
Page 98 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
Rationale for Change: Update of discontinuation criteria.
Section 7.5: Criteria for Discontinuation or Withdrawal of a Subject also contains this change.
Change 16: The safety risk related to mood changes in the criteria for premature discontinuation 
was limited to only severe changes in mood.
The primary change occurs in Section 6.3.1: Criteria for Premature Termination or Suspension of 
the Study
Initial Wording: Changes in subject mood, including feeling high, talkativeness, irritability, and 
hyperactivity.
New or Amended Wording: Severe cChanges in subject mood, including feeling high, 
talkativeness, irritability, and hyperactivity.
Rationale for Change: Update of discontinuation criteria.
Change 17: A safety risk for treatment-emergent serious adverse events (AEs) or severe AEs that 
are considered related to treatment was added to the criteria for premature discontinuation.
The primary change occurs in Section 6.3.1: Criteria for Premature Termination or Suspension of 
the Study
Added text: Any subject who experiences a treatment-emergent serious AE or a severe AE 
that is considered related to treatment.
Rationale for Change: Update of discontinuation criteria.
Section 7.5: Criteria for Discontinuation or Withdrawal of a Subject also contains this change.
Change 18: Text was added to clarify that, if a subject with a history of IH has a diagnostic 
nocturnal polysomnography (nPSG) or multiple sleep latency test (MSLT) older than 10 years (or 
the test results are not available), the investigator will obtain a current nPSG/MSLT.
The primary change occurs in Section 7.1: Inclusion Criteria, criterion #4.
Added text: Note: If there is a potential subject with a history of IH whose diagnostic 
nPSG/MSLT was performed more than 10 years ago or is not available and the subject 
continues to experience symptoms consistent with IH, the PI will obtain a current 
nPSG/MSLT.
Rationale for Change: Clarification of selection criteria.
Change 19: The apnea-hypopnea index (AHI) for subject selection was changed from ≤15 to 
≤10/hour. Also, it was added to the selection criteria that subjects should have a periodic limb 
movement arousal index (PLMAI) ≤15/hour.
The primary change occurs in Section 7.1: Inclusion Criteria.
Initial wording: nPSG (Study Day -2) demonstrates that subject does not have other comorbid 
sleep disorders (periodic limb movement index associated with arousals ≥15/hour) or clinically 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 99 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
significant nocturnal hypoxemia (oxygen saturation ≤80% for ≥5% of total sleep time) and that 
their AHI is ≤15 and total sleep time is ≥6.5 hours.
New or amended wording: nPSG (Study Day -2) demonstrates that subject does not have other 
comorbid sleep disorders (periodic limb movement index associated with arousals ≥15/hour) or 
clinically significant nocturnal hypoxemia (oxygen O2 saturation ≤80% for ≥5% of total sleep 
time) and that their AHI is ≤1510/hour, their PLMAI is ≤15/hour, and that their total sleep time 
is ≥6.5 hours.
Rationale for Change: Clarification of selection criteria.
The following sections also contain this change:

Section 2.0:STUDY SUMMARY.

Section 7.2: Exclusion Criteria.
Change 20: Redundant and/or duplicate selection criteria were removed from the protocol.
The primary change occurs in Section 7.1: Inclusion Criteria, formerly criterion #9.
Deleted text: Understand and be willing and able to comply with all study procedures and 
restrictions and agree to participate by providing written informed consent.
Rationale for Change: Clarification of selection criteria.
Change 21: Selection criteria related to contraception were reworded and clarified.
The primary change occurs in Section 7.1: Inclusion Criteria, criterion #12, #13 and #14.
Initial wording: For a male subject who is nonsterilized and sexually active with a female partner
of childbearing potential, the subject must meet the following birth control requirements:

Agrees to use an appropriate method of contraception, including a condom with or without 
spermicidal cream or jelly, from the first dose of study drug until 5 half-lives (1 day) plus 
90 days after the last dose of study drug. No restrictions are required for a vasectomized 
male subject, provided the subject is at least 1-year post-bilateral vasectomy procedure 
prior to the first dose of study drug. A male subject whose vasectomy procedure was 
performed less than 1 year prior to the first dose of study drug must follow the same 
restrictions as a non-vasectomized man. Appropriate documentation of surgical procedure 
should be provided.

Agrees to not donate sperm from the first dose of study drug until 5 half-lives plus 90 days 
after the last dose of study drug.
For a female subject of childbearing potential who is sexually active with a nonsterilized male 
partner, the subject must agree to use highly effective methods of contraception from signing of 
informed consent until 5 half-lives of TAK-925 (1 day) plus 30 days. Definitions and procedures 
for adequate contraception, pregnancy avoidance, and reporting responsibilities are defined in 
Appendix G.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 100 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
For female subjects to be classified as “not of childbearing potential”, the subject must meet 1 of 
the following requirements:

Postmenopausal (defined as 12 months of spontaneous amenorrhea in females aged 
>45 years or 6 months of spontaneous amenorrhea in females aged >45 years, with serum 
follicle-stimulating hormone [FSH] levels >40 mIU/mL).
Surgically sterile by hysterectomy and/or bilateral oophorectomy with appropriate documentation 
of surgical procedure.

Had a tubal ligation with appropriate documentation of surgical procedure.

Has a congenital condition resulting in no uterus.
New or amended wording: For a male subject who is nonsterilized and sexually active with a
female partner of childbearing potential, the subject must meet the following birth control 
requirements:

Agrees to use an appropriate method of contraception, including a condom with or without 
spermicidal cream or jelly, from the first dose of study drug until 5 half-lives (1 day) plus 
90 days after the last dose of study drug. No restrictions are required for a vasectomized 
male subject, provided the subject is at least 1-year post-bilateral vasectomy procedure 
prior to the first dose of study drug. A male subject whose vasectomy procedure was 
performed less than 1 year prior to the first dose of study drug must follow the same 
restrictions as a non-vasectomized man. Appropriate documentation of surgical procedure 
should be provided.

Agrees to not donate sperm from the first dose of study drug until 5 half-lives plus 90 days 
after the last dose of study drug.
For a female subject of childbearing potential who is sexually active with a nonsterilized male 
partner, the subject must agree to use highly effective methods of contraception from signing of 
informed consent until 5 half-lives of TAK-925 (1 day) plus 30 days. Definitions and procedures 
for adequate contraception, pregnancy avoidance, and reporting responsibilities are defined in 
Appendix G.
For female subjects to be classified as “not of childbearing potential”, the subject must meet 1 of 
the following requirements:

Postmenopausal (defined as 12 months of spontaneous amenorrhea in females aged 
>45 years or 6 months of spontaneous amenorrhea in females aged >45 years, with serum 
follicle-stimulating hormone [FSH] levels >40 mIU/mL).
Surgically sterile by hysterectomy and/or bilateral oophorectomy with appropriate documentation 
of surgical procedure.

Had a tubal ligation with appropriate documentation of surgical procedure.
Has a congenital condition resulting in no uterus.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 101 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
12. Male subjects who are non-sterilized and their female sexual partners of childbearing 
potential must follow the contraception methods described in Appendix G. In addition, male 
subjects must agree to not donate sperm from the first dose of study drug until 5 half-lives 
plus 90 days after the last dose of study drug.
13. Female subjects of childbearing potential who are sexually active with a non-sterilized 
male partner must agree to use a highly effective method of contraception as described in 
Appendix G from signing of informed consent until 5 half-lives of TAK-925 plus 30 days.
14. Female subjects who are post-menopausal or permanently sterile according to the 
definitions in Appendix G.
Rationale for Change: Clarification of selection criteria.
Change 22: It was added to the selection criteria that subjects with an average nightly sleep 
duration ≤8 hours (480 minutes) will be excluded.
The primary change occurs in Section 7.2: Exclusion Criteria, criterion #1.
Initial wording: Insufficient sleep syndrome as evidenced by sleeping >2 hours/night more on 
“off-days” relative to “work days” as determined by actigraphy and sleep diary obtained prior to 
the nPSG (Study Day -2).
New or amended wording: Insufficient Average nightly sleep duration is ≤8 hours (480 
minutes) and the subject has insufficient sleep syndrome as evidenced by sleeping >2 
hours/night more on “off-days” relative to “work days” as determined by actigraphy and sleep 
diary obtained prior to the nPSG (Study Day -2).
Rationale for Change: Clarification of study procedures.
Section 2.0: STUDY SUMMARY also contains this change.
Change 23: It was clarified in the selection criteria that the alcohol test used during the study will 
be a breathalyzer.
The primary change occurs in Section 7.2: Exclusion Criteria, criterion #2.
Initial wording: Positive urine screen for drugs of abuse and/or positive alcohol test at screening 
and Study Day -2. An exception at screening is made for stimulants or other drugs that the subject 
has been prescribed, but the drug screen must be negative at Study Day -2.
New or amended wording: Positive urine screen for drugs of abuse and/or positive alcohol 
breathalyzer test at screening and Study Day -2. An exception at screening is made for stimulants 
or other drugs that the subject has been prescribed, but the drug screen must be negative at Study 
Day -2.
Rationale for Change: Clarification of study procedures.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 102 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
Change 24: It was clarified that subjects with a resting heart rate (HR) outside of the range 
40-90 bpm (rather than 45-100 bpm) will not be eligible for selection.
The primary change occurs in Section 7.2: Exclusion Criteria, criterion #5.
Initial wording: During screening, the subject has a resting HR outside of the range of 45 to 100
bpm, confirmed on repeat testing within a maximum of 30 minutes.
New or amended wording: During screening, the subject has a rResting HR outside of the range of 
4540 to 10090 bpm, confirmed on repeat testing within a maximum of 30 minutes off stimulants.
Rationale for Change: Clarification of study procedures.
Section 2.0: STUDY SUMMARY also contains this change.
Change 25: It was clarified that subjects with a usual bedtime later than 2400 (midnight) rather 
than 0100 are not eligible to participate.
The primary change occurs in Section 7.2: Exclusion Criteria, criterion #7.
Initial wording: Usual bedtime later than 01:00 or an occupation requiring nighttime shift work or 
variable shift work within the past 6 months, or travel with significant jet lag within 14 days before 
Study Day -2
New or amended wording: Usual bedtime later than 0124:00 (midnight) or an occupation 
requiring nighttime shift work or variable shift work within the past 6 months, or travel with 
significant jet lag within 14 days before Study Day -2
Rationale for Change: Clarification of study procedures.
Section 2.0: STUDY SUMMARY also contains this change.
Change 26: The exclusion criterion on nicotine dependence that is likely to have an effect on sleep 
was expanded to include smoking ≥10 cigarettes per day.
The primary change occurs in Section 7.2: Exclusion Criteria, criterion #10.
Initial wording: Nicotine dependence that is likely to have an effect on sleep (eg, a subject who 
routinely awakens at night to smoke) and/or an unwillingness to discontinue all smoking and 
nicotine use during the confinement portion of the study (Day -2 to Day 4).
New or amended wording: Nicotine dependence that is likely to have an effect on sleep (eg, a 
subject who routinely awakens at night to smoke) or challenge the conduct of this study 
(smokes ≥10 cigarettes/day) and/or an unwillingness to discontinue all smoking and nicotine use 
during the confinement portion of the study (Day -2 to Day 4).
Rationale for Change: Clarification of study procedures.
Section 2.0: STUDY SUMMARY also contains this change.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 103 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
Change 27: It was added to the exclusion criteria that subjects unwilling to discontinue all 
caffeine during the confinement period of the study will not be eligible for selection.
The primary change occurs in Section 7.2: Exclusion Criteria, criterion #11.
Initial wording: Caffeine consumption of more than 600 mg/day for 7 days before Study Day 1 (1 
serving of coffee is approximately equivalent to 120 mg of caffeine).
New or amended wording: Caffeine consumption of more than 600 mg/day for 7 days before 
Study Day 1 (1 serving of coffee is approximately equivalent to 120 mg of caffeine) and/or 
unwilling to discontinue all caffeine during the confinement portion of the study (Day -2 to 
Day 4).
Rationale for Change: Clarification of study procedures.
Section 2.0: STUDY SUMMARY also contains this change.
Change 28: Major depression was added as an example of psychiatric disorders for which 
subjects will be excluded from participation.
The primary change occurs in Section 7.2: Exclusion Criteria, criterion #13.
Initial wording: History or presence of any unstable medical condition (eg, fibromyalgia, chronic 
fatigue syndrome, Lyme disease, chronic pain syndromes), behavioral or psychiatric disorder 
(including active suicidal ideation), or surgical history that could affect the safety of the subject or 
interfere with study efficacy, safety, PK assessments, or the ability of the subject to complete the 
trial per the judgment of the investigator.
New or amended wording: History or presence of any unstable medical condition (eg, 
fibromyalgia, chronic fatigue syndrome, Lyme disease, chronic pain syndromes), behavioral or 
psychiatric disorder (including major depression or active suicidal ideation), or surgical history 
that could affect the safety of the subject or interfere with study efficacy, safety, PK assessments, 
or the ability of the subject to complete the trialstudy per the judgment of the investigator.
Rationale for Change: Clarification of study procedures.
Section 2.0: STUDY SUMMARY also contains this change.
Change 29: The period for refraining from certain food products was corrected to be through 
Study Day 4 (including washout intervals between treatment periods) rather than until the 
follow-up visit.
The primary change occurs in Section 7.2: Exclusion Criteria, criterion #27.
Initial wording: The subject is unable to refrain from or anticipates using food products (Table 
7.b), including grapefruit juice, beginning approximately 7 days prior to administration of the first 
dose of study drug, throughout the study (including the washout interval between treatment 
periods), and until the follow-up visit.
New or amended wording: The subject is uUnable to refrain from or anticipates using food 
products (listed in Table 7.b), including grapefruit juice, beginning approximately 7 days prior to 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 104 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
administration of the first dose of study drug, throughout the studythrough Study Day 4 inclusive
(including the washout interval between treatment periods), and until the follow-up visit.
Rationale for Change: Clarification of study procedures.
Change 30: It was clarified that known in vivo cytochrome P-450 (CYP)3A (not only CYP3A4) 
inhibitors or inducers were prohibited drug classes.
The primary change occurs in Section 7.3: Excluded Medications within Table 7.aProhibited 
Drug Classes
Description of Changes: CYP3A4 was changed to CYP3A across the table.
Rationale for Change: Correction of prohibited drug classes.
Change 31: It was clarified that subjects will receive 3 standardized meals per day during 
confinement.
The primary change occurs in Section 7.4.1: Diet and Fluids.
Initial wording: Subjects will receive 3 standardized meals each day including approximately 30% 
fat (relative to the total calories) during confinement in the unit.
Amended or new wording: Subjects will receive 3 standardized meals per day each day including 
approximately 30% fat (relative to the total calories) during confinement in the unit.
Rationale for Change: Clarification of study procedures.
Change 32: Food, drink, and other product restrictions were clarified.
The primary change occurs in Section 7.4.1: Diet and Fluids within Table 7.b List of Restricted 
Food, Drinks and Other Products
Description of Changes:
In the xanthine and/or caffeine category, it was clarified that these products are to be completely 
restricted from Inpatient Study Day -2 to Discharge on Study Day 4.
Seville oranges were added to the list of food products to be completely restricted from Inpatient 
Study Day -2 to Discharge on Study Day 4. Consumption of all fruits other than grapefruit and 
Seville oranges is allowed on all days of the study.
Rationale for Change: Clarification of study procedures.
Change 33: It was added to the protocol that subjects will be allowed to go on short supervised 
walks on washout days.
The change occurs in Section 7.4.2: Activity.
Added text: Subjects will avoid unaccustomed strenuous physical activity (ie, weight lifting, 
running, bicycling) from the screening visit until administration of the initial dose of study drug, 
throughout the study (including the washout interval between treatment periods), and until the 
follow-up visit. Short supervised walks outside the unit are permitted on washout days.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 105 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
Rationale for Change: Clarification of study procedures.
Change 34: It was clarified that lack of efficacy should not be recorded in the voluntary 
withdrawal category of discontinuation criteria. It was also clarified that the criterion is applicable 
to subjects or their legally acceptable representative.
The change occurs in Section 7.5: Criteria for Discontinuation or Withdrawal of a Subject, 
criterion #4.
Added text: 4. Voluntary withdrawal: The subject (or subject’s legally acceptable 
representative) wishes to withdraw from the study. The reason for withdrawal, if provided, 
should be recorded in the eCRF 
Note: All attempts should be made to determine the underlying reason for the withdrawal and, 
where possible, the primary underlying reason should be recorded (ie, withdrawal due to an AE 
should not be recorded in the “voluntary withdrawal” category). Similarly, lack of efficacy 
should not be recorded in the “voluntary withdrawal” category.
Rationale for Change: Clarification of study procedures.
Change 35: It was corrected that details of the randomization schedule are provided in the 
pharmacy manual rather than the interactive voice response (IVRS) manual.
The change occurs in Section 8.3: Randomization Code Creation and Storage
Initial wording: Details are in the IVRS system manual.
New or amended wording: Details are in the IVRS system pharmacy manual.
Rationale for Change: Correction of study procedures.
Change 36: It was clarified that informed consent must be obtained before beginning withdrawal 
of excluded medications.
The change occurs in Section 9.1.1: Informed Consent Procedure
Initial wording: Informed consent must be obtained prior to the subject entering into the study, and 
before any protocol-directed procedures are performed.
New or amended wording: Informed consent must be obtained prior tobefore the subject entering 
intoenters the study, and before any protocol-directed procedures are performed, including
withdrawal of medications.
Rationale for Change: Clarification of study procedures.
Change 37: The time subjects should rest in a bed following dosing was corrected from 4 to 2 
hours.
The change occurs in Section 9.2.6: Vital Sign Procedure
Initial wording: Subjects should continue to rest in a bed with the head of the bed at 30 degrees 
from the time of dosing until 4 hours post-dose except to stand if necessary for trial-related 
procedures.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 106 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
New or amended wording: Subjects should continue to rest in a bed with the head of the bed at 30 
degrees from the time of dosing until 4 2 hours post-dose except to stand if necessary for trial
study-related procedures.
Rationale for Change: Clarification of study procedures.
Change 38: The actigraphy procedure was clarified.
The primary change occurs in Section 9.1.6: Actigraphy and Sleep Diary
Initial wording:
9.1.6 Actigraphy
Seven consecutive days of nocturnal actigraphy, supported by a sleep diary, will be obtained prior 
to the nPSG (Study Day 2) to ensure that a subject’s average nightly sleep duration is ≥420 
minutes during the subject’s normal nocturnal sleep period and the subject does not have 
“insufficient sleep syndrome” as evidenced by sleeping >2 hours/night more on “off-days” relative 
to “work days”.
New or amended wording:
9.1.6 Actigraphy and Sleep Diary
Seven Approximately 7 consecutive days of nocturnal actigraphy, supported by a sleep diary, will 
be obtained prior to the nPSG (recorded beginning on Study Day -29 and ending on Study Day 
-3 (ie, the day before their Study Day -2 admission to the clinical unit). Data from the 
actigraphy device will be downloaded by the site ) to ensure that a subject’s average nightly 
sleep duration is subject sleeps on average 420 min/night and does not have insufficient sleep 
syndrome, as specified in the exclusion criteria ≥420 minutes during the subject’s normal 
nocturnal sleep period and the subject does not have “insufficient sleep syndrome” as evidenced 
by sleeping >2 hours/night more on “off-days” relative to “work days”.
Rationale for Change: Clarification of study procedures.
The following sections also contain this change:

Section 2.0: STUDY SUMMARY.

Section 6.1: Study Design.

Section 7.1: Inclusion Criteria

Appendix A Schedule of Study Procedures, footnote “b”.
Change 39: The duration of the nPSG was clarified.
The primary change occurs in Section 9.3.1: nPSG
Initial wording: On Study Day -2, subjects will undergo an 8-hour nPSG, commencing at 
approximately the subject’s usual bedtime, to exclude any significant comorbid sleep disorders 
other than IH.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 107 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
New or amended wording: On Study Day -2, subjects will undergo an 8-hour nPSG, commencing 
at approximately the subject’s usual bedtime, but not after 2300, to exclude any significant 
comorbid sleep disorders other than IH.
Rationale for Change: Clarification of study procedures.
Rationale for Change: Clarification of study procedures.
Change 41: International normalized ratio (INR) measurement was added to the overview of 
laboratory tests for subjects with an alanine aminotransferase (ALT) or aspartate aminotransferase 
(AST) level >3 times the upper limit of normal (ULN).
The primary change occurs in Section 9.4: Laboratory Assessments/Procedures within Table 9.a
Clinical Laboratory Tests
Description of changes: INR was added to the list of serum tests along with a footnote that it 
should only be tested if ALT or AST >3 times the ULN.
Rationale for Change: Correction of study procedures.
Rationale for Change: Correction of study procedures.
Change 43: The procedure on collecting and reporting of serious adverse events (SAEs) was 
clarified.
The primary change occurs in Section 10.2.2: Collection and Reporting of SAEs
Initial wording: 
10.2.2 Collection and Reporting of SAEs
When an SAE occurs through the AE collection period it should be reported according to the 
following procedure:
A Takeda SAE form must be completed, in English or in Japanese, and signed by the investigator 
CCI
CCI
Property
Ini
Inititi
ty of Takeda: Fo
or Chan
or Cha
F
43
43: : Th
Th
ed.
ed.
da
The prim
e pr
f T
l Use Only and Subject to the 
he
was add
as add
(ALT) o
ALT)
to
Assessm
ssess
S
ist of se
ist of s
es the U
the
ly
udy
dy pro
pr
y
se
rms of Use
s o
ty 
For Non-Commercial U
e Applicable Term


TAK-925
Study No. TAK-925-2002
Page 108 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
immediately or within 24 hours of first onset or notification of the event. The information should 
be completed as fully as possible but contain, at a minimum:
A short description of the event and the reason why the event is categorized as serious.

Subject identification number.

Investigator’s name.

Name of the study drug(s).

Causality assessment.
The SAE form should be transmitted within 24 hours to the attention of the contact listed in 
Section 1.1.
Any SAE spontaneously reported to the investigator following the AE collection period should be 
reported to the sponsor if considered related to study participation.
Reporting of serious PTEs will follow the procedure described for SAEs
New or amended text:
10.2.2 Collection and Reporting of SAEs
When an SAE occurs through the AE collection period it should be reported according to the 
following procedure:
SAEs should be reported via SAE eCRF in Rave EDC, which is the preferred method of 
reporting SAEs. A Takeda SAE eCRF must be completed in English and signed by the 
investigator immediately or within 24 hours of first onset or notification of the event. The 
information should be completed as fully as possible but should contain, at a minimum:
A Takeda SAE form must be completed, in English or in Japanese, and signed by the investigator 
immediately or within 24 hours of first onset or notification of the event. The information should 
be completed as fully as possible but contain, at a minimum:

A short description of the event and the reason why the event is categorized as serious.

Subject identification number.

Investigator’s name.

Name of the study drug(s).

Causality assessment.
The SAE form should be transmitted within 24 hours to the attention of the contact listed in 
Section 1.1.
If access to Rave EDC is not feasible within 24 hours of receiving the event, the paper SAE 
forms should be submitted via fax. The SAE form should be completed within 24 hours of 
first onset or notification of the event, signed by the investigator, and transmitted via fax or 
email to the attention of the contact listed in Section 1.1. In case of fax, site personnel need to 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 109 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
confirm successful transmission of all pages and include an e-mail address on the fax cover 
sheet so that an acknowledgment of receipt can be returned via e-mail within 1 business day.
Email submission of SAE forms (to the appropriate e-mail address listed below) with a 
portable document format (PDF) attachment should only be used in the case where fax is not 
possible and access to Rave EDC is not feasible within 24 hours of receiving the event. In 
case of e mail, site personnel need to confirm successful transmission by awaiting an 
acknowledgment of the receipt via e mail within 1 business day.
!
United States and Canada: PVSafetyAmericas@tpna.com
!
Rest of World: eupv@tgrd.com
If SAEs are reported via fax or by email, Rave EDC must be updated as soon as possible 
with the appropriate information.
Any SAE spontaneously reported to the investigator following the AE collection period 
should be reported to the sponsor if considered related to study participation. 
Any SAE spontaneously reported to the investigator following the AE collection period should be 
reported to the sponsor if considered related to study participation.
Reporting of serious PTEs will follow the procedure described for SAEs.
Rationale for Change: Correction of study procedures.
Change 45: The term “adverse events of special interest” was removed from the description of the 
safety analyses.
The primary change occurs in 13.1.5: Safety Analysis
Deleted text: Standard summaries of TEAEs, AESIs, clinical safety labs, vital
Rationale for Change: correction
Change 46: A footnote was added to the Schedule of Study Procedures table to allow optional 
pre-screening on a case-by-case basis.
The changes occur in Appendix A Schedule of Study Procedures and in Appendix B
Added text: a Optional pre-screening testing on a case-by-case basis as approved by Takeda.
PI is responsible for performance and interpretation of nPSG/MSLT
CCI
CCI
Property of 
Ration
Ratio
of
Ch
C
Takeda: 
ry chang
chan
y
: For No
erm “ad
rm “a
No
:
d text:
text: S
ked
e Only and Subject to the Applicable Terms of Use
is not
s not
nt. In 
nt. In
g an 
an 
ated as s
ted a
ing the 
ng th
o study 
study
owing t
wing 
S
parti
articip
c
nd
dure
ure des
de
ly
procedu
oced
On
rty
Non-Commercial Use
f Ta


TAK-925
Study No. TAK-925-2002
Page 110 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
Rationale for Change: Correction of study procedures.
Change 47: The measurement of O2 saturation was added to the Schedule of Study Procedures 
table.
The primary change occurs in Appendix A Schedule of Study Procedures
Description of changes: A row was added for O2 saturation measurement at screening.
Rationale for Change: clarification of study procedures.
Rationale for Change: Correction of study procedures.
Change 49: It was added to the Schedule of Study Procedures that urine drug screen and 
pregnancy test results should be available before dosing on Day 1 of Treatment Period 1
The primary change occurs in Appendix A Schedule of Study Procedures
Description of changes: Footnote j “Urine drug screen and pregnancy test results should be
available before dosing on Day 1 of Treatment Period 1.” was added.
Rationale for Change: clarification of study procedures.
Rationale for Change: correction of study procedures.
This change also occurs in Section 9.6: Blood Volume
Change 51: The urine pregnancy test was moved from Study Day-1 to Study Day -2 in the 
Schedule of Study Procedures table.
The primary change occurs in Appendix A Schedule of Study Procedures
Description of changes: the X for the urine pregnancy test was moved from Study Day -1 to Study 
Day -2.
Rationale for Change: correction of study procedures.
Change 52: A footnote was added to the Schedule of Study Procedures table to clarify that 
CCI
CCI
Property of Takeda: Fo
r Chang
Cha
nge also
ge als
da
nge
nge 51
51:
chedule 
hedule
ke
The p
The
y o
rcial Use Only and Subje
bje
cedures
edure
sing on 
ng o
S
edule of
edule o
ly
drug scr
rug sc
atm
tment P
en
O
 of stud
of stu
al
cable Terms of Use
ms
Te
ble
D
pe
ject to the Applica
For Non-Commerc


TAK-925
Study No. TAK-925-2002
Page 111 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
glycosylated hemoglobin will be assessed only in diabetic subjects.
The primary change occurs in Appendix A Schedule of Study Procedures
Added text: h Glycosylated hemoglobin only in diabetic subjects.
Rationale for Change: clarification of study procedures.
This change also occurs in Section 9.4: Laboratory Assessments/Procedures, Table 9.a Clinical 
Laboratory Tests.
Change 53: Footnotes were added to the Schedule of Study Procedures table to clarify site staff 
will make every effort to keep subjects awake following completion of clinical testing procedures 
on Study Day -2 and during the day from 0700 until between 2200-2300 on Study Days 2 and 4.
The primary change occurs in Appendix A Schedule of Study Procedures
Added text: n Following completion of clinical testing procedures, site staff will make every 
effort to keep subjects awake until between 2200-2300.
o On Study Days 2 and 4, site staff will make every effort to keep subjects from sleeping 
during the day from 0700 until between 2200-2300.
Rationale for Change: clarification of study procedures.
CCI
Property of Takeda: For Non-Commercial Use Only and Subject t
dures, s
ures
ffort to
ffort to
.
t to the Applicable Terms of Use
of
m
.a.a Clini
Clin
T
to cl
o clari
ar
nical tes
ical te
0 on Stu
on S
ica
edures
dures
th
t t
cedures
edure
a
operty of Takeda: For Non-Commercial Use On


TAK-925
Study No. TAK-925-2002
Page 112 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Us


TAK-925
Study No. TAK-925-2002
Page 113 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
operty of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 114 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
operty of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 115 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 116 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
CCI
Pr
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 117 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
roperty of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925
Study No. TAK-925-2002
Page 118 of 118
Protocol Incorporating Amendment No. 02
04 March 2020
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use



(/(&7521,&6,*1$785(6
Signed by 
Meaning of Signature 
Server Date 
(dd-MMM-yyyy HH:mm ‘UTC’) 
GGG
䣃䣯䣧䣰䣦䣯䣧䣰䣶䢢䢲䢴䢢䣶䣱䢢䣃䢢䣒䣪䣣䣵䣧䢢䢳䣤䢢䣔䣣䣰䣦䣱䣯䣫䣼䣧䣦䢮䢢䣆䣱䣷䣤䣮䣧䢯䣄䣮䣫䣰䣦䢮䢢䣒䣮䣣䣥䣧䣤䣱䢯䣅䣱䣰䣶䣴䣱䣮䣮䣧䣦䢮䢢䣅䣴䣱䣵䣵䣱䣸䣧䣴䢢䣕䣶䣷䣦䣻䢢䣱䣨䢢䣣䢢䣕䣫䣰䣩䣮䣧
䣋䣰䣶䣴䣣䣸䣧䣰䣱䣷䣵䢢䣋䣰䣨䣷䣵䣫䣱䣰䢢䣆䣱䣵䣧䢢䣱䣨䢢䣖䣃䣍䢯䢻䢴䢷䢢䣫䣰䢢䣒䣣䣶䣫䣧䣰䣶䣵䢢䣙䣫䣶䣪䢢䣋䣦䣫䣱䣲䣣䣶䣪䣫䣥䢢䣊䣻䣲䣧䣴䣵䣱䣯䣰䣫䣣
%LRVWDWLVWLFV$SSURYDO
0DU87&
&OLQLFDO3KDUPDFRORJ\$SSURYDO
0DU87&
&OLQLFDO6FLHQFH$SSURYDO
0DU87&
PPD
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
e Te
ate 
te
ble T
HH:mm ‘U
H:mm
Ter
ble
87&
87


0DU
0DU

SAP_001.pdf: 


Other information as needed to protect confidentiality of Takeda or partners, personal
information, or to otherwise protect the integrity of the clinical study.
Title: A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Crossover Study of a Single 
Intravenous Infusion Dose of TAK-925 in Patients With Idiopathic Hypersomnia
NCT Number: NCT04091438
SAP Approve Date:  22 April 2020
Certain information within this Statistical Analysis Plan has been redacted (ie, specific content is masked 
irreversibly from view with a black/blue bar) to protect either personally identifiable (PPD) information 
or company confidential information (CCI). 
This may include, but is not limited to, redaction of the following: 
Named persons or organizations associated with the study.
Proprietary information, such as scales or coding systems, which are considered confidential 
information under prior agreements with license holder.


1.0
TITLE PAGE
STATISTICAL ANALYSIS PLAN
STUDY NUMBER: TAK-925-2002
A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Crossover Study of a Single
Intravenous Infusion Dose of TAK-925 in Patients With Idiopathic Hypersomnia
PHASE: 1b
Version: Final
Date: 22 April 2020
Prepared by:
Based on:
Protocol Version: Amendment 2
Protocol Date: 04 March 2020
PPD
Property of Takeda: For N
otocol
ocol V
l
mmercial Use Only and Subject to the Applicable Terms of Use
rossover
ssove
Idiopat
Idiop
: Final
Fina
22 Apri
22 Ap
Proto
Prot
Non-Com
Prope


TAK-925-2002
Page 2 of 23
Statistical Analysis Plan              Final
22 April 2020
2.0
TABLE OF CONTENTS
1.0
TITLE PAGE ..................................................................................................................1
2.0
TABLE OF CONTENTS.................................................................................................2
3.0
LIST OF ABBREVIATIONS..........................................................................................4
4.0
OBJECTIVES .................................................................................................................6
4.1
Primary Objectives ....................................................................................................6
4.2
Secondary Objectives.................................................................................................6
4.3
Exploratory Objectives ..............................................................................................6
4.4
Study Design .............................................................................................................6
5.0
ANALYSIS ENDPOINTS...............................................................................................9
5.1
Primary Endpoints .....................................................................................................9
5.2
Secondary Endpoints .................................................................................................9
5.3
Exploratory Endpoints ...............................................................................................9
6.0
DETERMINATION OF SAMPLE SIZE.......................................................................10
7.0
METHODS OF ANALYSIS AND PRESENTATION...................................................10
7.1
General Principles....................................................................................................10
7.1.1
Definition of Study Days....................................................................................10
7.1.2
Definition of Study Visit Windows ....................................................................11
7.1.3
Conventions for Missing Adverse Event Dates...................................................11
7.1.4
Conventions for Missing Concomitant Medication Dates...................................12
7.1.5
Conventions for Missing PK Data......................................................................12
7.2
Analysis Sets ...........................................................................................................12
7.3
Disposition of Subjects ............................................................................................12
7.4
Demographic and Other Baseline Characteristics.....................................................13
7.5
Medical History and Concurrent Medical Conditions...............................................13
7.6
Medication History and Concomitant Medications...................................................13
7.7
Study Drug Exposure and Compliance.....................................................................13
7.8
Efficacy Analysis.....................................................................................................13
7.9
Pharmacodynamic Analysis .....................................................................................13
7.10
Pharmacokinetic Analysis........................................................................................15
7.10.1 Pharmacokinetic Analysis ..................................................................................15
7.10.2 PK/PD and Safety Analysis................................................................................15
7.11
Safety Analysis........................................................................................................16
7.11.1 Adverse Events ..................................................................................................16
7.11.2 Clinical Laboratory Evaluations .........................................................................17
...2
........
..... 4
.........
....
.........
.....
........
.......
.........
.....
........
..
........
....
.........
....
........
.......
.........
.....
........
.
TATIO
TATI
.........
....
........
....
Window
Windo
ng Adve
ng Adv
issing C
ssing C
r Missin
Missi
........
....
of Subje
Sub
f
aphic an
phic a
cal Hist
cal His
edicat
dica io
Study
Study
Eff
E
7.9
7.
7.1
7


TAK-925-2002
Page 3 of 23
Statistical Analysis Plan              Final
22 April 2020
7.11.3 Vital Signs .........................................................................................................17
7.11.4 12-Lead ECGs ...................................................................................................18
7.11.5 Other Observations ............................................................................................19
7.12
Interim Analysis ......................................................................................................19
7.13
Changes in the Statistical Analysis Plan from Protocol.............................................19
8.0
REFERENCES..............................................................................................................20
LIST OF IN-TEXT TABLES
Table 4.a
Summary of Treatment Assignment for Each Sequence .......................................7
Table 4.b
Overview of the Inpatient Unit Study Schedule....................................................8
LIST OF APPENDICES
Appendix A
Criteria for Identification of Markedly Abnormal Laboratory Values .................21
Appendix B
Criteria for Markedly Abnormal Values for Vital Signs......................................22
Appendix C
Criteria for Markedly Abnormal Values for Electrocardiograms.........................23
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
19
.....
....19
19
.........
.......
........
......
........
.....
........
....
Abnorm
Abnorm
lues for
ues fo
Values
Value


TAK-925-2002
Page 4 of 23
Statistical Analysis Plan              Final
22 April 2020
3.0
LIST OF ABBREVIATIONS
AE
adverse event
AHI
apnea-hypopnea index
ALT
alanine aminotransferase
AST
aspartate aminotransferase
AUC∞
area under the plasma concentration-time curve from time 0 to infinity
AUClast
area under the plasma concentration-time curve from time 0 to time of the last 
quantifiable concentration
BDI-II
Beck Depression Inventory II
BLQ
below the limit of quantification
BMI
body mass index
BP
blood pressure
CI
confidence interval
Cmax
maximum observed plasma concentration
Ceoi
concentration at the end of the infusion
CPAP
continuous positive airway pressure
CRF
case report form
C-SSRS
Columbia - Suicide Severity Rating Scale
CV
coefficient of variation
DBP
diastolic blood pressure
ECG
electrocardiogram
eCRF
electronic case report form
EDS
excessive daytime somnolence
ESS
Epworth Sleepiness Scale
ET
early termination
FSH
follicle-stimulating hormone
HR
heart rate
ICH
International Conference on Harmonization
ICSD-3
International Classification of Sleep Disorders, 3rd edition
IH
idiopathic hypersomnia
IV
intravenous
LFT
liver function test
LS
least square
MAV
markedly abnormal value
MedDRA
Medical Dictionary for Regulatory Activities
MSLT
multiple sleep latency test
NPSG
nocturnal polysomnography
OSA
obstructive Sleep Apnea
CCI
CCI
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
he last 
he last
ting Scal
ting Sc
port form
ort for
time som
me so
Sleepines
eepine
erminatio
minat
icle
icle-stim
sti
heart ra
eart r
Inter
Int
I
S
MAV
MA
Me
M


TAK-925-2002
Page 5 of 23
Statistical Analysis Plan              Final
22 April 2020
PK
pharmacokinetic(s)
PLMAI
periodic limb movement arousal index
PSG
polysomnography
PTE
pretreatment event
QTcF
QT interval with Fridericia correction method
RT
reaction time
SAE
serious adverse event
SBP
Systolic blood pressure
SD
standard deviation
SE
standard error
SI
International System of Units
t1/2z
terminal phase half-life
TEAE
treatment-emergent adverse event
tmax
time of first occurrence of Cmax
ULN
upper limit of normal
WHO
World Health Organization
CCI


TAK-925-2002
Page 6 of 23
Statistical Analysis Plan              Final
22 April 2020
4.0
OBJECTIVES
4.1
Primary Objectives
The primary objective of this study is to evaluate the safety and tolerability of administering a 
single IV infusion of TAK-925 to adult subjects with IH.
4.2
Secondary Objectives
The secondary objective of this study is to investigate the PK of a single IV infusion of TAK-925 
in adult subjects with IH.
4.4
Study Design
This is a phase 1b, randomized, double-blind, placebo-controlled, 2-period, 2-treatment 
crossover study to evaluate the PK,
safety, and tolerability of a single IV infusion dose of 
TAK-925 in subjects with IH. Subjects will be males and females aged 18 through 75 years, 
inclusive, with IH diagnosed according to the ICSD-3 criteria as verified by a previous nocturnal 
polysomnography (nPSG) and multiple sleep latency test (MSLT) study performed within the 
last 10 years. 
The treatment periods begin on Day 1 of Treatment Period 1 (Study Day 1) with Treatment 
Period 2 commencing on Study Day 3. In the morning of Day 1 of Treatment Period 1, eligible 
subjects will be randomized to 1 of 2 sequence groups as listed in Table 4.a. After
randomization, the subject will be dosed in 2 treatment periods according to the order defined by 
the sequence group to which he/she is randomized. On Day 1 of each treatment period, TAK-925 
(or placebo) will be administered as a single 9-hour IV infusion commencing at approximately 
0800.
CCI
CCI
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
g a
usio
usion of
n o
uble
ble-blb
PK,
K,
H. Subje
Subj
sed acco
ed acc
SG) and
G) and
eriods b
eriods
mmencin
menc
will be ra
l be r
izat
zatioion,
equence
equenc
or plplaceb
a
0800.
0800
Use Only and Subject to the Ap
merc
CCI
CC
erty
e
C


TAK-925-2002
Page 7 of 23
Statistical Analysis Plan              Final
22 April 2020
A summary of the treatment assignment and sequence is presented below:
Table 4.a
Summary of Treatment Assignment for Each Sequence
Sequence
N
Treatment Period 1
Treatment Period 2
1
20
TAK-925
112 mg
Placebo
2
20
Placebo
TAK-925
112 mg
At the screening visit, eligible subjects who have an ESS score of ≥11 will complete medical 
histories and physical examinations, semi-recumbent vital signs assessment, a 12-lead ECG, 
Beck Depression Inventory II (BDI-II), Columbia Suicide Severity Rating Scale (C-SSRS), and 
clinical safety laboratory tests. Subjects with an ESS score of <11 who are taking stimulants at 
screening may continue the screening process and repeat the ESS at Study Day -2 following 
washout. A total of 40 subjects will be randomized so that at least 36 subjects will complete the 
study. To avoid enrollment of short sleepers with chronic sleep deprivation, prospective 
participants will complete approximately 7 consecutive days of actigraphy supported by a sleep 
diary beginning on Study Day -9 and ending on Study Day -3 (ie, the day before their Study
Day -2 admission to the clinical unit), to ensure an average nightly sleep duration of 
≥420 minutes (7 hours) during the subject’s normal nocturnal sleep period, and, if the subject’s 
average nightly sleep duration is ≤480 minutes (8 hours), that the subject does not have 
insufficient sleep syndrome (sleeping >2 hours/night more on “off days” than on “work days”). 
During screening, eligible subjects must discontinue their stimulant medications used for 
treatment of IH. Medications must be discontinued for a minimum of 7 days or at least 
5 half-lives of each medication, whichever is longer, before the first day of dosing (Day 1 of
Treatment Period 1). Sodium oxybate must be discontinued at least 4 weeks before screening. 
The screening period is up to 28 days. Following screening, subjects who meet all screening 
entry criteria will be admitted to the clinical unit (Study Day -2). Semi-recumbent vital signs will
be obtained following admission, and the ESS will be recorded in the late afternoon. An 
overnight 8-hour nPSG will be performed commencing at approximately the subject’s normal 
bedtime (eg, between 2200 and 2300) to confirm that the subject does not have other comorbid 
sleep disorders or clinically significant nocturnal hypoxemia (O2 saturation ≤80% for ≥5% of 
total sleep time), and to confirm the apnea hypopnea index (AHI) is ≤10/hour and the periodic 
limb movement index associated with arousals (PLMAI) is ≤15/hour.
Study Day -1 is the designated baseline assessment day and is also intended for accommodation 
to sleeping in the clinical unit. 
afety assessments including BP, pulse, respiration rate, and ECG 
will be collected per the Schedule of Study Procedures.
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
d 2
o
m
AK-925
92
112
112 m
ca
co
comp
mplel
ment, a 1
nt, a
ating S
ing 
who ar
who 
SS at St
S at S
least 3
least 
sleep d
sleep 
e days o
days 
udy Day
Da
y
an avera
n ave
ormal n
rmal 
utes (8
tes (8 h
hours/
hour
ust disc
ust d
be disc
be di
whiche
which
m oxyba
oxyb
up to 28
to 2
admitted
admitt
ing a
ng adm
dm
ur nPSG
ur nPS
between
betwe
rders or
ders o
eep time
ep tim
mo
movem
ve
Study
tudy D
y
to sl
to s
er


TAK-925-2002
Page 8 of 23
Statistical Analysis Plan              Final
22 April 2020
. 
There will be a minimum 24-hour washout interval between the end of TAK-925 infusion and 
the commencement of treatment in the subsequent treatment period to allow for complete 
elimination of the preceding treatment effect. Study Days 2 and 4 are washout days. 
Blood samples for 
determination of TAK-925 plasma concentrations will be collected predose and at specified time 
points postdose, 
. Safety assessments including AEs, vital signs, and ECGs will be recorded. During the 
study, AEs will be recorded, and clinical labs, vital signs, and safety ECGs will be obtained. 
Subjects will be discharged from the unit following completion of study exit procedures in the 
afternoon of Study Day 4 (Day 2 of Treatment Period 2). 
Subjects will return to the study site or be contacted by telephone approximately 7 days 
(±2 days) following unit discharge for a safety check and all women of childbearing potential 
must return to the study site to complete a urine pregnancy test at the end-of-study visit
An overview of inpatient unit study schedule is presented below:
Table 4.b
Overview of the Inpatient Unit Study Schedule
Screening 
Period
Check-in and 
Baseline
Treatment Periods 1 and 2
End-of-Study Visit
Dosing
Washout
Study 
Days -28
to -3
Study Days -2 
(nPSG a) and -1 
(Baseline)
Study Days 1 and 3
Study drug 
administration/
, 
PK, and safety 
assessments
Study Days 2 and 4 b
PK and safety 
assessments
Study Day 11 (±2 days)
Follow-up (in clinic or by
phone call)
Confinement
Study Day -2 to Study Day 4
nPSG: nocturnal polysomnography; 
; PK: pharmacokinetic.
a nPSG only on Study Day -2.
b Discharge from unit on Study Day 4.
CCI
C
CI
CCI
CCI
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Ap
recorde
record
CGs w
CGs w
study
tudy ex
y
phone ap
hone a
all wom
all wo
ancy
ncy tes
te
y
esented
esente
Unit Stu
nit Stu
Treatm
Treat
e
Dosin
Dosi
al
Study Da
tudy 
S
ad
rc
o
No
Fo
olysomno
lysomn
Study Da
Study 
from unit 
om uni
r N
plicable
d at spe
at sp
.
and 
nd 
for r 
Terms of Use
etete
ble T
CCI
CI
ms
Appli


TAK-925-2002
Page 9 of 23
Statistical Analysis Plan              Final
22 April 2020
5.0
ANALYSIS ENDPOINTS
5.1
Primary Endpoints
!
Percentage of subjects who experience at least 1 TEAE.
!
Percentage of subjects who meet the markedly abnormal criteria for clinical safety laboratory
tests at least once post a regimen.
!
Percentage of subjects who meet the markedly abnormal criteria for vital sign measurements 
at least once post a regimen.
!
Percentage of subjects who meet the markedly abnormal criteria for 12-lead safety 
electrocardiogram (ECG) parameters at least once post a regimen.
5.2
Secondary Endpoints
!
TAK-925 PK parameters:
–
Observed plasma concentration at the end of infusion (Ceoi).
–
Area under the plasma concentration-time curve from time 0 to infinity (AUC∞).
–
Area under the plasma concentration-time curve from time 0 to time of the last 
quantifiable concentration (AUClast).
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
aborato
borat
n measu
n meas
12-lead 
lead
usion (C
sion (
rve from
ve fro
e curve
curv
roperty of Takeda: For Non-Commercial Use


TAK-925-2002
Page 10 of 23
Statistical Analysis Plan              Final
22 April 2020
6.0
DETERMINATION OF SAMPLE SIZE
Up to 40 subjects are planned to be randomized equally to each treatment sequence to ensure 
36 subjects complete the study. This number of subjects is typical for phase 1 crossover study
designs and is considered sufficient for assessment of safety.
n addition, when the true difference between 
TAK-925 and placebo is minimal, the chance to observe the same event is no more than 10%. 
Non-informative prior distributions were used in the above probability calculation. Allowing for 
4 dropouts (10%), 40 subjects are planned to be randomized.
7.0
METHODS OF ANALYSIS AND PRESENTATION
7.1
General Principles 
Randomized subjects are the subjects who are enrolled and received a randomization number.
Continuous data will be summarized using the following descriptive statistics: number of 
subjects (N), mean, standard deviation (SD), median, minimum, and maximum, where 
appropriate. Where indicated, the coefficient of variation (%CV) and geometric mean will also 
be included in the summary of continuous data. Categorical data will be summarized using the 
number and percent of subjects for each category, where appropriate.
Except when noted as otherwise, all confidence intervals (CIs), statistical tests, and resulting p-
values will be reported as nominal 2-sided and will be assessed at the 5% significance level. No 
adjustments will be made for multiplicity. P-values will be reported to 3 decimal places. 
Posterior probabilities will be multiplied by 100 and rounded to one decimal point. 
Unless otherwise noted, baseline for the study will be defined as the last non-missing 
measurement prior to first dose of study drug in the entire study
Unless specified, for continuous variables, minimum and maximum values will be reported in 
the same precision as that for the individual values; means, medians, LS-means and posterior 
means will be reported after rounding the original reported value to one decimal place; SD, SE 
and confidence intervals will be calculated using the original reported values and rounded to the 
second decimal place. Percentages and %CV will be reported after rounding to one decimal 
place. 
All data analyses and figures will be generated using SAS System® Version 9.4 or higher.
7.1.1
Definition of Study Days
Study day prior to the first dose of study drug will be calculated as: date of assessment/event –
date of first dose of study drug; study day on or after the date of first dose of study drug will be 
calculated as: date of assessment/event – date of first dose of study drug + 1.
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicab
between
betwee
 more th
more 
culat
ulatioion
nd recei
nd rece
wing de
ing d
ian, min
an, mi
f variat
f variati
data. Cat
ta. C
category
catego
confiden
onfid
l 2-sided
sid
ultiti
l plic
pli
i
e mult
multi
baselin
basel
o first do
first d
for con
for co
ision
on as 
a
n
erms of Use
be repo
be rep
fidence 
fidence
d decim
d deci
ce.e.
All da
All 
7
Term
e Te
able 


TAK-925-2002
Page 11 of 23
Statistical Analysis Plan              Final
22 April 2020
Day prior to the first dose of study drug (up to Day -2) in a period will also be derived as: date of 
assessment/event – date of first dose of study drug in a period; Day on or after the date of first 
dose of study drug in a period (up to the last post dose procedure for that period) will be 
calculated as: date of assessment/event – date of first dose of study drug in that period + 1.
7.1.2
Definition of Study Visit Windows
There will be no visit windows.
7.1.3
Conventions for Missing Adverse Event Dates
7.1.3.1
Imputation of missing or partial dates of AE start dates
The following methods will be used to impute missing or partial dates of AE start dates.
!
Month/year available and day missing:
–
If the month and year are the same as those in the first dose date, the first dose date is 
to be used to impute the AE start date.
–
If the month and year are different from those in the first dose date, the first day of
the month will be used for the start date.
!
Year available and month/day missing:
–
If the year is the same as the year of the first dose, the first dose date is to be used to 
impute the AE start date.
–
If the year is not the same as the year of the first dose date, set the start date as 
January 1.
!
Year/month/day all missing:
–
The first dose date is to be used to impute the AE start date.
7.1.3.2
Imputation of missing or partial dates of AE end dates
The following methods will be used to impute missing or partial dates of AE end dates:
If the event is indicated as ongoing at the end of the study, no imputation is needed.
If the event is not indicated as ongoing:
!
Month/year available and day missing:
–
Use the last day of the month to impute the AE end date. If the imputed end date is 
before the AE start date, use the start date as the end date. If the subject died, use the 
date of death to impute the end date.
!
Year available and month/day missing:
–
If the year is the same as or before the year of the last dose, set the end date as 
December 31.
es of AE
s of A
e first do
first d
hose in t
ose in
e.
ear of
ar of th
me as th
e as t
missing
missin
se date i
e date
on of mi
n of m
g method
etho
nt is ind
t is in
event is
event 
!
M


TAK-925-2002
Page 12 of 23
Statistical Analysis Plan              Final
22 April 2020
–
If the year is after the year of the last dose, set the end date as January 1 or the last 
day of contact, whichever is later.
!
Year/month/day all missing:
–
Impute the end date as December 31 of the last dose year. If the imputed end date is 
before the AE start date, keep the end date same as the start date. If the subject died, 
use the date of death to impute the end date.
7.1.4
Conventions for Missing Concomitant Medication Dates
There will be no imputation of incomplete or missing concomitant medication dates.
7.1.5
Conventions for Missing PK Data
Plasma concentrations that are below the limit of quantification (BLQ) will be treated as zero in 
the summarization of concentration values and derivation of PK parameters. These values will be 
flagged in the data listings and deviations from this convention may be considered on a case-by-
case basis as deemed appropriate.
7.2
Analysis Sets
Safety analysis set
The safety analysis set will include all subjects who were randomized and received at least 1 
dose of the study drug. Subjects in this analysis set will be used for demographic, baseline 
characteristics, and safety summaries.
PK analysis set
The PK analysis set will consist of subjects who receive at least 1 dose of study drug and who 
have at least 1 measurable plasma concentration of TAK-925 
).
7.3
Disposition of Subjects
The number and percentage of randomized subjects who complete the study and those who 
prematurely discontinue the study will be summarized for each treatment sequence and overall. 
In addition, the reason of study discontinuation will be summarized for each sequence and 
overall.
CCI
CCI
Property of
7.3
7.3
Commercial Use Only and Subject to the Applicable Terms of Use
ate is
te is
ect died
ct die
ioion date
n da
BLQ)
LQ) w
K param
K para
ion ma
m
ects wh
cts wh
analysis 
nalysi
sist of su
st of 
plasma
plasm
Th
T
of Takeda: For Non-C


TAK-925-2002
Page 13 of 23
Statistical Analysis Plan              Final
22 April 2020
A summary of demographics (age, gender, ethnicity, and race) for screen failures and the 
primary reason for failure will also be provided. 
Subjects’ study completion data, including the dates of the first and last dose, and reasons for 
premature termination, will be listed. 
7.4
Demographic and Other Baseline Characteristics
Descriptive statistics (N, mean, SD, median, minimum, and maximum) will be generated for 
continuous demographic and baseline characteristics variables (including but not limited to age, 
height, weight, BMI, O2 saturation index, BDI-II total score (screening), Epworth Sleepiness 
Scale (ESS) total score, Day -1 mean sleep latency, 
and overall using the Safety Analysis Set. The number and percentage of subjects in each class 
of the categorical demographic variables and baseline characteristics variables (sex, ethnicity, 
race, substance use) will be tabulated by treatment sequence and overall.
All individual demographic and baseline characteristics will be listed by treatment sequence and 
subject number. The demographic data listing will include subject identifier, treatment sequence, 
date of informed consent, date of birth, age at date of informed consent, gender, ethnicity, race, 
height, baseline weight, baseline BMI. 
7.5
Medical History and Concurrent Medical Conditions
All medical history and concurrent medical conditions will be listed.
7.6
Medication History and Concomitant Medications
All medication history and concomitant medications data will be listed.
7.7
Study Drug Exposure and Compliance
The date and time of each dose for each subject will be reported in the data listing. Listings and 
summary statistics for TAK-925 plasma concentrations and pharmacokinetic parameters will be 
provided. No other summary statistics for the extent of exposure to study drug or compliance 
calculations will be performed for this study.
CCI
CCI
CCI
Property o
perty o
CI
CI
: For Non-Commercial Use Only and Subject to the A
of subje
of subj
s variab
varia
overall.
overal
be listed
be list
e subjec
subjec
nformed
forme
dical C
dical C
l condit
con
ncomita
ncom
mitant 
mitant
ure and
re an
ch dose
h dos
r TAK
r TAK
er summ
summ
ll be pe
l be p
Applicable Terms of Use
nerated 
erated
ot limite
ot limi
worth S
worth S
of Takeda: 
e App


TAK-925-2002
Page 14 of 23
Statistical Analysis Plan              Final
22 April 2020
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
operty of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use


TAK-925-2002
Page 15 of 23
Statistical Analysis Plan              Final
22 April 2020
7.10
Pharmacokinetic Analysis
7.10.1 Pharmacokinetic Analysis
The following PK parameters of TAK-925 
 will be determined from plasma 
concentrations from all evaluable subjects using noncompartmental analysis methods. Actual
sampling times, rather than scheduled sampling times, will be used in all computations involving 
sampling times. 
AUC∞
t1/2z
AUClast
Vss (TAK-925 only)
Cmax
Vz (TAK-925 only)
Ceoi
CL (TAK-925 only)
tmax
Additional PK parameters may be calculated as appropriate. A detailed PK analysis plan will be 
prepared before PK parameter computation.
Individual plasma concentrations and PK parameter estimates of TAK-925 
will be listed for each subject. Plasma concentrations will be summarized using descriptive 
statistics (N, mean, SD, %CV, median, minimum, and maximum) at each nominal time point.
PK parameters will be summarized for TAK-925 112 mg. Geometric means will also be 
computed for Ceoi, Cmax, AUClast, and AUC∞. Mean (±SD) concentration-time profiles will be 
plotted for TAK-925 
. Individual concentration-time profiles will be 
presented in spaghetti plots for TAK-925 112 mg.
7.10.2 PK
Safety Analysis
The relationships between TAK-925 plasma concentrations and selected 
 safety measures 
will be explored graphically as data permit. 
CCI
CCI
CCI
CCI
CCI
CCI
CCI
Property of Takeda: For Non-Commercial Use Only a
noncomp
oncom
g t
g times,
imes
ameters 
meter
PK para
PK p
lasma c
lasma 
sted for 
ed fo
ics (N, m
ics (N, 
parame
param
com
ompute
pu
m
plplott
ot
pr
p
d Subject to the Applicable Terms of Use
t to the Applicable Terms of Use
and 


TAK-925-2002
Page 16 of 23
Statistical Analysis Plan              Final
22 April 2020
Similar scatterplots will be produced for time-matched differences in HR, SBP, and DBP 
between TAK-925 and placebo. TAK-925 plasma concentration will be plotted on the x-axis; the 
difference in time-matched TAK-925 and placebo pairs in HR and BP (separately for SBP and 
DBP) will be plotted on the y-axis. 
In addition, mean profile plots of TAK-925 plasma concentration and the difference from time-
matched TAK-925/placebo pairs in HR, SBP, and DBP will be produced. The scheduled time 
point will be the x-axis, mean (± SD) TAK-925 plasma concentration will be on the left y-axis, 
and difference in the LS means (± SE) of time-matched TAK-925/placebo in HR, SBP or DBP 
will be on the right y-axis. Both dose levels of TAK-925 will be presented on the same plot. 
7.11
Safety Analysis
Safety measures include AEs, clinical laboratory parameters, vital sign parameters, 12-lead ECG 
results, and other safety parameters. The Safety analysis set will be used for all summaries for 
safety data.
7.11.1 Adverse Events
All AEs will be coded by system organ class (SOC) and preferred term (PT) using MedDRA.
The Treatment-Emergent Adverse Events (TEAE) summary tables will include numbers and 
percentages of subjects experiencing at least one TEAE by SOC and PT and will be tabulated by
treatment. The following is a list of TEAE summary tables to be generated: 
!
Overview of Treatment-Emergent Adverse Events 
!
Treatment-Emergent Adverse Events by System Organ Class and Preferred Term 
!
Treatment-Emergent Adverse Events by Preferred Term
!
Serious Treatment-Emergent Adverse Events by System Organ Class and Preferred Term 
!
Most Frequent (>=2 subjects in any treatment) Treatment-Emergent Adverse Events by 
Preferred Term
!
Most Frequent (> 5% subjects in any treatment) Non-Serious Treatment-Emergent 
Adverse Events by System Organ Class and Preferred Term
!
Relationship of Treatment-Emergent Adverse Events to Study Drug by System Organ 
Class and Preferred Term
!
Drug-Related Treatment-Emergent Adverse Events by System Organ Class and Preferred 
Term
!
Drug-Related Treatment-Emergent Adverse Events by Preferred Term
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
axis; th
axis; th
SBP an
BP an
ence fr
ence f
he sched
e sch
ll be on 
be on
cebo in H
ebo in
esented 
sented
ers, vi
ers, vitati
is set wi
set w
ass (SOC
ass (S
ents (TE
nts (T
g at leas
 at le
of TEA
of TE
nt-Em
Em
gent Ad
gent A
mergen
erge
Treatm
Treatm
st Frequ
t Freq
referre
referr
Mos
Mo
A


TAK-925-2002
Page 17 of 23
Statistical Analysis Plan              Final
22 April 2020
!
Intensity of Treatment-Emergent Adverse Events by System Organ Class and Preferred 
Term
!
Intensity of Drug-Related Treatment-Emergent Adverse Events by System Organ Class 
and Preferred Term 
A treatment-emergent adverse event (TEAE) is defined as an AE whose date/time of onset 
occurs on or after the first dose of study drug. TEAEs are assigned to the treatment received 
within a period: AEs with the start date on or after the first dose within the treatment period and 
before the first dose of study drug within the next period. 
In addition, subject mappings for the TEAEs by SOC and PT will be generated.
Data listings will be provided for all AEs including pre-treatment events (PTE), TEAEs, and AEs 
leading to death, AEs leading to study drug or study visit discontinuation, and SAEs
7.11.2 Clinical Laboratory Evaluations
Clinical safety laboratory tests include clinical chemistry, hematology, and urinalysis. They are 
measured at Study Day -2 and Study Day 4 prior to discharge or at early termination (ET). 
Descriptive statistics (N, mean, SD, median, minimum and maximum) of continuous clinical 
laboratory variables will be summarized for baseline, post-dose (at discharge or ET), and change 
from baseline to post-dose overall by treatment sequence. Only the scheduled measurements will 
be included in the summary. No statistical tests will be performed.
Individual results for clinical laboratory tests will be evaluated against the Takeda predefined 
laboratory markedly abnormal values (MAV) criteria (Appendix A). All subjects with at least 1 
post-dose laboratory result that meets the MAV criteria will be presented in a data listing.
The number and percentage of subjects with at least 1 post-dose markedly abnormal laboratory 
test result will be summarized overall for each laboratory parameter. The evaluation of clinical 
lab MAV will include scheduled and unscheduled results.
All clinical laboratory data will be presented in SI units in data listings. 
7.11.3 Vital Signs
Vital sign measurements include blood pressure (SBP and DBP), HR, respiratory rate, and body
temperature.
Heart rate, SBP, and DBP will be summarized (N, mean, SD, median, minimum and maximum) 
by treatment and time (before infusion and at the post dose timepoints). Only the scheduled 
measurements will be included in the summary. As there are time-matched baseline measures 
collected on Day -1, the time-matched baseline will be summarized by time-point for Day -1. 
Respiratory rate and temperature will be summarized at baseline, post dose time points and 
change from baseline by treatment. Measures at pre-dose on Day 1 of each period will be defined 
as the baseline for the period. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
s 
nset 
set 
eceived
eceiv
ment peri
nt pe
rated.
ated.
nts (PTE
ts (PT
uatition, a
on,
hemato
hemato
char
harge o
ge
mum and
um an
eline, po
line, 
ent sequ
t seq
tests w
tests 
ry tests 
tests
y
es (MA
s (MA
meets th
eets 
of subje
of sub
rized ov
zed o
schedul
ched
tory
ory dat
da
y
Signs
Sign
n measu
eas
rature.
rature
eart rate
art ra
by 
by trea
mea
mea


TAK-925-2002
Page 18 of 23
Statistical Analysis Plan              Final
22 April 2020
In addition, observed heart rate, SBP, and DBP at pre- and post-infusion start time points (0, 1, 3, 
5, 7, 9, 10, 13 and 24 hours) in each period will be analyzed using a linear mixed effect model
for repeated measures. The model will include sequence, period, treatment, time (as a categorical 
variable), and treatment by time point interaction as fixed effects and a random effect for subject 
within sequence. The least square (LS) mean HR, SBP and DBP for each treatment and the 
associated SE and 95% CI will be extracted from the model at each time point, along with all 
pairwise differences from placebo and associated SEs, 95% CIs, and p-values. The same 
quantities will be estimated from the model with the appropriate contrasts for the average over 
the time points during the infusion (0, 1, 3, 5, 7 hours post-infusion start) and the average over 
the time points after the end of the infusion (9, 10, 13, and 24 hours post-infusion start).
The LS- mean HR, SBP and DBP over time will be plotted. The scheduled time points will be on 
the x-axis; the least-square mean (± SE) (estimated from model above) will be on the y-axis. All 
treatments will be displayed on the same plot and differentiated by different symbols. The LS 
mean differences from placebo will also be plotted.
Individual plots of the HR, SBP, and DBP over time will be plotted. The scheduled time points 
will be on the x-axis; the observed values will be on the y-axis. All treatments and the time-
matched values from Day -1 will be displayed on the same plot and differentiated by different 
symbols.
Functional mixed-effect models may be performed for HR, SBP and DBP to take into account 
periodic (circadian) component of the signal and would allow to identify the parameters of the 
variation such as amplitude, phase, and intercept. Each parameter will have fixed and random 
components, while time dependence will be described by periodic function of time within each 
period. Fixed effects will include sequence, period, treatment and random effects will be 
specified for each subject within sequence as random intercept. The least square means and 
associated SE 95% CI for each parameter will be estimated from the model, along with the 
pairwise contrasts between treatment levels and corresponding SE, 95% CI, and p-values. 
No statistical testing or modeling will be performed for other vital signs (temperature).
All individual vital sign values that meet Takeda’s predefined criteria for MAVs (Appendix B)
will be listed. The number and percentage of subjects with at least 1 post-dose markedly 
abnormal vital sign measurement will be summarized by treatment for each vital sign parameter. 
The evaluation of MAV for vital signs will include both scheduled and unscheduled 
measurements.
All vital signs data will be presented in data listings.
7.11.4 12-Lead ECGs
A standard 12-lead ECG will be recorded. The investigator (or a qualified observer at the 
investigational site) will manually interpret the ECG using 1 of the following categories: within 
normal limits, abnormal but not clinically significant, or abnormal and clinically significant.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
al
bject 
ect 
e
with all
ith all
ame
ame
average
verag
the aver
he ave
fusio
sion s
n
uled tim
uled tim
ve) will 
e) wil
y dif
dif
y
fere
fe
f
e plotte
e plotte
y-axis. 
axis
same p
same 
rmed fo
med f
al and w
l and w
intercep
nterce
will be d
will b
sequenc
quen
n sequen
seque
ch param
h para
n treatm
n treat
or m
or mode
od
al sign v
l sign
The num
he nu
tal sign
tal sign
uation o
ation 
rement
remen
l vit
vital s
l
7.11
7.11


TAK-925-2002
Page 19 of 23
Statistical Analysis Plan              Final
22 April 2020
The following parameters will be calculated automatically by the third party vendor: heart rate, 
PR interval, QT interval, QRS interval, QT interval with Bazett’s correction formula (QTcB) and 
QT interval with Fridericia’s correction formula (QTcF).
Descriptive statistics of the continuous ECG parameters will be summarized including baseline, 
Day 1 post dose timepoint, and change from baseline by treatment. Measures at pre-dose on Day
1 of each period will be used as the baseline in these summaries. Only the ECGs collected at the 
scheduled visits or time points will be included in the summary. No statistical tests will be 
performed for the observed ECG parameters. 
All individual ECG values that meet Takeda’s predefined criteria for MAVs (Appendix C) will 
be listed. The number and percentage of subjects with at least 1 post-dose markedly abnormal 
ECG measurement will be summarized by treatment for each ECG parameter. The evaluation of 
MAV will include both scheduled and unscheduled measurements.
Individual subject ECGs will be presented in a data listing. 
7.11.5 Other Observations 
None.
7.12
Interim Analysis
Safety data, such as AEs, vital sign changes and MAV summaries, will also be used when 
determining whether continue the study in this case. If the study will continue, the sample size 
may be re-estimated. 
7.13
Changes in the Statistical Analysis Plan from Protocol
None.
CCI
Property of Taked
data, su
data, s
rmining
rminin
may be r
y be
Only and Subject to the Applicable Terms of Use
line,
ne,
e on Day
 on Da
cted at t
ed at
will be
will b
(Appen
App
e marke
mark
rameter
amete
7.1
7.1
keda: For Non-Commercial Use On


TAK-925-2002
Page 20 of 23
Statistical Analysis Plan              Final
22 April 2020
8.0
REFERENCES
1.
Thomann, J., Baumann, C.R., Landolt, H.P. and Werth, E., 2014. Psychomotor vigilance task 
demonstrates impaired vigilance in disorders with excessive daytime sleepiness. Journal of 
Clinical Sleep Medicine, 10(09), pp.1019-1024.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
f 


TAK-925-2002
Page 21 of 23
Statistical Analysis Plan              Final
22 April 2020
Appendix A
Criteria for Identification of Markedly Abnormal Laboratory Values
Hematology—Criteria for Markedly Abnormal Values
Parameter
Unit
Low Abnormal
High Abnormal
Hemoglobin
Both 
< 0.8 × LLN
> 1.2 × ULN
Hematocrit
Both
< 0.8 × LLN
> 1.2 × ULN
RBC count 
Both
< 0.8 × LLN 
> 1.2 × ULN
WBC count 
Both 
<0.5 x LLN
>1.5 x ULN
Platelet count
Conventional
<75 x 103/∀L
>600 x 103/∀L
SI
<75 x 109/L
>600 x 109/L
LLN=lower limit of normal, RBC=red blood cell, ULN=upper limit of normal, WBC=white blood cell. 
Serum Chemistry—Criteria for Markedly Abnormal Values
Parameter
Unit 
Low Abnormal
High Abnormal
ALT
Both
--
>3 x ULN
AST
Both
--
>3 x ULN
GGT
Both
--
>3 x ULN
Alkaline phosphatase
Both
--
>3 x ULN
Total bilirubin
Both
--
>1.5 x ULN
Albumin
Conventional 
<2.5 g/dL
--
SI 
<25 g/L
--
Total protein
Both
<0.8x LLN
>1.2 x ULN
Creatinine
Both 
--
>1.5 x ULN 
Blood urea nitrogen
Conventional 
--
>40 mg/dL
SI
--
>10.7 mmol/L
Sodium
Conventional
<130 mEq/L
>150 mEq/L
SI
<130 mmol/L
>150 mmol/L
Potassium
Conventional
<3.0 mEq/L
>5.3 mEq/L
SI
<3.0 mmol/L
>5.3 mmol/L
Glucose
Conventional
< 50 mg/dL
>300 mg/dL
SI
< 2.8 mmol/L
>19.4 mmol/L
Calcium
Conventional
<7.7 mg/dL
>11.1 mg/dL
SI
<1.92 mmol/L
>2.77 mmol/L
ALT=alanine aminotransferase, AST=aspartate aminotransferase, GGT=#-glutamyl transferase, LLN=lower limit of 
normal, ULN=upper limit of normal.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
o
m
∀L
09/L
/L
e
C=white 
C=whit
Hi
H
ctctct
ect
bje
2.5 g/dL
5 g/dL
<25 g/
<25 g
l
<0
<
al
tional
onal
Convent
onven
SI
SI
N
C
N
um
y o
ALT=
ALT
nor
no


TAK-925-2002
Page 22 of 23
Statistical Analysis Plan              Final
22 April 2020
Appendix B
Criteria for Markedly Abnormal Values for Vital Signs
Parameter
Unit
Lower Criteria 
Upper Criteria
Pulse
bpm
<40 
>115
Systolic blood pressure
mm Hg
<90 
≥ 160 
Diastolic blood pressure
mm Hg
<50 
≥100
Systolic blood pressure change from 
baseline*
mm Hg
>20
Diastolic blood pressure change from 
baseline*
mm Hg
>20
Body temperature
o C
>38.5 
Respiratory Rate
Breath/min
>21
* change in blood pressure from the pre-dose value in each treatment period
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
of
ms
er
e T
ica
>38.5 
>38.
Ap
>2
>
he
to


TAK-925-2002
Page 23 of 23
Statistical Analysis Plan              Final
22 April 2020
Appendix C
Criteria for Markedly Abnormal Values for Electrocardiograms
Parameter
Lower Criteria 
Upper Criteria
Heart rate
<40 beats per minute
>115 beats per minute
PR
≤80 milliseconds
≥200 milliseconds
QTcF Interval
≤300 milliseconds
>500 milliseconds OR 
≥30 milliseconds change from baseline and >450 
milliseconds
QRS
≤80 milliseconds
≥180 milliseconds
* change in blood pressure from the pre-dose value in each treatment period
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
of
ms
eline
ine and
a
e
er
ca
pp



(/(&7521,&6,*1$785(6
Signed by 
Meaning of Signature 
Server Date 
(dd-MMM-yyyy HH:mm ‘UTC’) 
GG
䢳䢸䢯䢳䢯䢻䢢䣕䣶䣣䣶䣫䣵䣶䣫䣥䣣䣮䢢䣃䣰䣣䣮䣻䣵䣫䣵䢢䣒䣮䣣䣰䢢䢴䢲䢴䢲䢯䢲䢶䢯䢴䢴
%LRVWDWLVWLFV$SSURYDO
$SU87&
PPD
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
e Te
ate 
te
ble T
HH:mm ‘U
H:mm
Ter
ble
87&
87&